-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QSh4/OmDD0OjELcilv9axY2LbYZB8JwNFTjOMQWzuYxUkkeNvaFF/s9BH9d6aU73 XtxJR2JQHhpbqi9lqDYaQw== 0001188112-06-000598.txt : 20060302 0001188112-06-000598.hdr.sgml : 20060302 20060302161843 ACCESSION NUMBER: 0001188112-06-000598 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20051231 FILED AS OF DATE: 20060302 DATE AS OF CHANGE: 20060302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NANO PROPRIETARY INC CENTRAL INDEX KEY: 0000891417 STANDARD INDUSTRIAL CLASSIFICATION: COMMUNICATIONS EQUIPMENT, NEC [3669] IRS NUMBER: 760273345 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11602 FILM NUMBER: 06660095 BUSINESS ADDRESS: STREET 1: 3006 LONGHORN BOULEVARD STREET 2: SUITE 107 CITY: AUSTIN STATE: TX ZIP: 78758 BUSINESS PHONE: 5123315020 MAIL ADDRESS: STREET 1: 12100 TECHNOLOGY BOULEVARD CITY: AUSTIN STATE: TX ZIP: 78727 FORMER COMPANY: FORMER CONFORMED NAME: SI DIAMOND TECHNOLOGY INC DATE OF NAME CHANGE: 19940318 10-K 1 t9048_10k.htm FORM 10-K Form 10-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-K
 
 ý
 
Annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended
December 31, 2005; or
   
 ¨
Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934
 
COMMISSION FILE NO. 1-11602
 
NANO-PROPRIETARY, INC.
(Exact name of registrant as specified in its charter)
 
TEXAS
(State of Incorporation)
 
76-0273345
(IRS Employer Identification Number)
 
3006 Longhorn Boulevard, Suite 107, Austin, Texas 78758
(Address of principal executive office, including Zip Code)
Registrant's telephone number, including area code: (512) 339-5020
 
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
Name of Each Exchange on Which Registered
Common Stock, $0.001 par value
OTC Bulletin Board
 
Securities registered pursuant to Section 12(g) of the Exchange Act: None
 
Indicate by check mark if the registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act. Yes  ¨    No  þ

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  ¨    No  þ

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes  þ    No  ¨
 
Indicate by check mark if disclosure of delinquent filers in response to Item 405 of Regulation S-K is not contained in this form and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.     ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Act.
Large Accelerated Filer  ¨    Accelerated Filer  þ    Non-Accelerated Filer  ¨
 
The aggregate market value of the Common Stock held by non-affiliates of the Registrant, based upon the average of the closing bid and asked price of the Common Stock on the OTC Bulletin Board system on June 30, 2005 of $2.20, was approximately $216 million.
 
As of February 24, 2006, the registrant had 100,496,440 shares of Common Stock issued and outstanding.
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.
Yes  ¨    No  þ
 
Documents Incorporated by Reference
 
No documents are incorporated by reference into this annual report on Form 10-K



 
TABLE OF CONTENTS
 
 
Page
 
1
 
10
 
15
 
15
 
16
 
16
 
 
 
 
 
17
 
18
 
19
 
24
 
25
 
47
 
47
 
49
 
 
 
 
 
50
 
53
 
56
 
58
 
58
 
59
 
Important Information Concerning Forward-Looking Statements 
 
Our disclosure and analysis in this report contains some forward-looking statements. Forward-looking statements give our current expectations or forecasts of future events. They use words such as “anticipate”, “believe”, “expect”, “estimate”, “project”, “intend”, “plan”, and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. From time to time, we also may provide oral or written forward-looking statements in other materials we release to the public.
 
Any or all of our forward-looking statements in this report and in any other public statements we make may turn out to be wrong. They can be affected by inaccurate assumptions we might make, or by known or unknown risks or uncertainties. Many factors mentioned in the risk factors are important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially.
 
We undertake no obligation to publicly update any forward-looking statements, whether as the result of new information, future events, or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our 10-Q, 8-K, and 10-K reports to the SEC. Also note that we include a cautionary discussion of risks, uncertainties, and possibly inaccurate assumptions relevant to our business. These are factors that we think could cause our actual results to differ materially from expected and historical results. Other factors besides those listed here could also adversely affect us. 
 


 
When used in this document, the words “anticipate”, “believe”, “expect”, “estimate”, “project”, “intend”, “plan”, and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks, uncertainties, and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, expected, estimated, projected, intended, or planned. For additional discussion of such risks, uncertainties, and assumptions, see “Important Information Concerning Forward-Looking Statements” and “Risk Factors” included at the beginning of this report.
 
Item 1.   Business.
 
DESCRIPTION OF BUSINESS
 
General
 
Nano-Proprietary, Inc. is engaged in the development of proof of concepts of products and materials, and the performance of services based principally on novel applications of carbon nanotube technology, as well as other nanotechnology areas based on intellectual property and expertise that we have developed over the years. We were incorporated in Texas in 1987 and completed our initial public offering in 1993. Our initial focus was on a next generation display technology called field emission display (“FED”). The majority of our research over the years has been related to FED technology, and we have accumulated significant intellectual property in this area. FED technology has evolved significantly over the life of the company, and we have been at the forefront of that evolution, accumulating intellectual property at each step of the way. We believe our FED intellectual property will be required by any entity that develops a display using this technology. As discussed in greater detail under the heading “Display activities”, our FED technology includes both carbon nanotube based field emission displays and thin-film based field emission technology, such as the technology recently introduced by Canon and Toshiba referred to as SED.
 
While focusing primarily on FED technology, over the years we have performed research in many other areas. Much of this research was an outgrowth of our work in the FED area. This research was in other display technologies, used processes learned while we were working with FED technology, used raw materials used in our FED research, or capitalized on other unique capabilities within our organization. As a result we have developed significant intellectual property in the area of sensor technology and other areas beyond the FED technology. At present, we have over 250 total patents, including 116 issued, 99 pending, and 26 provisional.  
 
Research and Development
 
As a result of our focus on developing and protecting our intellectual property, we spend significant amounts on research and development. We spent $2,525,292, $2,611,583, and $1,861,660 on research and development in the years ended December 31, 2005, 2004, and 2003, respectively. This represents approximately 48%, 52%, and 38% of our total operating costs and expenses in 2005, 2004, and 2003, respectively. We expect to continue to invest heavily in research and development and expect our research and development costs for 2006 to be in excess of 50% of our operating costs.
 
Business  Segments
 
Our operations currently consist of three reportable business segments.
 
Applied Nanotech, Inc ANI is the main focus of our current efforts. It was incorporated in January 1997 and is developing our proprietary carbon nanotube and related technology. Accordingly, our research is focused in the broad area of carbon nanotube technology and its application to the display, electronics, sensor, medical, x-ray, and other industries. Our development plans for this technology are discussed later in this report.
 
Electronic Billboard Technology, Inc. EBT was incorporated in January 1997 and initially focused on developing sun-readable display products for outdoor use.  Its primary product initially was an electronic billboard that would enable the outdoor advertising industry to exploit the Internet and information revolution by placing ads at different locations at different times. The focus of EBT was rapidly shifted to displays for indoor use that could be used as part of an overall point of purchase advertising program. We also developed a patented product called the E-Window™, as well as patents surrounding the process of communicating with electronic displays for the purpose of  placing advertisements. In 2002, we restructured EBT and stopped selling products directly and instead limited ourselves to licensing our intellectual property. We did this to focus on our business at ANI, which had higher potential in the short run and was less capital intensive. At the present time, we are pursuing license agreements related to our intellectual property in this area, although we are not currently spending money to further develop EBT’s technology.


 
Other.  We also incur general overhead to operate Nano-Proprietary that is not associated with any specific subsidiary or other segment. This overhead is the approximate cost of being a public company, which is the amount in excess of that which might be incurred by a private company performing these same activities. To the extent that EBT is basically inactive, information relative to this segment is not that meaningful.
 
 
Following is a summary of revenues, net loss, and total assets for each segment for each of the last three years.
 
   
2005
 
2004
 
2003
 
Revenues
             
ANI
 
$
565,660
 
$
382,522
 
$
773,959
 
EBT
 
$
 
$
 
$
 
Other
 
$
 
$
 
$
 
Total Revenues
 
$
565,660
 
$
382,522
   
773,959
 
                     
Net loss from continuing operations
                   
ANI
 
$
(3,730,450
)
$
(4,030,353
)
$
(2,890,175
)
EBT
 
$
(3,734
)
$
106,251
 
$
(361,784
)
Other
 
$
(927,350
)
$
(687,924
)
$
(962,243
)
Total
 
$
(4,661,534
)
$
(4,612,026
)
$
(4,214,202
)
Assets
                   
ANI
 
$
301,870
 
$
310,005
 
$
1,424,724
 
EBT
 
$
 
$
 
$
527
 
Other
 
$
886,111
 
$
834,363
 
$
2,358,766
 
Total
 
$
1,187,981
 
$
1,144,368
 
$
3,784,017
 
 
 
 
Applied Nanotech, Inc.
 
Overall
 
We are primarily a nanotechnology company.  We are focusing our efforts on research, proof of concept development for products, and licensing our technology to others. ANI is developing world-class technologies that generally fall into one of four markets or categories. These categories are display, sensors, functional nanomaterials, and other specific electronic applications. We intend to license our technology to others to allow them to manufacture products using our technology. We have no plans to establish any manufacturing facilities in the foreseeable future and manufacturing is not a part of our core strategy. To the extent that we would need to develop manufacturing capabilities, we intend to use manufacturing partnerships, joint ventures, or arrange to have products manufactured through contract manufacturers. 
 
Display activities
 
Our main focus for virtually the entire life of Nano-Proprietary has been on Field Emission Display (“FED”) technology. We have performed significant research and accumulated significant intellectual property in this area. Field emission display is a next generation display technology that is ideally suited for use in large flat screen televisions, with “large” being defined as 50-inch diagonal or greater. TVs using FED technology are intended to compete with and improve on the plasma, projection, and CRT displays currently available in the large screen TV market. FED technology can also be used for large outdoor electronic displays in products such as roadside billboards, stadium displays, and other outdoor electronic signs. We have developed an extensive patent portfolio covering numerous aspects of FED technology.
 
 

 


 
Carbon-nanotube based large area flat screen color field emission displays. Because of cost advantages carbon nanotubes are currently the preferred method in the display industry for construction of large area flat screen color TVs using FED technology. As discussed in more detail in the Technology Agreements section below, we licensed 6 patents from Till Keesman in 2000. These patents are basic patents covering the use of emissions from carbon nanotubes. The U.S. Patent (No. RE38,223 E) was reissued in August 2003. This reissuance strengthened and reinforced the basic nature of this patent. It is our belief that any company using a carbon nanotubes in an emission mode, regardless of application, will be required to license this, and other patents from us. No companies have yet obtained the right to use this patent from us. We have an equally significant patent that we refer to as the Raman Spectrum patent. This patent covers all carbon based FEDs, regardless of whether the emission is from carbon nanotubes, carbon films, or other forms of carbon.
 
Other companies are developing large area color TVs that may be, in part, based on our carbon nanotube based field emission technology. Companies including Samsung, Dupont, Noritake, and Motorola all have made public announcements related to the development of large area carbon nanotube based field emission displays, or manufacturing processes for such displays. To the extent that these companies, or any other companies, bring a TV to market using carbon nanotube based field emission display technology, they would be required to license one or more of our patents.
 
We have also developed our own proofs of concepts of carbon nanotube based field emission display TVs. We currently have both a 14-inch monochrome and a 14-inch color proof of concept that we built internally. We have also developed a 25-inch color prototype in conjunction with a consortium of Japanese component manufacturers. Each member of the consortium contributed its own particular expertise to the prototype at its own expense. The purpose of the 25-inch color prototype was to demonstrate that scalability is not an issue with the carbon nanotube-based field emission display. It was built to specifications enabling it to be expanded to a 60-inch display; however, it was built at 25 inches due to cost considerations. We completed the 25-inch color prototype in the fall of 2005, and it is our goal to start a pilot line with a major manufacturer and license the technology. This manufacturer could be one that has done extensive work on its own related to carbon nanotube based field emission displays, or one that perceives itself as behind the curve in this area and would use this as an opportunity to catch up to others in the area. Other members of the consortium would have the opportunity to become equipment suppliers, component manufacturers, or manufacturers of carbon nanotube based TVs.
 
Other large area flat screen color field emission displays. Canon, Inc. and Toshiba have jointly developed a large area flat screen color TV based on our FED technology. Canon and Toshiba have announced that they have formed a joint venture to manufacture components for this TV, have constructed a manufacturing line, demonstrated this product at the January 2006 consumer electronics show in Las Vegas, and announced that they would have product available in the fall of 2006. We signed a non-exclusive license with Canon in 1999 that covered substantially all of our field emission patents, but excluded the basic carbon nanotube patent and specific applications for the other field emission display patents including, but not limited to, large area color displays. Toshiba and the joint venture formed by Canon and Toshiba have no licenses from us. It is our belief that all entities involved will require licenses from us in order to manufacture and sell large area flat screen color TVs using this FED technology. The license agreement with Canon is currently the subject of litigation. See Item 3 of this Annual Report on Form10-K for further information on this litigation.
 
HyFED™ - We have developed a new display technology that we call the HyFED™. We expect the HyFED™ to be phased in as an improvement to the way our FED technology will be used in the large area color displays previously described. HyFED™ combines what we believe to be the best properties of CRTs and our field emission technology. We expect the HyFED™ to significantly cut the cost of the drivers used in a field emission display. In January 1999, we formed an International Development Team to develop the first HyFED™ based on our FED technology. The International Development Team was composed of six organizations - four from Japan, one from Europe, and ourselves. The International Development Team completed a working four-inch monochrome prototype of the HyFED™ in January 2000. The team was expanded and developed a prototype with an active gray scale. Each member of the team was focused on the development of a specific portion of the prototype and members funded their own portion of the work. Work on the HyFED™ has been frozen until our basic FED technology is being used in the production of large area color TVs. These team members will be given the first opportunity to license the HyFED™ technology. We expect to license our HyFED™ technology in the future, although there is no assurance that this will occur. 
 
Backlights for displays. Our carbon nanotube technology is ideally suited to be developed as a backlight for other types of displays, such as LCDs and we have performed some initial research in this area. Many other significant companies have also performed research in this area. Successful development of a backlight device using carbon nanotubes will require a license to our intellectual property.
 


 
PETS for medium resolution large area electronic billboards- The PET, or Picture Element Tube, is a basic display device that could be used in many display applications in addition to electronic billboards. The carbon nanotube field emission technology provides several advantages over the existing technologies used in these areas. It generally has a higher image quality, better sunlight readability, lower cost, lower energy usage, improved viewing angle and excellent video capabilities. We do not intend to manufacture these PETs ourselves, but rather license other manufacturers to produce them. We have currently licensed a previous version of field emission display technology that is not based on carbon nanotubes to a large Japanese display manufacturer that is now working internally to complete development of the product.
 
Licensing agreements. We have an extensive patent portfolio that we have developed and acquired over the years. Licensing of this technology to major companies is a critical part of our overall strategic plan and critical to achieving profitability in the short run. We currently have two license agreements related to our FED technology. In March 1999, we signed our first significant license agreement with Canon, Inc. In exchange for a one-time, up-front payment of approximately $5.6 million, Canon was granted a non-exclusive right to use a portion of our FED technology, but excluding the basic carbon nanotube patent and specific applications for other field emission display patents including, but not limited to, large area color displays. In 2002, we signed another license agreement with a large Japanese display manufacturer. This license calls for royalties of 2% of the licensee’s sales of products using our technology. The licensee will receive credit against royalties due under the agreement for $2 million of research funding that the licensee provided to us from 2001 to 2003. Accordingly, no royalties will be due under the agreement until sales of the licensee’s products exceed $100 million. We expect to sign multiple additional license agreements over the next few years, and we expect that such license agreements will include both an up-front payment and a continuing royalty stream based on the products sold by the licensee.
 
 Competition. Because of the strength of our intellectual property in the FED area, our competition comes from other technologies, rather than other companies. Any company developing a carbon nanotube based FED large area flat screen color TV will be required to license our patents. There are other companies attempting to develop non-carbon nanotube based field emission display technologies. It is our opinion that these technologies will not be as cost efficient or demonstrate as high a level of brightness as the field emission technology, whether carbon nanotube based or the SED. However, even companies developing these non-carbon nanotube based field emission displays will likely be required to license other portions of our patent portfolio in order to bring a product to market.
 
In the large area flat screen color TV industry, the primary competition comes from plasma panel displays, LCD displays, organic LED displays, and color picture tubes. We believe our technology, when fully developed, will primarily compete with plasma displays and LCD displays, and generally compares favorably visually and technically with both types of displays. In addition, carbon nanotube based field emission displays are expected to be less costly than plasma displays. LCD displays have quality issues related to the viewing angle and are generally not economical once the size exceeds 45 inches, and therefore are not considered strong competition because our technology is targeted at displays greater than 50 inches. Several companies are currently developing backlights for LCDs using carbon nanotubes. Successful development of a carbon nanotube backlight would require a license to our intellectual property.
 
Sensors
 
Overview. We have greatly expanded or work and intellectual property in the area of sensors, including biosensors, hydrogen sensors, carbon monoxide sensors, and other sensors. This is becoming an increasingly important part of our business and we expect it to become even more important in the future.
 
Biosensors. Our carbon nanotube technology is ideally suited for use in biosensors. Sensors based on carbon nanotubes can be used to detect chemical, organic, or biological warfare agents, as well as explosives, hydrogen, ammonia and numerous other chemicals., We have developed several proof of concepts demonstrating the viability of our sensor technology and are currently seeking development partners to license the technology and integrate it into specific products.
 
Hydrogen sensors. These sensors are targeted for use in fuel cells for automobiles and for remote monitoring of large power transformers. We currently have two agreements related to our hydrogen sensors.
 
The first is a development, purchase, and license agreement with Kelman, Ltd., an international company which operates primarily in the area of power products, transformer services, and emission monitoring products. The agreement, signed in July 2005, gave the licensee the exclusive right for the use of the technology for the measurement of hydrogen in power transformer products, if certain minimum royalty payments are made. ANI provided pre-production design, development, and engineering work. The licensee will pay a royalty of 10% of the sales of the products containing the hydrogen sensors. In order to maintain its exclusivity, Kelman must make cumulative minimum royalty payments of $1.0 million by June 30, 2006, $2.5 million by June 30, 2007, and $4.5 million by June 30, 2008. Due to a redesign of the hydrogen sensor, the introduction of Kelman’s product has been delayed beyond the date anticipated when the agreement was signed. It is likely that the time period for the previously mentioned minimum royalty payments will be extended by some amount of time.

 
 
We also have a research and development agreement with KRI, Inc, the research and development subsidiary of Osaka Gas Co. Ltd., the second largest gas utility company in Japan, to develop a hydrogen sensor for automotive fuel cell applications. This contract is the result of a joint proposal submitted by KRI and ANI to NEDO, the New Energy Industrial Technology Development Organization established by the Japanese Government in 1980. The initial phase of the project was completed by the end of 2005, and we are currently seeking additional funding in this area.
 
Carbon Monoxide Sensors. We have developed a carbon monoxide sensor that is based on a “gated” metal oxide approach that allows the sensor to operate without heating, as compared with most carbon monoxide sensors that require heating to greater than 250 degrees Celsius. Our carbon monoxide sensor was originally developed in connection with a SBIR phase I government contract with the Department of Defense. We expect to receive a SBIR phase II contract to continue development to of this sensor. Our approach to the carbon monoxide sensor allows the sensor to operate at low power with instant-on operation. The sensor will be specific to carbon monoxide with no cross sensitivity to other gases and elements and is also easily portable and highly sensitive.
 
Other sensors. We have also demonstrated that carbon nanotubes can be used to develop sensors for chemical, organic, and biological warfare agents. We have also demonstrated that carbon nanotubes and other nanodetectors can be used for the remote detection of explosives, and sensors used in environmental monitoring, health care, the food industry, biotech-biopharma applications, genetic biosensors, and immunosensors. We are currently seeking funding to take our research in this area to the next level of development, which would include proofs of concept, and product development. Ideally we would do this with a development partner that would fund the development and license the technology for manufacturing upon completion, or in conjunction with a development partner under a government funding program. We most likely would have different development partners for different sensors that may be used in different industries.
 
Competition. Our competition in the sensor area will come from a variety of technologies and companies depending on the purpose and use of the sensor. There are other technologies used as sensors; however, we believe carbon nanotube based sensors and other nanodetectors are more versatile, can sense a broader range of materials, and are more selective (sensitive) in their sensor results. We believe that selecting the right strategic partners for development of proof of concepts for our sensor technology is an important step in the market acceptance of sensors using our technology.
 
Functional Nanomaterials
 
We are in the advanced stages of research into nanomaterials using carbon nanotube composites. We believe that some of the first widespread use of nanotechnology by established companies will be in this area as they work to improve existing products, materials, and processes. A significant opportunity exists in this area for us to develop and license our technology. We are currently exploring opportunities with several companies in this area.
 
Shimane Institute of Technology. We recently completed a research and development agreement with Shimane Institute for Industrial Technology (SIIT) to develop a new aluminum alloy using carbon nanotubes that has thermal conductivity 4-5 times greater than aluminum metal. SIIT is a technology organization fully supported by the government of Shimane Prefecture, Japan. We recently completed the first phase of the contract and are negotiating a second phase of the project to continue development. Applications include any microelectronic device that generates heat, including circuit boards for computers and high powered radar. These alloys can also improve the strength of the aluminum without adding weight.



Photoscrub™ Technology. We developed a concept called Photoscrub™ which is based on an air purification technology originally developed by one of our strategic partners, Andes Electric Co., Ltd. The Photoscrub™ is a thin film coating on a flexible fiberglass cloth that decomposes pollutants at the molecular level in liquids and gases. The 2006 Defense Appropriations Bill signed by President Bush in December 2005 included $1 million in funding for ANI to improve the efficiency of the concept and explore other air purification concepts.

Large Sporting Goods Manufacturer. In September 2005, we signed a development contract with a large sporting goods manufacture to develop nanocomposites to be used in the manufacturer’s sporting equipment. ANI will receive $240,000 for the initial phase of the project, which is expected to last approximately one year. The goal of the project is to improve the existing base materials currently used by the contractor to make the equipment stronger, lighter, and more powerful.

Competition. Since this is a developing area of nanotechnology, there are not established competitors. Our competition would come from companies working with other materials. Since each project is unique, there are not necessarily established competitors in the market.
 
Other Electronic Applications
 
We are working in several other areas that have grown out of our basic work in the FED area. These technologies are related to previously discussed applications in that they use common materials, such as carbon nanotubes, use similar processes, capitalize on knowledge that we have gained in our research in other areas, or take advantage of unique capabilities of our technical staff. Following is a summary of some of these technology areas.
 
Cathodes. We have developed a carbon nanotube cold cathode electron source, which can be utilized for many non-display related applications such as x-ray tubes, medical devices, microelectronics, low-power thrusters, CRT electron guns, wireless communications, and polluted air scrubbing. In previous years we sold cathodes using this technology to Oxford Instruments for use in their portable Horizon 600 hand-held XRF Spectrometer, an X-ray device used for alloy sorting, materials identification, and inorganic analysis. These cathodes use our proprietary carbon nanotube technology, however Oxford Instruments claims that they discontinued use of these cathodes in their product and moved to a different technology.
 
Memory Chips. We have a license option agreement with the University of Texas at Austin to further the development of a next generation memory chip using the university’s information storage technology based on thin photo-conductive films. The ultimate goal is to make a low cost non-volatile memory device with increased capacity. We have demonstrated an initial proof of concept of the technology and in the next step we will be designing, fabricating, and optimizing a 10,000-bit proof of concept using this technology. We have had initial discussions with major chip manufacturers regarding this technology, however additional development work is needed before these manufactures are willing to enter a license agreement. We retain our exclusive right to license this technology, including the right to sublicense, within certain pre-defined parameters through the end of 2006.
 
Shimane Masuda Electronics. We completed a development project with Shimane Masuda Electronics (“SME”) in 2005. Upon completion of this project we entered into an agreement with SME to establish a joint pilot line for the development and production of carbon nanotube electron emission based lighting devices. This pilot line will be located in an SME facility, and SME will supply all necessary equipment and personnel to develop, engineer, and operate the line. ANI will contribute technical support, intellectual property, and know-how. The pilot period is expected to be completed by June 30, 2006, and should SME decide to go into volume production, they will license ANI’s technology for an upfront payment of 10 to 25 million yen (approximately $85,000 to $213,000 at current exchange rates) and an ongoing royalty rate of 5% of all product sales using CNT electron sources. SME’s territory will be limited under the license to products sold in Asia.
 
Competition. Numerous other companies are working with other technologies with the goal of achieving results similar to the goals of our technology. The ultimate success of products using our technology will be dependent up on the results of our research compared with results achieved by others.


 
EBT
 
Electronic Display Products.  EBT was formed to develop sun-readable display products for outdoor use.  We quickly expanded our focus to large area displays for indoor use that would compete with Plasma and could be used as part of an overall point of purchase advertising program and developed a patented product called the E-Window™. We restructured EBT, stopped selling products directly, and instead limited ourselves to licensing our intellectual property. At the present time, we are not developing the technology further, but are actively pursuing technology licenses at EBT.
 
We expect that any license agreements would include both an upfront payment and ongoing royalties based on product sales by the licensee. We expect that potential licensees for the E-Window™ would market it, primarily to major retailers and to either manufacture the product, or contract with others to manufacture the product.
 
EBT also has acquired the right to certain patented Liquid Crystal Display (“LCD”) technology that is ideal for use in outdoor electronic billboards. All research and development related to this technology has been suspended until we procure funding specifically to further develop this technology.
 
Communication patents. We have applied for patents covering a system of selling advertising for electronic displays over the internet and other digital networks. The first of the patents, which was filed in April 2000 with a priority date of April 1999, was recently allowed in February 2006. The allowed claims on this patent relate to methods, systems and computer programs that facilitate displaying advertising information on multiple indoor or outdoor electronic displays. We have also applied for similar patents and have applications pending in Europe, Canada, Korea, and Japan.
 
With the exponential growth that digital advertising is currently experiencing, we expect these patents to have significant value, and we expect to generate significant revenue in 2006 as a result of these patents. These patents apply to situations where the placement of digital ads is remotely controlled using the internet and other digital networks. Examples of locations where these displays may be located include high traffic locations such as airport or trains stations, indoor and outdoor sports arenas, digital point of purchase and other advertising in national, regional, and local retailers, as well as other high traffic locations. We expect to generate revenue with these patents by licensing them to others, or combining our resources with industry leaders to deploy the technology resulting from this intellectual property, or through some combination of these two methods.
 
Competition Our E- Window™ product is a unique patented product. It does, however, face competition from a variety of other indoor display products from a variety of sources. Our success in this area will be dependent on the ability of licensees to successfully market our products. Our communication patents are unique and any organization involved in digital advertising using these methods will require a license. Competition would come from more manual and less efficient methods of deploying the advertising.
 
We are unaware of any other organizations that have developed an electronic billboard using an LCD technology. However, we are not currently continuing development of this technology, and LCD technology is an existing technology used in many applications. Competition from other manufacturers could develop at any time. There are several other companies either producing or developing electronic billboards using other technologies.
 
Technology Agreements
 
Till Keesman. We have licensed certain patents related to carbon nanotube technology from Till Keesman (“the Keesman patents”). We licensed 6 patents in 2000 in exchange for a payment of $250,000. Under the terms of the agreement, we are obligated to pay license fees equal to 50% of any royalties received by the Company related to these patents. We are allowed to offset certain expenses, up to a maximum of $50,000 per year, against payments due under this agreement. The agreement also contains provisions related to minimum license fee payments. A total of $1,000,000 of minimum payments has been made, with the last payment made in May 2004. No future minimum payments are due and the minimum payments made to date can be offset against future royalties due under the license agreement. Certain of the products that we are developing may, in part, be based on some of the patents that we have licensed. These patents cover areas using the emission from a carbon nanotube, such as displays. There are other areas of carbon nanotube technology, such as biosensors, that are not based on an emission from the carbon nanotube, and therefore would not require payment of a royalty under this license agreement.
 


 
MCC. We acquired 62 patents and patent applications related to the carbon film based field emission technology from MCC in 1998.  We are obligated to pay MCC a royalty of 2% of future commercial revenues related to these patents. We can, however, offset certain pre-defined expenses against these royalty payments. Based on the expenses incurred and cost of maintaining the patents, it is considered remote that we will be required to pay MCC any royalties at any time in the future.
 
Intellectual  Property Rights
 
An important part of our product development strategy is to seek, when appropriate, protection for our products and proprietary technology through the use of various United States and foreign patents. Our patent portfolio consists of 116 issued patents, 4 allowed patents, 99 patent applications pending before foreign and United States Patent and Trademark Offices, 26 provisional patent applications, and 4 published patents. We also have several unsubmitted patent applications in process. The patents, allowances and applications relate to the carbon nanotube field emission technology and other technologies. In addition, there are foreign counterparts to certain United States patents and applications. We consider our patent portfolio to be extremely valuable.
 
The patenting of technology-related products and processes involves uncertain and complex legal and factual questions. To date, no consistent policy has emerged regarding the breadth of claims of such technology patents. Therefore, there is no assurance that our pending United States and foreign applications will issue, or what scope of protection any issued patents will provide, or whether any such patents ultimately will be upheld as valid by a court of competent jurisdiction in the event of a legal challenge. Interference proceedings, to determine priority of invention, also could arise in any of our pending patent applications. The costs of such proceedings would be significant and an unfavorable outcome could result in the loss of rights to the invention at issue in the proceedings. If we fail to obtain patents for our technology, and are required to rely on unpatented proprietary technology, there is no assurance that we can protect our rights in such unpatented proprietary technology, or that others will not independently develop substantially equivalent proprietary products and techniques, or otherwise gain access to our proprietary technology.
 
Competitors have filed applications for, or have been issued patents, and may obtain additional patents and proprietary rights relating to products or processes used in, necessary to, competitive with, or otherwise related to, our patents. The scope and validity of these patents, the extent to which we may be required to obtain licenses under these patents, or under other proprietary rights and the cost and availability of licenses are unknown. This may limit our ability to license our technology. Litigation concerning these or other patents could be protracted and expensive. If suit were brought against us for patent infringement, a challenge in the suit by us as to the validity of the other patent would have to overcome a legal presumption of validity. There can be no assurance that the validity of the patent would not be upheld by the court or that, in such event, a license of the patent to us would be available. Moreover, even if a license were available, the payments that would be required are unknown and could materially reduce the value of our  interest in the affected products. We do, however, consider our patents to be very strong and defendable in any action that may be brought against us. A major law firm has reviewed our patent portfolio and agreed to handle litigation related to certain of our patents on a contingency basis.
 
We also rely upon unpatented trade secrets. No assurances can be given that others will not independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose such technology or that we can meaningfully protect our rights to our unpatented trade secrets.
 
We require our employees, directors, consultants, outside scientific collaborators, sponsored researchers, and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information developed or made known to the individual during the course of the relationship is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual shall be our exclusive property. There is no assurance, however, that these agreements will provide meaningful protection for our trade secrets in the event of unauthorized use or disclosure of such information.
 


Government Regulation
 
Products using our technology will be subject to extensive government regulation in the United States and in other countries. In order to produce and market existing and proposed products using our technology, our licensees must satisfy mandatory safety standards established by the U.S. Occupational Safety and Health Administration ("OSHA"), pollution control standards established by the U.S. Environmental Protection Agency ("EPA") and comparable state and foreign regulatory agencies. We may also be subject to regulation under the Radiation Control for Health and Safety Act administered by the Center for Devices and Radiological Health ("CDRH") of the U.S. Food and Drug Administration. We do not believe that carbon nanotube field emission products will present any significant occupational risks to the operators of such equipment.  In addition, the carbon nanotube field emission products are not expected to produce significant hazardous or toxic waste that would require extraordinary disposal procedures.   Nevertheless, OSHA, the EPA, the CDRH and other governmental agencies, both in the United States and in foreign countries, may adopt additional rules and regulations that may affect us and products using our technology. Additionally, our arrangements with our licensees and their affiliates may subject products using our technology to export and import control regulations of the U.S. and other countries. The cost of compliance with these regulations has not been significant in the past and is not expected to be material in the future.
 
A portion of our revenue has consisted of reimbursement of expenditures under U.S. government contracts. We recognized $208,211 of revenue in 2005, $305,721 in 2004, and $339,790 in 2003 related to government contracts. These reimbursements represent all or a portion of the costs associated with such contracts. As of December 31, 2005, we have three grants in process that have minor amounts of revenue yet to be recognized. We also have commitments for three additional grants which, in total, will result in approximately $2.5 million of future revenue. Government contracts are subject to delays and risk of cancellation. Also, government contractors generally are subject to various kinds of audits and investigations by government agencies. These audits and investigations involve review of a contractor's performance on its contracts, as well as its pricing practices, the costs it incurs and its compliance with all applicable laws, regulations and standards. We are, and in the future expect to be, audited by the government.
 
Employees
 
As of February 24, 2006 we had 29 full-time employees, including 4 executive officers. Within the next twelve months, based on new government contracts that we have received and expect to receive, we likely will hire two to four additional employees to support our plans for increasing research levels. We are not subject to any collective bargaining agreements and we consider our relations with our employees to be good.
 
Available Information
 
Our website is http://www.nano-proprietary.com. Our periodic reports and all amendments to those reports required to be filed or furnished pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 are available free of charge through its website. During the period covered by this report, the Company made its periodic reports on Form 10-K, and Form 10-Q and its current reports on Form 8-K and amendments to those documents available on its website as soon as reasonably practicable after those reports were filed with or furnished electronically to the Securities and Exchange Commission. The Company will continue to make such reports and amendments to those reports available on its website as soon as reasonably practicable after those reports are filed with or furnished to the Securities and Exchange Commission. Material contained on our website is not incorporated by reference in this Annual Report on Form 10-K.
 


 
Item 1A.   Risk Factors
 
Our success is dependent on our principal technologies
 
Our technologies, which include sensors, field emission displays, nano-electronics, and functional nano-materials, are emerging technologies. Our financial condition and prospects are dependent upon our licensing these technologies to others. Additional R&D needs to be conducted on many of our technologies before others can produce products using this technology. Market acceptance of products using our technology will be dependent upon the acceptance within the industries of those products of the quality, reliability, performance, efficiency, and breadth of application and cost-effectiveness of the products. There can be no assurances that these products will be able to gain commercial market acceptance.
 
Products using our technology may not be accepted by the market
 
Since our inception, we have focused our product development and R&D efforts on technologies that we believe will be a significant advancement over currently available technologies. With any new technology, there is a risk that the market may not appreciate the benefits or recognize the potential applications of the technology. Market acceptance of products using our technology will depend, in part, on our ability to convince potential customers of the advantages of such products as compared to competitive products. It will also depend upon our ability to train manufacturers and others to use our products.
 
Our technology development is in its early stages and the outcome is uncertain
 
Our many applications of nanotechnologies, and certain products that use these technologies, will require significant additional development, engineering, testing and investment prior to commercialization. We are exploring the use of our technology in several different types of products, in addition to the cathodes that we have developed that currently use carbon nanotube technology. We have developed proof of concepts of potential products based on carbon nanotube technologies. In some cases, we are developing products jointly with others based on our technology. Upon successful completion of the development process, our development partners will be required to license our technology to produce and sell the products. Our development partners retain all rights to any intellectual property that they develop in the process.
 
If any of the potential products that are being developed using our technologies are successfully developed, it may not be possible for potential licensees to produce these products in significant quantities at a price that is competitive with other similar products. At the present time, the only significant revenue that we receive related to our technology is related to reimbursed research expenditures, and development fees. These revenues are identified in our quarterly filings on Form 10-Q and our annual filings on Form 10-K as revenues of our Applied Nanotech, Inc. subsidiary in the related “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections. We also anticipate receiving up-front license fees in 2006.
 
Our development partners have certain rights to jointly developed property and to license our technology
 
We have committed to license our technology to our development partners upon completion of certain development projects that are in process. The terms of any such license have not yet been determined. One of our development partners, a large Japanese display company, has paid us $2.0 million for research services and has the right to offset this payment against any future license fee payments due as a result of an existing license agreement that we have with this company. Our development partners in the HYFED™ project also have rights to any jointly developed property; however, any such jointly developed property would be based, at least in part, on our underlying technology and would require our partners to enter into an agreement with us. See also “Our technology development is in its early stages and the outcome is uncertain” above for further discussion.
 
We have limited resources and our focus on particular products may result in our failure to capitalize on other opportunities
 
We have limited resources available to successfully develop and commercialize our technology. As of February 24, 2006, we had 29 full-time employees. There is a wide array of potential applications for our technology and our limited resources require us to focus on specific product areas, while ignoring others.
 


 
We may not be able to provide system integration
 
In order to prove that our technologies work and will produce a complete product, we must ordinarily integrate a number of highly technical and complicated subsystems into a fully integrated prototype. There is no assurance that we will be able to successfully complete the development work on some of our proposed products or that there will ultimately be any market for those products.
 
Many products that may be developed using our technology will have to be integrated into end-user products by manufacturers of those products. Although we intend to develop products to be integrated into existing manufacturing capabilities, manufacturers may be required to make modifications to, or expand their manufacturing capabilities. Manufacturers may not elect to integrate products using our technology into their end-user products, or they may not devote adequate resources to modifying their manufacturing capabilities so that our technologies can be successfully incorporated into their end-user products. The complexity of integration may delay the introduction of products using our technology.
 
Rapid technological changes could render our technology obsolete and we may not remain competitive
 
The display industry and other industries in which we compete are highly competitive and are characterized by rapid technological change. Our existing and proposed products will compete with other existing products and may compete against other developing technologies. Development by others of new or improved products, processes or technologies may reduce the size of potential markets for our products. There is no assurance that other products, processes or technologies will not render our proposed products obsolete or less competitive. Many of our competitors have greater financial, managerial, distribution, and technical resources than we do. We will be required to devote substantial financial resources and effort to further R&D. There is no assurance that we will successfully differentiate our technology from our competitors' technology, or that we will adapt to evolving markets and technologies, develop new technologies, or achieve and maintain technological advantages.
 
We have limited manufacturing capacity and experience
 
We have no established commercial manufacturing facilities in the areas in which we are conducting our principal research. At the present time, we have no intention of establishing a manufacturing facility related to our field emission technology, sensors, nanomaterials which include using composites, or any other aspects of our technology. We are focusing our efforts on licensing our technology to others for use in their manufacturing processes. To the extent that any of our other products require manufacturing facilities, we intend to contract with a qualified manufacturer.
 
The health effects of nanotechnology are unknown
 
There is no scientific agreement on the health effects of nanomaterials, but some scientists believe that in some cases, nanomaterials may be hazardous to an individual’s health or the environment. The science of nanotechnology is based on arranging atoms in such a way as to modify or build materials not made in nature; therefore the effects are unknown. The Company takes appropriate precautions for its employees working with carbon nanotubes and believes that any health risks related to carbon nanotubes used in potential products can be minimized. Future research into the effects of nanomaterials in general, and carbon nanotubes in particular, on health and environmental issues may have an adverse effect on products using our technology.
 
The loss of key personnel could adversely affect our business
 
Our future success will depend on our ability to attract and retain highly qualified scientific, technical and managerial personnel. Competition for such personnel may be intense. We may not be able to attract and retain all personnel necessary for the development of our business. In addition, much of the know-how and processes developed by us reside in our key scientific and technical personnel. The loss of the services of key scientific, technical and managerial personnel could have a material adverse effect on us until we are able to replace those personnel.
 


 
We have a history of net losses
 
We have a history of net losses. From our inception through December 31, 2005, we incurred net losses of approximately $85 million. Our only profitable year was 1999, based on the strength of a license agreement of approximately $5.6 million signed in March 1999.  We have incurred net income and  losses as shown below:
 
 
Year Ended December 31 
 
Net Income
(Loss)
 
 
 
1995
 
($14,389,856)
1996
 
($13,709,006)
1997
 
($6,320,901)
1998
 
($3,557,548)
1999
 
$1,118,134 
2000
 
($7,671,014)
2001
 
($5,081,559)
2002
 
($4,908,856)
2003
 
($4,214,202)
2004
 
($4,612,026)
2005
 
($4,661,534)
 
Although we expect to be profitable in the future, we may not be.  Our profitability in 2006 is dependent on the signing of additional license agreements or obtaining additional research funding. We may, however, continue to incur additional operating losses for an extended period of time as we continue to develop our technologies. We do, however, expect the magnitude of those losses, if they continue, to decrease. We have funded our operations to date primarily through the proceeds from the sale of our equity securities and debt offerings. We are primarily a contract research and development organization and are dependent on license agreements and research funding to achieve profitability.   In order to continue development of our technology, we anticipate that substantial research and development expenditures will continue to be incurred.
 
We have no current royalty agreements producing significant revenue
 
Our future strategy is dependent on licensing our technology to other companies and obtaining royalties based on products that these licensees develop and sell. We have no plans to manufacture and sell any carbon nanotube field emission products ourselves, and as such, we have no carbon nanotube field emission product revenues. We signed a license agreement in 1999, for a one-time, up front, payment of approximately $5.6 million. This was a non-exclusive license to Canon, Inc. that covered substantially all of our field emission patents, but excluding the basic carbon nanotube patent and specific applications for other field emission display patents including, but not limited to, large area color displays. This license will produce no future revenue unless Canon decides to license the additional patents or the excluded field emission display applications. In 2002, we signed another license agreement with a large Japanese display manufacturer. This license agreement calls for us to be paid royalties equal to 2% of the licensee’s sales of products using our technology. The licensee also will receive credit against royalties due under the agreement for $2 million of research funding and up-front payments that the licensee has provided to us from 2001 to 2003. Accordingly, no royalties will be due under the agreement until sales of the licensee’s products exceed $100 million.
 
We expect to license our technology to be used in other applications. See additional discussion in the risk factor “Our technology development is in its early stages and the outcome is uncertain”. It is our intention that all future license agreements will include a provision that requires the payment of ongoing royalties, although there is no assurance that will occur. 
 
We are dependent on the availability of materials and suppliers
 
The materials used in producing current and future products using our technology are purchased from other vendors. We anticipate that the majority of raw materials used in products to be developed by us will be readily available to manufacturers. However, there is no assurance that the current availability of these materials will continue in the future, or if available, will be procurable at favorable prices.
 


Our revenues have been dependent on government contracts in the past
 
In many years, a significant part of our revenues is derived from contracts with agencies of the United States government. Following is a summary of those revenues for the past eleven years:
 
Year Ended December 31
 
 
 
Revenues from
Government
Contracts
 
 
 
Percentage of
Total Revenue
1995
 
$1,009,000
 
33%
1996
 
$2,869,000
 
50%
1997
 
   $854,000
 
24%
1998
 
             $0
 
 0%
1999
 
             $0
 
 0%
2000
 
   $352,341
 
13%
2001
 
   $466,680
 
15%
2002
 
   $254,152
 
18%
2003
 
   $339,790
 
44%
2004
 
   $305,721
 
80%
2005
 
   $208,211
 
37%
 
We currently have commitments for future government funding of approximately $2.6 million. We do not intend to seek any government funding unless it directly relates to achievement of our strategic objectives.
 
Contracts involving the United States government are, or may be, subject to various risks including, but not limited to, the following:
 
·  
Unilateral termination for the convenience of the government
 
·  
Reduction or modification in the event of changes in the government's requirements or budgetary constraints
 
·  
Increased or unexpected costs causing losses or reduced profits under fixed-price contracts or unallowable costs under cost reimbursement contracts
 
·  
Potential disclosure of our confidential information to third parties
 
·  
The failure or inability of the prime contractor to perform its prime contract in circumstances
 
 where we are a subcontractor
 
·  
The failure of the government to exercise options provided for in the contracts
 
·  
The right of the government to obtain a non-exclusive, royalty free, irrevocable world-wide license to technology developed under contracts  funded by the government if we fail to continue to develop the technology
 
We have technologies subject to licenses
 
As a licensee of certain research technologies through license and assignment agreements with Microelectronics and Computer Technology Corporation (“MCC”), we have acquired rights to develop and commercialize certain research technologies. In certain cases, we are required to pay royalties on the sale of products developed from the licensed technologies and fees on revenues from sublicensees. We also have to pay for the costs of filing and prosecuting patent applications. The agreement is subject to termination by either party, upon notice, in the event of certain defaults by the other party. We consider it unlikely that any royalty payments would be required to be made to MCC based on the substantial amounts of revenues that would have to be generated to offset the costs of maintaining the patents over the years.
 
We have also licensed certain patents related to carbon nanotube technology from Till Keesman (“the Keesman patents”). We licensed 6 patents in 2000 in exchange for a payment of $250,000. Under the terms of the agreement, we are obligated to pay license fees equal to 50% of any royalties received by the Company related to these patents. We are allowed to offset certain expenses, up to a maximum of $50,000 per year, against payments due under this agreement. The agreement also contains provisions related to minimum license fee payments. A total of $1,000,000 of minimum payments has been made, with the last payment made in May 2004. No future minimum payments are due and the minimum payments made to date can be offset against future royalties due under the license agreement. No license agreements have yet been signed that involve the Keesman patents. Certain of the products that we are developing may, in part, be based on some of the patents that we have licensed.
 


 
We may have future capital needs and the source of that funding is uncertain
 
We expect to continue to incur substantial expenses for R&D, product testing, and administrative overhead. The majority of R&D expenditures are for the development of our technologies. Some of the proposed products using our technology may not be available for commercial sale or routine use in the immediate future. Commercialization of existing and proposed products that would use our technology may require additional capital in excess of that currently available to us. A shortage of capital could prevent us from achieving profitability for an extended period of time. Because the timing and receipt of revenues from the sale of products using our technology will be tied to the achievement of certain product development, testing, manufacturing and marketing objectives, which cannot be predicted with certainty, there may be substantial fluctuations in our results of operations. If revenues do not increase as rapidly as anticipated, or if product development and testing require more funding than anticipated, we may be required to curtail our activities and/or seek additional financing from other sources. We may seek additional financing through the offer of debt, equity, or any combination of the two at any time, although we do not expect to seek any significant additional financing for the remainder of the year.
 
We have developed a plan to allow us to maintain operations until we are able to sustain ourselves and we believe our current cash levels are sufficient to fund operations until we reach that point. We have the existing resources, including expected revenue, to continue operations for a period through at least the end of 2006. Our plan is primarily dependent on raising funds through the licensing of our technology and revenue generated from performing contract research services. We intend to raise additional capital through debt or equity offerings, only if necessary. We expect to sign significant license and development contracts within the next year, although there is no assurance that this will occur.
 
Our plan is based on current development plans, current operating plans, the current regulatory environment, historical experience in the development of electronic products and general economic conditions. Changes could occur which would cause certain assumptions on which this plan is based to be no longer valid. Our plan is primarily dependent on increasing revenues, licensing our technology, and raising additional funds through additional debt and equity offerings, only if necessary. If adequate funds were not available from operations or additional sources of financing, we may have to eliminate, or reduce substantially, expenditures for research and development, and testing of our products. We may have to obtain funds through arrangements with other entities that may require us to relinquish rights to certain of our technologies or products. These actions could materially and adversely affect us.
 
We may be unable to enforce or defend our ownership and use of proprietary technology
 
Our ability to compete effectively with other companies will depend on our ability to maintain the proprietary nature of our technology. Although we have been awarded patents, have filed applications for patents, or have licensed technology under patents that we do not own, the degree of protection offered by these patents or the likelihood that pending patents will be issued is uncertain. Competitors in both the United States and foreign countries, many of which have substantially greater resources and have made substantial investment in competing technologies, may already have, or may apply for and obtain patents that will prevent, limit or interfere with our licensees ability to make and sell our products using our technology. Competitors may also intentionally infringe on our patents. The defense and prosecution of patent suits is both costly and time-consuming, even if the outcome is favorable to us. In foreign countries, the expenses associated with such proceedings can be prohibitive. In addition, there is an inherent unpredictability in obtaining and enforcing patents in foreign countries. An adverse outcome in the defense of a patent suit could subject us to significant liabilities to third parties. Although third parties have not asserted infringement claims against us, there is no assurance that third parties will not assert such claims in the future. A major law firm has reviewed our patent portfolio and agreed to handle litigation related to certain of our patents on a contingency basis.
 
We also rely on unpatented proprietary technology, and there is no assurance that others will not independently develop the same or similar technology, or otherwise obtain access to our proprietary technology. To protect our rights in these areas, we require employees, consultants, advisors and collaborators to enter into confidentiality agreements. These agreements may not provide meaningful protection for our trade secrets, know-how, or other proprietary information in the event of any unauthorized use, misappropriation or disclosure of such trade secrets, know-how, or other proprietary information. While we have attempted to protect proprietary technology that we develop or acquire and will continue to attempt to protect future proprietary technology through patents, copyrights and trade secrets, we believe that our success will depend upon further innovation and technological expertise.
 
 

 


 
We are exposed to litigation liability
 
We have lawsuits that arise in the normal course of business. We have been subject to litigation in the past and have settled litigation in the past that has in rare instances resulted in material payments. We expect all current lawsuits to be resolved with no material negative impact on our financial statements, and we are unaware of any other potential significant litigation. If we were to become subject to a judgment that exceeds our ability to pay, that judgment would have a material impact on our financial condition and could affect our ability to continue in existence. 
 
As described in more detail in Item 3, we are the plaintiff in litigation against, Canon, Inc. While there is risk associated with any litigation, we expect no negative impact on our financial condition as a result of this litigation.
 
Item 1B.  Unresolved Staff Comments 
 
None.
 
 
We lease a facility in Austin that is used for our corporate headquarters and research and development activities under a lease expiring in February 2007. We also lease office space in Dallas on a month to month basis.
 
We believe that these facilities are suitable and will be adequate for our anticipated research, development, and administrative activities for the foreseeable future.  If we embark on significant new research that requires significant additional employees, we may have to establish additional facilities.
 
We do not currently invest in real estate or interests in real estate, real estate mortgages, or securities of or interests in persons primarily engaged in real estate activities. However, the Company has no policy, either for or against, making such investments.
 
 

 


 Item 3.   Legal Proceedings

In April 2005, we filed suit against Canon, Inc. and Canon USA, Inc. in the U.S. District Court for the Western District of Texas, Austin Division. We are seeking a declaratory judgment that new SED color television products, scheduled to be manufactured by SED, Inc. and sold by Canon and/or Toshiba beginning in 2006, are not covered under a 1999 patent license agreement that we have with Canon.  We assert that Canon’s license does not cover its surface conductor electron emitter display screens (SED) for a new generation of flat screen color televisions. We also assert that SED,Inc., the joint venture formed by Canon and Toshiba Corporation to produce the SED display screens, is not a licensed subsidiary under the 1999 agreement and that Canon is improperly transferring its license rights under Nano-Proprietary's patents to the joint venture and Toshiba.

The suit also contained three additional claims related to a Lanham Act violation by Canon, tortious interference by Canon, and a breach of covenant of good faith and fair dealings against Canon. Canon filed its response in July 2005 denying liability in the matter. In September 2005, Canon filed a motion to dismiss Canon USA, Inc. from the case and dismiss the Lanham Act claim, the tortious interference claim, and the breach of covenant of good faith and fair dealings. In October 2005, the judge in the case denied Canon’s motion to dismiss Canon, USA, Inc. and the breach of covenant of good faith and fair dealings claim. The judge granted Canon’s motion, without prejudice, to dismiss the Lanham Act claim and the tortious interference claim. Dismissal without prejudice allows us to re-file these claims at any time if additional evidence supporting these claims becomes available to us in the discovery process. The first two claims described above were not at issue in the dismissal motion by Canon. The case is currently in the discovery phase and a trial may occur as soon as March 2007. We believe that the ultimate resolution of this matter will not have a negative impact on the consolidated financial statements of the Company.
 
From time to time the Company and its subsidiaries are also defendants in various lawsuits that may arise related to minor matters. It is expected that any such lawsuits would be settled for an amount no greater than the liability recorded in the financial statements for such matters.  If resolution of any of these suits results in a liability greater than that recorded, it could have a material impact on us.
 
 

 
There were no matters submitted to a vote of security holders during the fourth quarter of 2005.
 
 
 
 
 


 
 
Item 5.   Market for Registrant's Common Stock, Related Stockholder Matters and Issuer Purchases of Equity Securities
 
Our common stock, $0.001 par value, trades on the OTC Bulletin Board system under the symbol “NNPP”. The following table sets forth, on a per share basis for the periods indicated, the high and low sale prices for the common stock as reported by the OTC Bulletin Board system. These quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.
 
   
High
Low
       
2004
First Quarter 
$3.23
$1.98
 
Second Quarter
$2.70
$1.38
 
Third Quarter 
$2.14
$1.29
 
Fourth Quarter 
$2.52
$1.80
 
 
 
 
2005
First Quarter
$3.53
$2.01
 
Second Quarter
$3.99
$1.56
 
Third Quarter 
$2.81
$1.86
 
Fourth Quarter 
$2.45
$1.97
 
 
   
2006
First Quarter (through February 24, 2006)
$2.68
$2.05
 
On February 24, 2006, the closing sale price for our common stock as reported on the OTC Bulletin Board system was $2.55.  As of February 24, 2006, there were approximately 350 shareholders of record for our common stock. This does not include shareholders holding stock in street name in brokerage accounts.
 
We have never paid cash dividends on our common stock, nor do we have any plans to pay dividends. Our board of directors currently intends to invest future earnings, if any, to finance expansion of our business. Any payment of cash dividends in the future will be dependent upon our earnings, financial condition, capital requirements, and other factors deemed relevant by our board of directors. It is unlikely that any dividends on our common stock will be paid in the foreseeable future.
 
Recent Sales of Unregistered Securities
 
In October 2005, we issued 482,393 shares of our common stock for $1,000,000 in a private placement under Rule 506 of Regulation D of the Securities Act of 1933 to the Pinnacle Fund, LP.
 
 

















Item 6. Selected Financial Data

   
2005
 
2004
 
2003
 
2002
 
2001
                     
Revenues from continuing operations
$
565,660 
$
382,522 
$
773,959 
$
1,414,848 
$
1,101,951 
                     
Income (loss) from continuing operations
$
(4,661,534)
$
(4,612,026)
$
(4,214,202)
$
(4,683,419)
$
(4,850,770)
                     
Income (loss) from continuing operations per share
$
(0.05)
$
(0.05)
$
(0.05)
$
(0.07)
$
(0.07)
                     
Total assets
$
1,187,981 
$
1,144,368 
$
3,784,017 
$
321,955 
$
1,839,055 
                     
Long-term obligations
$
— 
$
5,944 
$
27,353 
$
46,283 
$
121,651 
                     
Net shareholders’ equity (deficit)
$
859,339 
$
846,456 
$
3,552,829 
$
(2,460,595)
$
(945,614)
                     
Cash dividends per common share
$
— 
$
— 
$
— 
$
— 
$
— 


In 2002, we sold our Sign Builders of America, Inc. subsidiary. All information related to Sign Builders has been removed from this summary as a result of its presentation as a discontinued operation. Also in 2002, we restructured our Electronic Billboard Technology, Inc. subsidiary. EBT no longer sells products or services, but seeks to license its intellectual property to others. Revenue from continuing operations includes $130,386 and $10,000 in 2003 and 2002, respectively. There was no revenue from EBT in all other years presented.

 
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
The following discussion should assist in understanding our financial condition, liquidity, and capital resources as of December 31, 2005, and the results of operations for the years ended December 31, 2005, 2004 and 2003. The Notes to our Consolidated Financial Statements included later in this report contain detailed information that should also be read in conjunction with this discussion.
 
OVERVIEW
 
Nano-Proprietary, Inc. is engaged in research and development related to nanotechnology products, primarily those involving carbon nanotubes, to be used in the display, electronics, sensor, and other industries. Our technology and many of its potential applications are still new and in the early stages of development. Our revenue has primarily consisted of development projects involving either the U.S. government or large multinational corporations.
 
OUTLOOK
 
We expect our cash needs for 2006 to be approximately $6.0 million. We intend to fund those needs through a combination of sales, reimbursements for research, and license agreements. We anticipate receiving significantly more revenue in 2006 than was received in 2005. We have developed a plan to enable us to achieve positive cash flow from operations with approximately $6.0 million of revenue. As of February 24, 2006, we have approximately $2.0 million in cash to cover any potential revenue shortfall that may occur for the year. Our cash balance includes $1.5 million from equity that we raised in February 2006. We do not expect to need to raise any additional equity in 2006.
 
Our plan is to generate sufficient revenues in 2006 to achieve breakeven or better; however, losses may continue as we continue to fund the development of field emission technology, sensors, nano-electronics, and nanomaterials. There can be no assurances that we will be profitable in the future.  Full commercial development of our technology may require additional funds in the future.   We expect to continue our concentrated research and development of ANI’s technology in 2006.
 
We have developed a plan to allow ourselves to maintain operations until we are able to sustain ourselves on our own revenue. Our plan is primarily dependent on raising funds through the licensing of our technology and through reimbursed research arrangements. Our current cash balances are adequate to insure that we can maintain our operations at the present level. We believe that we have the ability to continue to secure short term funding, if needed, to enable us to continue operations until our plan can be completed if this plan takes longer than anticipated.
 
This plan is based on current development plans, current operating plans, the current regulatory environment, historical experience in the development of electronic products, and general economic conditions. Changes could occur which would cause certain assumptions on which this plan is based to be no longer valid. Our plan is primarily dependent on increasing revenues. Although we do not expect funding our operations to be a problem, if adequate funds are not available from operations, or additional sources of financing, we may have to eliminate, or reduce substantially, expenditures for research and development, testing of our products, or obtain funds through arrangements with other entities that may require us to relinquish rights to certain technologies or products. Such results could materially and adversely affect us.
 
Critical Accounting Policies
 
Our significant accounting policies are summarized in the footnotes to our financial statements. Some of the most critical policies are also discussed below.
 
Stock based compensation - We have granted stock options to employees and others. In addition, all employees have the opportunity to earn additional goal-based option awards each year. In December 2004, the FASB issued Statement of Financial Accounting Standards No. 123R (Revised 2004), Share-Based Payment ("SFAS No. 123R"), which requires that the compensation cost relating to share-based payment transactions be recognized in financial statements based on the provisions of SFAS 123 issued in 1995. Up until this time, we have accounted for stock based compensation under the provisions of APB 25 and disclosed pro-forma compensation expense calculated using the Black-Scholes model in the footnotes to the financial statements.
 


 
We will be required to adopt the provisions of SFAS No. 123R in the financial statements for the quarter ended March 31, 2006. Under the provisions of SFAS No. 123R, pro-forma presentation is no longer allowed, and we will be required to record compensation expense for option grants in the financial statements. It is likely that implementation of SFAS No. 123R will have a material impact on our financial statements. The exact impact cannot be predicted because it is dependent on future factors that can not be determined at the present time, such as the volatility of our common stock and the number of options granted. Had we been accounting for stock based compensation using SFAS 123 during the period covered by the report, the effect would have been as shown in the following table:
 
   
2005
       
2004
       
2003
Net Loss  
 
 
 
 
 
As reported
$(4,661,534)
 
$(4,612,026)
 
$(4,214,202)
SFAS No. 123 Charge
   1,182,482
 
   2,259,387
 
     552,927
Pro Forma
  (5,844,016)
 
 (6,871,413)
 
   (4,767,129)
Net income (loss) per common share - basic and diluted 
 
 
 
 
 
As reported
$(0.05)
 
$(0.05)
 
$(0.05)
Pro Forma 
$(0.06)
 
$(0.07)
 
$(0.05)
 
Other - As a matter of policy, we review our major assets for impairment. Our major operating assets are accounts receivable, and property and equipment. We depreciate our property and equipment over their estimated useful lives. We recorded impairment charges in 2002, but did not identify any impaired items in 2003, 2004 or 2005. We have not experienced significant bad debts expense, and we do not believe that we need an allowance for doubtful accounts for any exposure to loss in our December 31, 2005 accounts receivable.      
 
 
LIQUIDITY AND CAPITAL RESOURCES
 
 
Our cash balance was $897,247 at December 31, 2005, which was approximately the same as the cash balance of $901,585 at December 31, 2004. Our working capital was approximately $700,000 at both December 31, 2005 and 2004. During the same period, our current ratio remained relatively constant at approximately 3.3 to 1.
 
 
The principal source of our liquidity has been funds received from exempt offerings of common stock. Cash provided by financing activities was $4,519,913, $2,037,390, and $7,267,465 in 2005, 2004, and 2003, respectively. Of this, the majority came from private placements of our common stock in the amounts of $4,000,000, $1,065,000, and $4,812,943 in 2005, 2004, and 2003, respectively. The majority of the balance of the cash provided by financing activities in all years came from proceeds from the exercise of stock options by current and former employees. The larger than normal amount of fundraising activity in 2003 was the result of a conscious decision to raise money to solidify our financial condition and to insure that we had sufficient funds to last through the end of 2004 regardless of the revenue received in 2004, which accounts for the relatively small amount of fundraising in 2004. The fundraising activity in 2005 was to provide operating funds for 2005.
 
 
We completed another private placement of our common stock in February 2006. We raised a total of $1.5 million by issuing 750,000 shares of our common stock to provide liquidity until we reach breakeven. As of February 24, 2006, our cash balance is approximately $2.0 million. This combined with expected revenue is enough for us to operate into 2007, even if there were no significant new positive developments. We may receive additional funds from the exercise of warrants, although there is no assurance that warrants will be exercised. We may receive additional funds from the exercise of employee stock options, although a significant portion of the funds received from stock option exercises in 2005, 2004 and 2003 was from former employees that had options expiring in 2003 and 2004. There are no remaining options held by former employees and only minimal options expiring in 2006.
 
 
In the unlikely event that we need additional funds in 2006 beyond the amount that we have as of the date of this filing and those that we expect to receive as revenues, we may seek to sell additional debt or equity securities. We have no plans to do this, however. While we expect to be able to obtain any funds needed for operations, there is no assurance that any financing alternatives can be arranged on commercially acceptable terms. We believe that our success in reaching profitability will be dependent upon the viability of products using our technology and their acceptance in the marketplace.
 
 
Net cash used in operating activities was $4,507,579 in 2005, $4,581,513 in 2004, and $3,716,964 in 2003. The cash used in operations was primarily the result of the net losses incurred in each year. We expect a reduction in cash used in operating activities in 2006 as the result of an expected increase in revenues. We have a plan to
 


 
generate positive cash from operations; however, since that will require significantly increased revenues, there is no assurance that will be achieved. Such significantly increased revenues would most likely result from license agreements with significant up-front payments, or substantial research contracts. The cash used in operations was virtually unchanged from 2004 to 2005. The increase in the cash used in operating activities from 2003 to 2004 was primarily the result of three factors: A decrease in revenue of roughly $400,000, an increase in royalty payments of approximately $100,000, and generally increased spending on research and development, particularly related to prototype displays.
 
 
Cash used in investing activities was the result of the purchase of capital assets in all years. We would expect minimal cash to be used in investing activities in 2006. No material commitments exist as of December 31, 2005, for future purchases of capital assets. 
 
 
A summary of our contractual cash obligations at December 31, 2005 is as follows:
 
Contractual Obligations
   
Total
   
2006
   
2007
   
2008
   
2009
 
Notes payable including interest
 
$
 
$
 
$
 
$
 
$
 
Long-term debt including interest
   
   
   
   
   
 
Operating leases
   
207,003
   
131,891
   
34,862
   
21,000
   
19,250
 
Capital leases including interest
   
4,368
   
4,368
   
   
   
 
Total contractual cash obligations
 
$
211,371
 
$
136,259
 
$
34,862
 
$
21,000
 
$
19,250
 
 
During 2003, all convertible notes payable were converted into common stock and all long-term debt was paid in 2003 as well. We currently have no notes payable or long-term debt. We believe that we have currently have the cash available to meet our cash requirements for fiscal 2006.
 
RESULTS OF OPERATIONS
 
Business Segments. We have three reportable business segments, our Applied Nanotech, Inc. subsidiary, our Electronic Billboard Technology, Inc. subsidiary and our remaining activities, primarily corporate overhead. Because our Electronic Billboard Technology, Inc. subsidiary has only minimal activity, our management discussion and analysis related to results of operations is much more meaningful if done on a consolidated basis. To the extent that EBT activity had a significant impact on consolidated activity, it will be discussed in the context of the consolidated results. The only significant financial activity at EBT in 2004 was the variable option pricing effect of options held by former EBT employees.
 
Revenues. Following is a summary of revenues for the three years covered by this report.
 
   
2005
 
2004
 
2003
 
               
Government Revenues
 
$
208,211
 
$
305,721
 
$
339,790
 
Futaba Contract Research
 
$
 
$
 
$
400,000
 
Total ANI Revenues
 
$
565,660
 
$
382,522
 
$
773,959
 
Total EBT Revenues
 
$
 
$
 
$
 
Total Revenues
 
$
565,660
 
$
382,522
 
$
773,959
 
                     
Revenue backlog at December 31
 
$
2,764,000
 
$
130,000
 
$
425,000
 
 

 
All of the revenues during the 3-year period came from ANI. The Government revenues in 2003 and 2004 resulted from a project for the Department of Defense (“DOD”) being done in conjunction with Northrop Grumman. The Government revenues in 2005 came from the same Department of Defense grant plus two new SBIR Phase I grants from the Department of Defense. The Futaba revenues in 2003 resulted from the completion of a project started in 2001. EBT changed its business model in 2002 and no longer sells products. EBT is pursuing licenses for its technology, but is not currently actively pursuing further development of its technology. EBT had no revenue in any of the years presented.
 


 
The revenue backlog as of December 31, 2005 results primarily from six government programs. In addition, we have a backlog of $180,000 related to a project being done for a large sporting goods manufacturer. The revenue backlog at both December 31, 2004 and 2003 consists of revenue related to our project being done in conjunction with Northrop Grumman for the Department of Defense.
 
We expect revenue to be significantly higher in 2006 than in 2005 and we plan to generate minimum revenues in 2006 of $5.0 million at ANI. We have specifically identified approximately $3.7 million of potential revenue for 2006, although there is no guarantee that these revenues will be obtained, and expect the remaining $1.3 million to come from some of the many opportunities currently being explored. Revenues could increase above these levels as a result of royalty agreements or additional research revenues, but there is no assurance that this will occur, or that even $3.7 million in revenue will be achieved. All of the $3.7 million in revenue is from customers with whom we have existing relationships and have previously recognized revenue of some amount. We are actively pursuing revenue producing contracts from numerous additional sources in several different areas.
 
Of the $3.7 million of specifically identified revenues, we expect a minimum of $1.7 million to come from government contracts. There is approximately $100,000 of revenue yet to be recognized on the three previously mentioned projects that resulted in revenue in 2005. In addition, we have been notified by the Department of Defense of its intent to award two SBIR Phase II awards as continuations to the two SBIR Phase I awards that we are currently in the process of completing. Each of these awards are expected to be approximately $750,000 and are expected to start in the second quarter of 2006. In addition, ANI received funding of $1 million to develop its PhotoscrubTM concept. This project is expected to start no later than the second quarter of 2006. In addition, we have applied for, and expect to receive additional SBIR Phase I grants during 2006.
 
The non-governmental revenue specifically identified as part of the $3.7 million is expected to come from Kelman related to the sale of hydrogen sensors and royalties from Kelman products containing the sensors, from SME upon completion of the prototype line that it is building and from other existing customers. We have many additional opportunities beyond those quantified above and expect our revenues at ANI to exceed the minimum of $5.0 million for ANI to break even.
 
We also expect EBT to generate significant revenue in 2006 as a result of licensing its intellectual property. In particular, we expect to license the communication patent described in more detail in the description of Business section of this Annual Report on Form 10-K
 
Cost of sales. Because we do not ship products or provide homogenous services, we do not incur costs of sales in the traditional sense. We do keep track of our costs on individual projects, but because there is a wide variation in cost percentages, presenting cost of sales information is not meaningful. Government sponsored research has nominal or no gross margins and is primarily just a reimbursement of costs. In some cases we charge nominal amounts for projects that have much higher costs because we are proving a concept that will be helpful to us in other areas, or are seeking a significantly larger follow up contract with the customer. In other instances we may perform research contracts that have significant positive margins because we are able to capitalize on work that we have done and knowledge that we have gained in the past. At the present stage of our development, it is more meaningful to look at total research and development costs in conjunction with revenues than to look at solely internally funded research projects and the cost of research associated with revenue producing contracts.
 
Research and development. Following is a summary of research and development expenditures for the three years.
 
   
2005
 
2004
 
2003
 
               
ANI Research and development
 
$
2,525,292
 
$
2,611,583
 
$
1,861,660
 
EBT Research and development
 
$
 
$
 
$
 
Total Research and development
 
$
2,525,292
 
$
2,611,583
 
$
1,861,660
 
 
Company sponsored research and development expenses at Applied Nanotech, Inc. increased substantially from 2003 to 2004, but remained relatively constant from 2004 to 2005. This increase in 2004 was primarily the result of spending on two prototype carbon nanotube based field emission displays that we developed. One is a 14-inch prototype done entirely by us and the other is a 25-inch prototype that was done in conjunction with an international consortium of display component manufacturers. Even though the 25-inch prototype was done in conjunction with the consortium, we incurred a significant amount of expenses related to this prototype in 2005. In addition, we incurred significant expenses related to development of our sensor technologies.
 


 
We expect to continue to incur substantial expenses in support of additional research and development activities related to the commercial development of our field emission technology, sensors, nano-electronics, and functional nanomaterials. We expect to incur approximately $3.1 million in research related expenditures in 2006. We expect our research expenditures to increase in 2006 because of the new research contracts that we have obtained for 2006. We may, however, incur more research and development expense in 2006 than presently expected. We are pursuing numerous opportunities for research contracts and depending upon the nature of the contracts signed, we may require more research materials than expected, or we may require additional personnel.
 
Selling, general, and administrative. Following are key components of selling, general, and administrative expense:
 
   
 
2005
 
 
 
2004
 
 
 
2003
 
 
               
Variable option pricing
 
$
25,200
 
$
(267,696
)
$
749,755
 
EBT related S, G, & A
 
$
3,734
 
$
   
 
Other S, G, & A
 
$
2,703,724
 
$
2,171,059
 
$
1,934,357
 
Total selling, general, and administrative
 
$
2,732,658
 
$
1,903,363
 
$
2,684,112
 
                     
Pro-forma SFAS No. 123 Expense
 
$
1,182,482
 
$
2,259,387
 
$
552,927
 
 
Total selling, general and administrative expense declined significantly from 2003 to 2004 and then increased back to slightly above 2003 levels in 2005, however the total is significantly impacted by variable option pricing, which is dependent upon the market price of our common stock, as explained below.
 
As explained in greater detail in Note 8 to the financial statements, we repriced a total of 900,500 options in April 2001. These options, all with an exercise price greater than $1.50 per share, were repriced to $1.50 per share. At the time of the repricing our common stock was trading at approximately $0.95 per share. No compensation expense related to the employees was recorded at the time. The repricing of these options resulted in a new measurement date for accounting purposes and reclassification of these options as variable plan awards beginning on the date of the repricing. We previously accounted for these option grants as fixed plan awards. From the date of the repricing through December 31, 2002, the quoted value of our common stock did not exceed the exercise price of the options, and as such, no compensation expense was recognized at any period through that date. In 2003, our common stock price exceeded the exercise price and remained above it, closing at $2.73 per share on December 31, 2003, $2.17 on December 31, 2004, and $2.15 on December 31, 2005. We recorded $749,755 in non-cash option expense for the cumulative effects of the repricing in the year ended December 31, 2003. In the year ended December 31, 2004, a total of $267,696 was recorded as a reduction in expense as a result of the reduction in our stock price in 2004. In the year ended December 31, 2005 we recorded additional expense of $25,200 related to a portion of these options that were exercised while the price was higher at an interim date during the year. As of December 31, 2005, a total of 167,500 of these options held by employees and 5,000 options held by a consultant remain outstanding.
 
The increase in other selling, general, and administrative expense from 2003 to 2004 is primarily related to payroll. Virtually all employees, including all officers, took salary reductions effective November 1, 2002. These reductions remained in effect until November 1, 2003, for employees, and December 1, 2003, for officers. As such, these reductions were in effect for the majority of 2003. The reinstated levels were in effect for all of 2004. Non-payroll related expense remained relatively constant from year to year. The increase in other selling, general, and administrative expense from 2004 to 2005 of approximately $500,000 was primarily the result of two components. The first component was the litigation against Canon. While our attorney’s are handling this litigation on a contingency basis, we are still responsible for out-of-pocket costs. We incurred approximately $175,000 of cost related to this litigation in 2005. The remaining component of the increase related primarily to payroll. We hired an additional executive officer effective May 1, 2005. This officer also was a consultant for the Company during the first four months of the year. In addition to the increased number of employees, all administrative personnel received salary increases in 2005.
 
We expect selling, general and administrative expense in 2006 to be approximately $2.9 million, before considering the effects of the implementation of SFAS No. 123R. The expected increase in selling, general, and administrative expense in 2006 is the result of expected increased fringe benefit costs, the estimated cost of an annual meeting, an exchange listing fee, and the Canon litigation. The Canon litigation is set for trial in March 2007. If Canon does not choose to settle prior to that date, we would expect to incur approximately $250,000 in costs in 2006 related to that litigation.
 


 
As previously discussed, we will be required to implement SFAS No. 123R in our financial statements for the quarter ended March 31, 2006. Implementation will likely have a material impact on our selling, general, and administrative expense. The table presented in the Critical Accounting Policies section above shows the amount of expense that would have been recorded in the years ended December 31, 2005, 2004, and 2003, if we had recorded the amounts calculated under SFAS No. 123 in those years, rather than disclosing pro-forma information in the footnotes to the financial statements. It is not possible to accurately predict the exact effect of SFAS No. 123R on future periods because the expense to be calculated is dependent up on future events including the number of options granted, the number of options vested, volatility as impacted by changes in the price of our common stock, and others.
 
The largest single component of cost that we incur is payroll related expense. Excluding the cost related to variable option accounting, we incurred payroll related expense of approximately $1.7 million in 2003, $1.9 million in 2004, and $2.3 million in 2005. We expect payroll related expense in 2006 to be approximately $2.9 million as a result of anticipated new personnel. We expect our burn rate for 2006 to average about $500,000 per month, excluding revenues. Based on this we believe we can reach breakeven at a revenue level of $6.0 million, but there is no assurance that this will occur, or that we can achieve that level of revenue.
 
Other income. Following is a summary of other income for the last three calendar years.

   
2005
 
2004
 
2003
 
               
Interest expense
 
$
(2,590
)
$
(4,584
)
$
(56,065
)
Miscellaneous other income
 
$
33,346
 
$
24,982
 
$
13,676
 



Interest expense decreased substantially from $56,065 in 2003 to $4,584 in 2004, and again to $2,590 in 2005. A significant portion of the interest expense in 2003 resulted from the amortization of the value of beneficial conversion features associated with convertible debt and interest payments on that convertible debt. All of the convertible notes payable outstanding at December 31, 2002 were converted into common stock in 2003. We had no debt outstanding at December 31, 2003, 2004, or 2005, and expect to incur no debt in 2006. We expect our interest expense to continue to be negligible in 2006. The majority of the miscellaneous other income is interest income earned on excess cash balances. We expect miscellaneous other income to continue to be insignificant in 2005.
 
SEASONALITY AND INFLATION
 
Nano-Proprietary's business is not seasonal in nature. Management believes that Nano-Proprietary's operations have not been affected by inflation.
 
ACCOUNTING PRONOUNCEMENTS 
 
In December 2004, the FASB issued Statement of Financial Accounting Standards No. 123R (Revised 2004), Share-Based Payment ("SFAS No. 123R"), which requires that the compensation cost relating to share-based payment transactions be recognized in financial statements based on the provisions of SFAS 123 issued in 1995. The Company currently accounts for stock-based compensation using APB 25 and discloses pro forma compensation expense quarterly and annually by calculating the stock option grants' fair value using the Black-Scholes model and disclosing the impact on net income and earnings (loss) per share in a Note to the Consolidated Financial Statements. Upon adoption, pro forma disclosure will no longer be an alternative. SFAS 123R is effective for the first annual period beginning after June 15, 2005. Accordingly, we will adopt this provision for its financial statements for the period ended March 31, 2006. The financial impact of adopting SFAS 123R can not be predicted; however it will likely have a material impact on the Company’s financial statements.
 
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 

We do not use any derivative financial instruments for hedging, speculative, or trading purposes. Our exposure to market risk is currently immaterial.

 
 
 
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
OF NANO-PROPRIETARY, INC.
 
 

CONSOLIDATED FINANCIAL STATEMENTS 
 
 Independent Auditor’s Report
26
Consolidated Balance Sheets - December 31, 2005 and 2004
27
Consolidated Statement of Operations - Years Ended December 31, 2005, 2004, and 2003
28
Consolidated Statements of Shareholders’ Equity - Years Ended December 31, 2005, 2004, and 2003
29
Consolidated Statements of Cash Flows - Years Ended December 31, 2005, 2004, and 2003
30
Notes to Consolidated Financial Statements
31
 

 
 
 
 
 
 
 


 
To the Board of Directors and Shareholders
Nano-Proprietary, Inc.
Austin, Texas
 
We have audited the accompanying consolidated balance sheets of Nano-Proprietary, Inc. and Subsidiaries (collectively, the “Company”) as of December 31, 2005 and 2004 and the related consolidated statements of operations, shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2005.  These consolidated financial statements are the responsibility of the Company's management.  Our responsibility is to express an opinion on these financial statements based on our audits.
 
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.  An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audits provide a reasonable basis for our opinion.
 
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Nano-Proprietary, Inc. and Subsidiaries as of December 31, 2005 and 2004, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2005 in conformity with U.S. generally accepted accounting principles.
 
 
 
Sprouse & Anderson, L.L.P.
Austin, Texas
January 27, 2006
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 


NANO-PROPRIETARY, INC. AND SUBSIDIARIES
 
ASSETS
 
 
 
 
 
December 31,
 
 
 
2005
 
2004
 
Current assets:
         
       Cash and cash equivalents
 
$
897,247
 
$
901,585
 
       Accounts receivable, trade - net of allowance for doubtful accounts
   
94,103
   
6,735
 
       Prepaid expenses and other current assets
   
85,306
   
85,135
 
          Total current assets
   
1,076,656
   
993,455
 
Property and equipment, net
   
101,785
   
141,373
 
Other assets
   
9,540
   
9,540
 
              Total assets
 
$
1,187,981
 
$
1,144,368
 
               
LIABILITIES AND SHAREHOLDERS' EQUITY
             
               
Current liabilities:
         
       Accounts payable
 
$
231,131
 
$
140,597
 
       Obligations under capital lease
   
4,348
   
21,430
 
       Accrued liabilities
   
93,163
   
74,956
 
       Deferred Revenue
   
   
54,985
 
              Total current liabilities
   
328,642
   
291,968
 
Obligations under capital lease, long-term
   
   
5,944
 
 
Commitments and contingencies
   
   
 
              Total liabilities 
   
328,642
   
297,912
 
Shareholders’ equity :
             
       Preferred stock, $1.00 par value, 2,000,000 shares authorized;
              no shares issued and outstanding
   
   
 
       Common stock, 120,000,000 shares authorized, $.001 par value, 99,746,440
              and 97,246,422 shares issued and outstanding, respectively
   
99,746
   
97,246
 
       Additional paid-in capital
   
85,494,542
   
80,822,625
 
       Accumulated deficit
   
(84,734,949
)
 
(80,073,415
)
              Total shareholders’ equity 
   
859,339
   
846,456
 
              Total liabilities and shareholders’ equity
 
$
1,187,981
 
$
1,144,368
 
 

 
 

 
 

 
 

 
 
See notes to consolidated financial statements.

 
NANO-PROPRIETARY, INC. AND SUBSIDIARIES
   
Year ended December 31,
 
 
 
2005 
 
2004
 
2003
 
  
             
Revenues
             
     Contract research
 
$
59,995
 
$
 
$
400,000
 
     Government contracts
   
208,211
   
305,721
   
339,790
 
     License fees and royalties
   
   
10,852
   
2,248
 
     Other
   
297,454
   
65,949
   
31,921
 
  
                   
                    Total revenues 
   
565,660
   
382,522
   
773,959
 
                     
Operating costs
                   
Research and development 
   
2,525,292
   
2,611,583
   
1,861,660
 
Selling, general and administrative expenses
   
2,732,658
   
1,903,363
   
2,684,112
 
Royalty expense
   
   
500,000
   
400,000
 
          Total operating costs
   
5,257,950
   
5,014,946
   
4,945,772
 
  
                   
                    Income (loss) from operations
   
(4,692,290
)
 
(4,632,424
)
 
(4,171,813
)
  
                   
Other income (expense):
                 
          Gain (loss) on disposal of assets 
   
   
125
   
4,695
 
          Interest income
   
33,346
   
24,857
   
8,981
 
          Interest expense
   
(2,590
)
 
(4,584
)
 
(56,065
)
          Other income (loss)
   
   
   
 
  
                   
Loss before taxes
   
(4,661,534
)
 
(4,612,026
)
 
(4,214,202
)
  
                   
Provision for taxes
   
   
   
 
 
                   
Net (loss) applicable to common shareholders
 
$
(4,661,534
)
$
(4,612,026
)
$
(4,214,202
)
Earnings (loss) per share
                 
          Basic and diluted 
 
$
(0.05
)
$
(0.05
)
$
(0.05
)
Weighted average common shares outstanding
                   
          Basic and diluted 
   
98,957,812
   
96,609,237
   
87,366,507
 
 


 
 

 
 
 See notes to consolidated financial statements.


 
NANO-PROPRIETARY, INC. AND SUBSIDIARIES

   
Preferred
 
Common
 
Additional
 
Accumulated
     
   
Shares
 
Amount
 
Shares
 
Amount
 
Paid-In Capital
 
Deficit
 
Total
 
                               
Balance January 1, 2003
   
-
 
$
-
   
76,970,792
 
$
76,971
 
$
68,709,621
 
$
(71,247,187
)
$
(2,460,595
)
                                             
Issuance of common stock as compensation
   
-
   
-
   
-
   
-
   
101,400
   
-
   
101,400
 
Issuance of common stock for patents
   
-
   
-
   
71,021
   
71
   
13,565
   
-
   
13,636
 
Issuance of common stock as a result of the exercise of employee stock options
   
-
   
-
   
3,132,060
   
3,132
   
2,508,765
   
-
   
2,511,897
 
Issuance of common stock for cash
   
-
   
-
   
7,607,097
   
7,607
   
4,805,336
   
-
   
4,812,943
 
Issuance of common stock in payment of accounts payable
   
-
   
-
   
125,000
   
125
   
276,657
   
-
   
276,782
 
Issuance of common stock as result of convertible notes payable
   
-
   
-
   
7,707,020
   
7,707
   
1,753,506
   
-
   
1,761,213
 
Variable Option Pricing
   
-
   
-
   
-
   
-
   
749,755
   
-
   
749,755
 
Net (loss)
   
-
   
-
   
-
   
-
   
-
   
(4,214,202
)
 
(4,214,202
)
                                             
Balance December 31, 2003
   
-
   
-
   
95,612,990
   
95,613
   
78,918,605
   
(75,461,389
)
 
3,552,829
 
                                             
Issuance of common stock options as compensation
   
-
   
-
   
-
   
-
   
116,600
   
-
   
116,600
 
Issuance of common stock as a result of the exercise of employee stock options
   
-
   
-
   
1,211,545
   
1,211
   
972,138
   
-
   
973,349
 
Issuance of common stock for cash
   
-
   
-
   
421,887
   
422
   
1,082,978
   
-
   
1,083,400
 
Variable Option Pricing
   
-
   
-
   
-
   
-
   
(267,696
)
 
-
   
(267,696
)
Net (loss)
   
-
   
-
   
-
   
-
   
-
   
(4,612,026
)
 
(4,612,026
)
                                             
Balance December 31, 2004
   
-
   
-
   
97,246,422
   
97,246
   
80,822,625
   
(80,073,415
)
 
846,456
 
                                             
Issuance of common stock options as compensation
   
-
   
-
   
-
   
-
   
106,278
   
-
   
106,278
 
Issuance of common stock as a result of the exercise of employee stock options
   
-
   
-
   
817,625
   
818
   
542,121
   
-
   
542,939
 
Issuance of common stock for cash
   
-
   
-
   
1,682,393
   
1,682
   
3,998,318
   
-
   
4,000,000
 
Variable Option Pricing
   
-
   
-
   
-
   
-
   
25,200
   
-
   
25,200
 
Net (loss)
   
-
   
-
   
-
   
-
   
-
   
(4,661,534
)
 
(4,661,534
)
 
                                           
Balance December 31, 2005
   
-
 
$
-
   
99,746,440
 
$
99,746
 
$
85,494,542
 
$
(84,734,949
)
$
859,339
 
 

 
 

 
 
See notes to consolidated financial statements.


 
NANO-PROPRIETARY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
 
   
Year Ended
December 31,
 
 
 
2005
 
2004
 
2003
 
Cash flows from operating activities:
 
              
 
 
 
 
 
  Net loss
 
$
(4,661,534
)
$
(4,612,026
)
$
(4,214,202
)
Adjustments to reconcile loss to net
     cash used in operating activities:
               
 
  Depreciation and amortization expense
   
56,260
   
54,928
   
44,419
 
  (Gain) loss on disposal of assets
   
   
(125
)
 
(4,695
)
  Stock and options issued for services
   
106,278
   
116,600
   
101,400
 
Stock issued for patent option
   
   
   
13,636
 
  Variable option accounting charge
   
25,200
   
(267,696
)
 
749,755
 
  Changes in assets and liabilities:
               
 
       Accounts receivable, trade
   
(87,368
)
 
34,397
   
(8,816
)
       Prepaid expenses and other assets
   
(171
)
 
6,326
   
57,531
 
       Accounts payable
   
90,534
   
13,788
   
(181,287
)
       Accrued expenses
   
18,207
   
17,310
   
(274,705
)
       Customer deposits and other current liabilities
   
(54,985
)
 
54,985
   
 
 
                   
            Total adjustments
   
153,955
   
30,513
   
497,238
 
 
                   
       Net cash used in operating activities
   
(4,507,579
)
 
(4,581,513
)
 
(3,716,964
)
 
                   
Cash flows from investing activities:
   
   
   
 
  Capital expenditures
   
(16,672
)
 
(118,987
)
 
(6,494
)
  Proceeds from sale of assets
   
   
125
   
4,695
 
   
                   
       Net cash provided by (used in) investing activities
   
(16,672
)
 
(118,862
)
 
(1,799
)
 
                   
Cash flows from financing activities:
               
 
  Proceeds from issuance of common stock
   
4,542,939
   
2,056,749
   
7,324,840
 
  Repayment of long-term notes payable and capital lease
        obligations
   
(23,026
)
 
(19,359
)
 
(57,375
)
 
               
 
Net cash provided by financing activities
   
4,519,913
   
2,037,390
   
7,267,465
 
Net increase (decrease) in cash and cash equivalents
   
(4,338
)
 
(2,662,985
)
 
3,548,702
 
Cash and cash equivalents, beginning of year 
   
901,585
   
3,564,570
   
15,868
 
Cash and cash equivalents, end of year
 
$
897,247
 
$
901,585
 
$
3,564,570
 
 

 
 

 
 

 
 
See notes to consolidated financial statements.

NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 

 
 
1.    Organization, Operations, and Liquidity:
 
Nano-Proprietary, Inc. and its subsidiaries (“the Company”) are engaged in the development of products for applications using proprietary field emission technology, sensors, nanoelectronics, and nanomaterials, as well as the performance of significant research in that area. The Company has also developed patented electronic sign technology, sold products using that technology, but has now limited itself to licensing that technology to others. It intends to obtain development revenues for applying its technology to specific applications for customers and royalty revenues from licensing its technology to others.
 
Until the Company is able to operate profitably as a result of revenues from either reimbursed research or license agreements, it may continue to seek additional funds through the equity markets, or raise funds through debt instruments to allow it to maintain operations. There is no assurance that license agreements will be signed, that commercialization of the Company’s technology and products will result in income from operations, or that funds will be available in the equity or debt markets. Management believes it will continue to be able to secure additional short term funding, if necessary, to allow the Company to continue operations until it achieves profitability.
 
The principal source of the Company's liquidity since the time of its initial public offering in 1993 has been from the funds received from exempt offerings of common stock, preferred stock, and convertible debt securities, as well as license and development revenues.  The Company will likely receive additional funds from the exercise of warrants or options. The Company may also seek to increase its liquidity through bank borrowings or other financings.  There can be no assurance that any of these financing alternatives can be arranged on commercially acceptable terms.  The Company believes that its success in reaching profitability will depend on the viability of its technology and products using that technology, their acceptance in the marketplace, and the Company’s ability to obtain additional debt or equity financings in the future.
 
A portion of the Company's research and development has been funded by others.  To the extent that other funding is not available, the research and development performed is internally funded by the Company.
 
 

2. Summary of Significant Accounting Policies:
 
Principles of consolidation
 
The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, Applied Nanotech, Inc. (“ANI”), and Electronic Billboard Technology, Inc. (“EBT”), after the elimination of all significant intercompany accounts and transactions. ANI is primarily involved in developing products for applications using the Company’s proprietary field emission technology, sensors, and nanomaterials which include composites. EBT was primarily involved in the commercialization of electronic digitized sign technology, but has now limited itself to licensing that technology. 
 
Management’s estimates
 
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses, as well as the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Significant estimates include NOL reserves, bad debt reserves, and litigation reserves.
 
 

 


NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 
2.    Summary of Significant Accounting Policies (continued):
 
Revenue recognition
 
The Company's revenues include reimbursements under agreements to perform research and development for government agencies and others. The Company does not perform research contracts that are contingent upon successful results. Larger projects are broken down in phases to allow the customer to determine at the end of each phase if they wish to move to the next phase. The agreements with federal government agencies generally provide that, upon completion of a technology development program, the funding agency is granted a royalty-free license to use the newly developed technology for its own purposes.  The Company retains all other rights to use, develop, and commercialize the technology and recognizes revenue when it is billed pursuant to the terms of the contract. Agreements with other entities generally allow the other entity to license the technology from the Company upon completion of the project.
The Company revenues also include royalties from licensing its technology, revenue from the sale of products, and other miscellaneous revenues. Many of the companies projects may involve a combination of these types of revenues. Revenues are recognized as follows.
 
 
Government Contracts - Revenue from government contracts is recognized when it is earned pursuant to the terms of the contract. Long-term projects, such as SBIR Phase II grants that usually total $500,000 to $1,000,000 and usually extend for a period of approximately two years, are generally based on reimbursement of costs. These projects are usually billed monthly based on costs, hours, or some other measure of activity during the month. Revenue from these projects is recognized as it is billed. Short-term projects, such as SBIR Phase I grants that usually are less than $100,000 and usually extend for a period of approximately 6 months, are usually billed at periodic intervals as specified in the contract. Revenue from this type of contract is generally recognized as billed, unless the billing terms specified by the contract would result in a distortion in the amount of revenue being recognized relative to the activity level. For example, if the grant called for one billing at the end of the grant, the revenue would be recognized based on the activity level incurred in the period as compared with total projected activity level. A situation like this would be unusual and rarely happens.
 
Other Research Contracts - Revenue from nongovernment contracts is recognized when it is earned pursuant to the terms of the contract. Each contract is unique and tailored to the needs of the customer and goals of the project. Some contracts may call for a monthly payment for a fixed period of time. Other contracts may be for a fixed dollar amount with an unspecified time period, although there is frequently a targeted completion date. These contracts generally involve some sort of up front payment. Some contracts may call for the delivery of samples, or may call for the transfer of equipment or other items developed during the project to the customer. As a general rule, we recognize revenue on long term contracts based on the activity level of the contract during the period as compared with total estimated activity. This generally would be a measure of cost incurred as compared with total expected cost. However, to the extent there are other significant contract provisions such as the delivery of more than a nominal amount of samples or delivery of equipment, we would modify this as appropriate. For other short term contracts, generally less than $50,000, we recognize revenue when it is billed under the terms of the contract.
 
Royalty Revenue - The Company recognizes royalty revenues based on the shipment of products by a licensee at the time the underlying product upon which the royalty is based is shipped by the entity paying the royalty. For minimum royalty payments paid by a licensee that are required for the licensee to maintain exclusivity, royalty revenue is recognized at the time the minimum royalty payment, or notice of intended payment, is received. The Company recognizes royalty payments received at the time of the signing of a royalty agreement at the time of receipt, unless the terms of the agreement make it clear that the up-front payment was a prepayment of future royalties.
 
Product Sales - Revenue from product sales is recognized at the time the product shipped. The Company’s primary business is research and development and the licensing of its technology, not the sale of products. Product sales are generally insignificant in number, and are usually limited to the sale of samples, proofs of concepts, prototypes, or other items resulting from its research.
 
Other Revenue - Other miscellaneous revenue is recognized as deemed appropriate given the facts of the situation and is generally not material.
 


NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 

 
 
2.    Summary of Significant Accounting Policies (continued):
 
Cash and cash equivalents
 
The Company considers all highly liquid investments purchased with a maturity of approximately three months or less to be cash equivalents.
 
Accounts receivable
 
The Company occasionally sells products to others on credit; however most sales are to large financially stable companies, or the Federal government. It is the Company's policy to record reserves for potential credit losses.  Since inception, the Company has experienced minimal losses. The Company considered no reserves to be necessary at December 31, 2005, 2004, or 2003.
 
Property and equipment
 
Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is provided on the straight-line method over the estimated useful lives of the assets, which range from three to seven years, or the lease term for leasehold improvements, if less.  Expenses for major renewals and betterments that extend the original estimated economic useful lives of the applicable assets are capitalized. Expenses for normal repairs and maintenance are charged to operations as incurred.  The cost and related accumulated depreciation of assets sold or otherwise disposed of are removed from the accounts, and any gain or loss is included in income.
 
Impairment
 
At each balance sheet date, the Company evaluates the carrying amount and the amortization period for its long-lived assets. If an indicator of impairment exists, it is recorded at that time. There were no impairment charges recorded in any of the years presented in these financial statements.
 
Income taxes
 
The Company accounts for income taxes using the liability method pursuant to Statement of Financial Accounting Standards (“SFAS”) No. 109.  Under this method, deferred income taxes are recorded to reflect the tax consequences on future years of temporary differences between the tax basis of the assets and liabilities and their financial amounts at year-end.  The Company provides a valuation allowance to reduce deferred tax assets to their net realizable value.
 
Research and development expenses
 
Costs of research and development for Company-sponsored projects are expensed as incurred.
 
Disclosures about fair value of financial instruments
 
The following methods and assumptions were used to estimate the fair value of each class of certain financial instruments for which it is practicable to estimate that fair value. For cash equivalents and accounts receivable,  the carrying amount approximates fair value because of the short-term nature of these instruments. The fair value of the Company’s capital lease obligations is estimated based on the quoted market prices for the same, or similar issues, or on the current rates offered to the Company for obligations of the same remaining maturities with similar collateral requirements. For all years presented, the fair value of the Company’s capital lease obligations approximate their carrying values.
 


NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 

 
 
 2.    Summary of Significant Accounting Policies (continued):
 
Income (loss) per common share
 
Basic per share amounts are computed, generally, by dividing net income or loss by the weighted average number of common shares outstanding.  Diluted per-share amounts assume the conversion, exercise, or issuance of all potential common stock instruments unless the effect is anti-dilutive, thereby reducing the loss or increasing the income per common share.  As described in Notes 7, 8 and 9, the Company had options and warrants outstanding as indicated in the table below. However, because the Company incurred losses in all years presented, the inclusion of those potential common shares in the calculation of diluted loss per-share would have an anti-dilutive effect.  Therefore, basic and diluted per-share amounts are the same in all years presented.
 
   
2005
 
2004
 
2003
             
Options
 
6,703,151
 
5,398,703
 
5,253,175
Warrants
 
95,000
 
95,000
 
155,000
Weighted average exercise price
 
$1.57
 
$1.29
 
$1.10
 
 
 
Stock-based employee compensation
 
The Company uses the intrinsic value method to account for stock-based employee compensation. During the years presented, the Company did not incur any compensation cost under APB No. 25 for options granted under the Plans. Had the compensation cost for the Company’s compensation plans been determined consistent with SFAS No. 123 and SFAS No. 148 using the fair value method, the Company’s net loss and net loss per common share for 2005, 2004, and 2003 would approximate the pro forma amounts as shown below:
 
   
2005
       
2004
       
2003
Net Loss                                                                         
 
 
 
 
 
As reported
$(4,661,534)
 
$(4,612,026)
 
$(4,214,202)
SFAS No. 123 Charge
   1,182,482
 
   2,259,387
 
     552,927
Pro Forma
  (5,844,016)
 
 (6,871,413)
 
 (4,767,129)
Net income (loss) per common share - basic and diluted 
 
 
 
 
 
As reported
$(0.05)
 
$(0.05)
 
$(0.05)
Pro Forma 
$(0.06)
 
$(0.07)
 
$(0.05)
 
The effects of applying SFAS No. 123 in this pro forma disclosure are not necessarily indicative of future amounts. SFAS No. 123 does not apply to awards prior to 1995, and the Company anticipates making awards in the future under its compensation plans. The Company also granted 50,000 options to a non-employee consultant in 2003, 100,000 options to a non-employee consultant in 2004, and 120,000 options to non-employee consultants in 2005. We recorded expense of $101,400, $116,600, and $106,278 in 2003, 2004, and 2005, respectively, related to those options. These expenses were calculating using approximately the same assumptions used to determine the SFAS No. 123 charge in 2003 and 2004. In 2005 this charge was computed using volatility rates ranging from 72% to 78%, risk free interest rates of 3.5% to 4.35%, expected option terms of 1.5 to 2.5 years, and dividend and forfeiture rates of zero.
 



NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 
 
 
 
2. Summary of Significant Accounting Policies (continued):
 
The fair value of each stock option granted to employees in 2005, 2004, and 2003 is estimated on the date of the grant using the Black-Scholes option pricing-model with the following weighted-average assumptions:
 
   
2005
 
2004
 
2003
             
Dividend Yield
 
0%
 
0%
 
0%
Risk Free Interest Rate
 
3.5%
 
3.5%
 
3%
Expected Option Life
 
3.5 Years
 
5 Years
 
5 Years
Turnover/Forfeiture Rate
 
0%
 
45%
 
25%
Volatility
 
100%
 
72%
 
108%
 
The Black-Scholes option valuation model and other existing models were developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. These option valuation models require the input of, and are highly sensitive to, subjective assumptions including the expected stock price volatility. Nano-Proprietary’s stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions could materially affect the fair value estimate.
 
Recently issued accounting pronouncements
 
In December 2004, the FASB issued Statement of Financial Accounting Standards No. 123R (Revised 2004), Share-Based Payment ("SFAS No. 123R"), which requires that the compensation cost relating to share-based payment transactions be recognized in financial statements based on the provisions of SFAS 123 issued in 1995. The Company currently accounts for stock-based compensation using APB 25 and discloses pro forma compensation expense quarterly and annually by calculating the stock option grants' fair value using the Black-Scholes model and disclosing the impact on net income and earnings (loss) per share in a Note to the Consolidated Financial Statements. Upon adoption, pro forma disclosure will no longer be an alternative. The Statement is effective for the first annual reporting period beginning after June 15, 2005. Accordingly, the Company will adopt this provision for its financial statements for the period ended March 31, 2006. The financial impact of adopting this statement can not be predicted, however it will likely have a material impact on the Company’s financial statements.
 
3.    Operating Lease Obligations :
 
The Company leases various facilities and equipment under operating lease agreements having terms expiring at various dates through 2009. Rental expense was $133,487, $115,217, and $124,425 for the years ended December 31, 2005, 2004 and 2003,  respectively.
 
Future minimum lease payments under operating leases that have initial or remaining noncancelable lease terms in excess of one year at December 31, 2005, were as follows:
 
2006 
 
$
131,891
 
2007
   
34,862
 
2008
   
21,000
 
2009 and thereafter 
   
19,250
 
Total future minimum lease payments
 
$
207,003
 



NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 
 
 
4.    Capital Lease Obligations :
 
Capital leases payable at December 31, 2005 and 2004 consisted of the following:
 
                                                                                                         
 
2005
 
2004
 
Capital leases for copier equipment due in
monthly installments  totaling $1,932 through 2006.
The equipment value and lease obligation was determined
using a discount rate of 10%.  The equipment is included in
office equipment at December 31, 2005 at a cost of $94,383
and with accumulated amortization of $91,018.
 
$
4,368
 
$
29,228
 
               
Less interest
   
(20
)
 
(1,854
)
Less current portion
   
(4,348
)
 
(21,430
)
               
Capital Lease Obligations, long-term
 
$
 
$
5,944
 

 

5.    Details of Certain Balance Sheet Accounts:
 
Additional information regarding certain balance sheet accounts at December 31, 2005 and 2004 is as follows:
 
   
December 31,
 
 
 
2005
 
 2004
 
 
          
Property and equipment:
   
   
 
       Plant and equipment
 
$
755,436
 
$
755,436
 
       Furniture and office equipment
   
199,184
   
182,512
 
       Leasehold Improvements
   
14,382
   
14,382
 
            Total carrying cost
   
969,002
   
952,330
 
       Less accumulated depreciation
   
(867,217
)
 
(810,957
)
  
 
$
101,785
 
$
141,373
 
               
Accrued liabilities:
             
     Payroll and related accruals
 
$
65,507
 
$
37,927
 
     Other
   
27,656
   
37,029
 
 Total 
 
$
93,163
 
$
74,956
 


Depreciation for the years ended December 31, 2005, 2004, and 2003 was $56,260, $54,928, and $44,419, respectively.


NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
 
 
 
6.    Income Taxes :
 
The components of deferred tax assets (liabilities) at December 31, 2005 and 2004, were as follows:
 
   
December 31,
 
   
2005
 
 2004
 
Deferred tax assets:
          
Net operating loss carry forwards
 
$
30,849,000
 
$
28,759,000
 
Research and experimentation credits
   
468,000
   
469,000
 
Capitalized intangible assets
   
185,000
   
223,000
 
Depreciation assets
   
6,000
   
12,000
 
Accrued expenses not deductible until paid
   
24,000
   
15,000
 
Total deferred tax assets
   
31,532,000
   
29,478,000
 
 
             
Deferred tax liabilities:
   
   
 
               
Net deferred tax assets before valuation allowance
   
31,532,000
   
29,478,000
 
 
             
Valuation allowance
   
(31,532,000
)
 
(29,478,000
)
 
             
Net deferred tax asset
             
   
$
 
$
 
 
The following is a reconciliation of the amount of the income tax expense (benefit) that would result from applying the statutory federal income tax rates to pretax income (loss) and the reported amount of income tax expense (benefit) for the periods ended December 31, 2005, 2004, and 2003.
 
    
 
December 31,
 
 
 
2005
 
2004
 
2003
 
 
 
 
 
 
 
 
 
Expected income tax expense (benefit)
 
$
(1,585,000
)
$
(1,568,000
)
$
(1,433,000
)
Deductible expenses not charged against book income
   
(528,000
)
 
(614,000
)
 
(1,158,000
)
Non-taxable income
   
   
(91,000
)
 
 
Non-deductible expenses
   
56,000
   
7,000
   
260,000
 
Expiration of Tax Credit Carryforwards
   
1,000
   
556,000
   
 
Other
   
2,000
   
1,000
   
11,000
 
Increase in Valuation Allowance
   
2,054,000
   
1,709,000
   
2,320,000
 
Total Tax
 
$
 
$
 
$
 
 
As of December 31, 2005, the Company had net operating loss carry forwards of approximately $90 million that expire from 2006 through 2025, and are available to offset future taxable income. The majority of these carry forwards expire after 2009. Additionally, the Company has tax credit carry forwards related to research and development expenditures of approximately $468,000 that expire through 2011.
 
The Company’s IPO, completed in 1993, and subsequent issuances of stock have effected ownership changes under Internal Revenue Code Section 382. The ownership changes resulting from these stock issuances will likely limit the Company's ability to utilize any net operating loss carry forwards or credits generated before the changes in ownership.  
 


NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
 
 
 
7.    Capital Stock:
 
Preferred stock
 
The Company has authorization for the issuance of 2,000,000 shares of $1.00 par value preferred stock. As of December 31, 2005, 2004 and 2003, no preferred shares were outstanding.
 
Common stock
 
During 2003, 2004, and 2005, the Company issued shares of its common stock in a series of private placements in exempt offerings under Regulation D of the Securities Act of 1933. These shares were issued at prices that represented a slight discount to the market price of the stock at the time of the offerings. All of these shares were registered to enable the shareholder to be able to sell the shares, with the latest registration statement declared effective October 27, 2005.
 
   
Shares
 
Proceeds
 
2005
   
1,682,393
 
$
4,000,000
 
2004
   
401,887
 
$
1,065,000
 
2003
   
7,607,097
 
$
4,812,943
 
 
In a series of private placements of the Company’s common stock in exempt offerings under Regulation D of the Securities Act of 1933, the Company also issued 71,021 shares in 2003, valued at $13,636 in payment for the Keesman patent described in more detail in Note 11. The Company also issued 125,000 shares of its common stock in 2003 in payment of accounts payable. These shares were valued at $276,782. The Company also issued 7,707,020 shares in 2003 as the result of the conversion of convertible notes payable issued in previous years and related accrued interest totaling $1,761,213.
 
At December 31, 2005, common stock was reserved for the following reasons:
 
Exercise of stock warrants
   
95,000
 
Exercise and future grants of stock options
   
8,724,260
 
 
       
Total shares reserved
   
8,819,260
 


 
8.    Stock Options:
 
The Company sponsors four stock-based incentive compensation plans (the “Plans”). The Company applies Accounting Principles Board (“APB”) Opinion No. 25 and related interpretations in accounting for the Plans. In 1995, the FASB issued SFAS No. 123 “Accounting for Stock-Based Compensation” which, if fully adopted by the Company, would change the methods the Company applies in recognizing the cost of the Plans. Adoption of the cost recognition provisions of SFAS No. 123 is optional and the Company has decided not to elect these provisions of SFAS No. 123. However, pro forma disclosures as if the Company adopted the cost recognition provisions of SFAS No. 123 are required by SFAS No. 123 and are presented in Note 2.
 


NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
 
 
 
8.    Stock Options (continued):
 
The plans allow the Company to grant either incentive stock options or non-qualified stock options. The incentive stock options are exercisable for up to ten years, at an option price per share not less than the fair market value on the date the option is granted. The incentive stock options are limited to persons who have been regular full-time employees of the Company or its present and future subsidiaries for more than one (1) year and at the date of the grant of any option are in the employ of the Company or its present and future subsidiaries. Non-qualified options may be granted to any person, including, but not limited to, employees, independent agents, consultants and attorneys, who the Company's Compensation Committee believes have contributed, or will contribute, to the success of the Company.  Non-qualified options may be issued at option prices of less than fair market value on the date of grant and are exercisable for up to ten years from date of grant. The option-vesting schedule for options granted is determined by the Compensation Committee of the Board of Directors at the time of the grant. 
 
In April 2001, the Company repriced a total of 900,500 options. All options with an exercise price greater than $1.50 per share, which was approximately 160% of the market price of the stock at the time of the repricing, held by individuals employed by the Company as of the repricing date, including one consultant under contract at the time, were repriced to $1.50 per share. No compensation expense related to the employees was recorded at the time. The repricing of these options resulted in a new measurement date for accounting purposes and reclassification of these options as variable plan awards beginning on the date of the repricing. The Company previously accounted for these option grants as fixed plan awards. From the date of the repricing through December 31, 2002, the quoted value of the Company’s common stock did not exceed the exercise price of the options, and as such, no compensation expense was recognized at any period through that date. In 2003, the Company’s common stock price exceeded the exercise price and remained above it, closing at $2.73 per share on December 31, 2003, $2.17 on December 31, 2004, and $2.15 on December 31, 2005. The Company recorded $749,755 in non-cash option expense for the cumulative effects of the repricing and increased additional paid in capital by the same amount in the year ended December 31, 2003. In the year ended December 31, 2004, a total of $267,696 was recorded as a reduction in expense and a reduction to paid in capital as a result of the reduction in the Company’s stock price in 2004. The Company recorded additional expense of $25,200 in the year ended December 31, 2005. As of December 31, 2005, a total of 167,500 of these options held by employees and 5,000 options held by a consultant remain outstanding.
 
In March 1992, the shareholders of the Company approved the 1992 Employees Stock Option Plan (the "1992 Employees Plan") for purposes of granting incentive or non-qualified stock options. The plan was amended several times by the Company’s Board of Directors to increase the number of shares authorized under the plan. The latest amendment, in December 1999, increased the authorized shares under the plan to 6,500,000. This plan expired in March 2002; however, options granted under this plan prior to expiration remain outstanding until they are exercised, forfeited, or the exercise period expires. At December 31, 2005, no shares remained available for grant under the 1992 Employees Plan.
 
In March 1992, the Board of Directors adopted the 1992 Outside Directors’ Stock Option Plan (the "1992 Directors Plan"), for purposes of granting non-qualified options to non-employee directors of the Company. The plan was amended several times, the latest being in December 1999. A total of 1,000,000 shares were reserved for issuance under the plan and were issued each year based on a formula defined by the plan. The stock options granted under the 1992 Directors Plan are exercisable for up to 10 years at an option price equal to the fair market value on the date the option is granted.  This plan expired in March 2002; however, options granted under the plan prior to expiration remain outstanding until they are exercised, forfeited, or the exercise period expires. At December 31, 2005, no shares remained available for grant under the 1992 Directors Plan.
 
In May 1998, the Board of Directors of the Company established the 1998 Officers and Directors Stock Option Plan (the “1998 Officers and Directors Plan”) and reserved a total of 1,200,000 shares for issuance under the Plan. The plan was amended in January 1999 by the Board of Directors of the Company to increase the shares reserved for issuance under the plan to 2,500,000. Options under this plan are granted at the discretion of the Board of Directors. No additional shares are currently available under this plan and no shares will be come available under this plan in the future.
 



NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
 
 8.    Stock Options (continued):
 
In September 2002, the Board of Directors of the Company established the 2002 Equity Compensation Plan and reserved a total of 5,000,000 shares for issuance under the Plan, effective March 2002. The purpose of this plan was to replace the 1992 Employees Plan and the 1992 Directors Plan, both of which expired in March 2002. The plan was amended effective December 31, 2004 to increase the authorized shares to 8,000,000. A total of 2,010,109 shares remain available for grant under this at December 31, 2005.
 
The following is a summary of stock option activity under all four plans:
 
                                                                                                            
 
 
Number of
Shares
 
Wgtd. Ave.
Exercise
Price
 
 
         
Options outstanding at January 1, 2003
   
6,965,629
 
$0.79
 
  
         
 
Granted
   
1,496,995
 
$1.88
 
Exercised
   
(3,132,060
)
$0.80
 
Canceled
   
(77,389
)
$0.82
 
 
             
Options outstanding at December 31, 2003
   
5,253,175
 
$1.09
 
               
Granted
   
2,457,073
 
$2.73
 
Exercised
   
(1,211,545
)
$0.80
 
Cancelled
   
(1,100,000
)
$2.94
 
               
Options outstanding at December 31, 2004
   
5,398,703
 
$1.52
 
               
Granted
   
2,872,073
 
$2.25
 
Exercised
   
(817,625
)
$0.66
 
Cancelled
   
(750,000
)
$2.42
 
             
Options outstanding at December 31, 2005
   
6,703,151
 
$1.84
 

 
The following table summarizes information about stock options outstanding and exercisable under all four stock option plans at December 31, 2005:
 
 
 
Options Outstanding
 
Options Exercisable
 
Range of
Exercise Prices
 
 
Number
Outstanding
at 12/31/05
 
Wgtd.  Avg.
Remaining 
Contractual
Life
 
Wgtd. Avg.
Exercise Price
 
Number
Exercisable
at 12/31/05
 
Wgtd. Avg.
Exercise Price
 
 
  
 
 
 
 
 
 
 
 
$0.00 - $0.50
 
    804,089
 
3.9 Years
 
$0.44
 
    804,089
 
$0.44
$0.51 - $1.00
 
 1,124,083
 
5.7 Years
 
$0.83
 
 1,124,083
 
$0.83
$1.01 - $2.00
 
    745,833
 
5.8 Years
 
$1.54
 
    745,833
 
$1.54
$2.01 - $2.99
 
 4,029,146
 
8.6 Years
 
$2.45
 
 1,929,146
 
$2.49
 
     
  
 
 
     
 
Total
 
6,703,151
 
7.3 Years
 
$1.84
 
4,603,151
 
$1.57
 
     
 
 
 
     
 


NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)

 
8.    Stock Options (continued) :
 
The weighted-average fair values of options under the plans granted during 2005, 2004, and 2003 were as follows:
 
   
2005
 
2004
      
2003
Discounted options
$0.00
 
$0.00
 
$0.00
At-the-money options
$1.50
 
$1.71
 
$1.58
Premium options
$1.41
 
$1.28
 
$0.38

9.     Stock Warrants :
 
Common stock warrants
 
In 1996, the Company issued 35,000 warrants to an advisor in connection with the Company’s fundraising activities. These warrants enable the holder to purchase shares of the Company’s common stock at a price of $2.00 per share through 2006. These warrants expired unexercised at the end of January 2006. In 1997, the Company issued 75,000 additional warrants to this advisor in connection with services related to a joint venture agreement. A total of 15,000 of these warrants were exercised in 1999. These warrants enable the holder to purchase shares of the Company’s Common Stock at a price of $1.00 per share through 2007.
 
In 1999, the Company issued a total of 60,000 warrants to three separate individuals in connection with services rendered to the Company. The exercise price of these warrants was based on the fair market value of the Company’s common stock at the time of issuance and ranged from $0.92 to $2.15 per share. These warrants were exercisable for a period of 5 years from the date of issuance and were either exercised or expired in 2004.
 
The following is a summary of outstanding warrants:
 
                                                                                                                            
 
Number of
Shares
 
Exercise Price
 
  
 
 
 
 
 
 
Warrants outstanding at January 1, 2003
   
155,000
 
$0.92-2.15
 
Expired or canceled
   
 
 
 
 
   
     
Warrants outstanding at December 31, 2003
   
155,000
 
$0.92-2.15
 
Exercised
   
(20,000
)
$0.92        
 
Expired or canceled
   
(40,000
)
 $2.15         
 
               
Warrants outstanding at December 31, 2004
   
95,000
 
$1.00-2.00
 
Exercised
   
 
 
 
Expired
   
 
 
 
 
   
     
Warrants outstanding at December 31, 2005
   
95,000
 
$1.00-2.00
 


NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
 
 
 
10.    Supplemental Cash Flow Information:
 
Cash paid for interest was $2,590, $4,584, and $10,503 for 2005, 2004, and 2003, respectively.  The following non-cash transactions have been excluded from the accompanying consolidated statement of cash flows:
 
   
2005
 
2004
 
2003
 
 
             
Non-cash financing activities:
                   
Conversion of notes payable and interest into common shares
   
 
$
 
$
1,761,213
 
Issuance of common shares in payment of accounts payable
   
 
$
 
$
276,782
 
Non-cash investing activities:
               
 
Common shares issued for patent
   
 
$
 
$
13,636
 
 

 
11.    Commitments and Contingencies:
 
Till Keesman Agreement
 
In May 2000, the Company licensed the rights to 6 carbon nanotube patents that, at the time, had been applied for by Till Keesman in exchange for a payment of $250,000 payable in shares of the Company’s common stock. Under the terms of the agreement, the Company is obligated to pay license fees equal to 50% of any royalties received by the Company related to these patents. The Company is allowed to offset certain expenses, up to a maximum of $50,000 per year, against payments due under this agreement. The agreement also contained provisions related to minimum license fee payments. These minimum payments, totaling $1,000,000, have been made and no further minimum payments are due. The Company is allowed to offset these minimum payments against future royalty payments, however once these minimum payments and the expenses have been offset, the Company may be liable for additional royalty payments.
 
Research and development commitments
 
As of December 31, 2005, the Company was in the process of a SBIR Phase II contract for research from the US Department of Defense. The total contract amount is $742,212 and $704,243 of the revenue was recognized as of December 31, 2005. In addition, the company had two SBIR Phase I contracts totaling $167,289 at December 31, 2005. A total of $117,000 of the revenue related to these contracts had been recognized as of December 31, 2005. The Company also had a $240,000 contract with a large sporting goods manufacturer in process as of December 31, 2005. A total of $59,995 of revenue related to that contract has been recognized as of December 31, 2005. The revenue to be received from  these research contracts in 2006 is expected to exceed the cost of this research.
 
Agreements with MCC
 
The Company entered into an agreement in 1994 with Microelectronics and Computer Technology Corporation (“MCC”) that was amended on several subsequent occasions to cross license and pool technologies. As part of this relationship with MCC, 62 Diamond Field Emission patents and patent applications were assigned directly to the Company and the Company has agreed to pay a royalty fee of 2% of future commercial revenues related to the patents received. The Company has the right to offset one half of the costs of maintaining these patents against any royalties due under the agreement. No payments have been made to, or are due to, MCC under this agreement and the possibility is remote that any payments will ever be due under this agreement.
 


NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
 

 
11.    Commitments and Contingencies (continued):
 
Legal proceedings
 
In April 2005, we filed suit against Canon, Inc. and Canon USA, Inc. in the U.S. District Court for the Western District of Texas, Austin Division. We are seeking a declaratory judgment that new SED color television products, scheduled to be manufactured by SED, Inc. and sold by Canon and/or Toshiba beginning in 2006, are not covered under a 1999 patent license agreement that we have with Canon.  We assert that Canon’s license does not cover its surface conductor electron emitter display screens (SED) for a new generation of flat screen color televisions. We also assert that SED,Inc., the joint venture formed by Canon and Toshiba Corporation to produce the SED display screens, is not a licensed subsidiary under the 1999 agreement and that Canon is improperly transferring its license rights under Nano-Proprietary's patents to the joint venture and Toshiba. The suit also contained three additional claims related to a Lanham Act violation by Canon, tortious interference by Canon, and a breach of covenant of good faith and fair dealings against Canon. Canon filed its response in July 2005 denying liability in the matter. In September 2005, Canon filed a motion to dismiss Canon USA, Inc. from the case and dismiss the Lanham Act claim, the tortious interference claim, and the breach of covenant of good faith and fair dealings. In October 2005, the judge in the case denied Canon’s motion to dismiss Canon, USA, Inc. and the breach of covenant of good faith and fair dealings claim. The judge granted Canon’s motion, without prejudice, to dismiss the Lanham Act claim and the tortious interference claim. Dismissal without prejudice allows us to re-file these claims at any time if additional evidence supporting these claims becomes available to us in the discovery process. The first two claims described above were not at issue in the dismissal motion by Canon. The case is currently in the discovery phase and a trial may occur as soon as March 2007. We believe that the ultimate resolution of this matter will not have a negative impact on the consolidated financial statements of the Company.
 
On July 20, 1998, TFI Telemark, Inc. filed a complaint in the County Court at Law No. 2 of Travis County, Texas against the Company for debts of its now defunct subsidiary, Plasmatron. The Company was served with notice of this suit on August 5, 1998. The Company believes that no amounts are due to TFI; however, all amounts claimed as owing by TFI are recorded as liabilities in the consolidated financial statements of the Company. The Company believes the ultimate resolution of this matter will not have a material impact on the consolidated financial statements of the Company.
 
From time to time the Company and its subsidiaries are also defendants in various lawsuits that may arise related to minor matters. It is expected that all such lawsuits will be settled for an amount no greater than the liability recorded in the financial statements for such matters.  If resolution of any of these suits results in a liability greater than that recorded, it could have a material impact on us.
 
Government contracts
 
Governmental contractors are subject to many levels of audit and investigation.  Among United States agencies that oversee contract performance are: the Defense Contract Audit Agency, the Inspector General, the Defense Criminal Investigative Service, the General Accounting Office, the Department of Commerce, the Department of Justice and Congressional Committees. The Company's management believes that an audit or investigation, if any, as a result of such oversight would not have any material adverse effect upon the Company's financial condition or results of operations.
 
12.    Concentrations of Credit Risk:
 
The Company’s financial instruments that are exposed to concentrations of credit risk consist of cash and cash equivalents and receivables. The Company places its cash and cash equivalents with high credit quality financial institutions; however for periods of time during the year, bank balances on deposit were in excess of the Federal Deposit Insurance Corporation insurance limit. No amounts in excess of the FDIC limit were held in bank accounts at December 31, 2005. At December 31, 2004 and 2003, amounts in excess of the FDIC limit of $175,058 and $1,263,331, respectively, were held at JP Morgan Chase.
 


NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
 

 
12.    Concentrations of Credit Risk (continued):
 
The Company’s receivables are uncollateralized and result primarily from its research and development projects performed primarily for U.S. Federal Government Agencies and services performed for large U.S. and multinational corporations. The Company has not incurred any material losses on these receivables.
 
13.    Research and Development Contracts :
 
The Company makes significant expenditures for research and development. On occasion, the Company may seek funding for a portion of its research and development costs to reduce the cost of such expenditures to the Company. The Company only seeks funding for projects that it already intended to do, or for projects that would apply its technology for other uses in instances where that application would allow the Company to achieve technical milestones that are part of its strategic plan. A substantial portion of the Company’s funded research has been from government contracts. Under government contracts, the government has the right to utilize the results for its purposes and the Company has the right to utilize the technology for commercial purposes.  Generally, when the Company contracts with other entities, the entity is also conducting its own internal research related to application of the Company’s technology to its products and such expenditures by the entity may exceed the amount of funding provided to the Company. Usually the entity has the right to license the technology at the conclusion of the project, if they desire. The costs of a particular research program may significantly exceed the funding received, however since the research was part of planned research, these contracts generally involve only nominal additional costs to the Company.
 
The following schedule summarizes certain information with respect to research and development contracts:
 
   
2005
 
2004
 
2003
 
Contract research revenues
 
$
268,206
 
$
305,721
 
$
739,790
 
Costs incurred charged to operations included in research and development
 
$
254,656
 
$
278,928
 
$
405,962
 
Amount of additional funding commitments at December 31
 
$
268,258
 
$
129,090
 
$
424,075
 

 
14.    Retirement Plan :
 
The Company sponsors a defined contribution 401(k) profit sharing plan. No company contributions were made in any of the years presented.
 
15.    Significant Customers :
 
Applied Nanotech, Inc. received research and development revenues from the U.S. Government in the three years as disclosed on the income statement. ANI’s revenues tend to be project oriented and are not necessarily recurring with a particular customer. Net revenue from a project with one customer was $109,970 in 2005. No revenue was received from this customer in 2004 or 2003. Net revenues for contract research with a different major customer of Applied Nanotech, Inc. totaled  $400,000 in 2003. No revenue was received from this customer in 2004 or 2005.
 


NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
  
 
16.    Segment Information :
 
The Company’s operations are classified into three principal reportable segments that provide slightly different products or services.
 
                                                  
 
 
 
                        
 
                      
 
                     
 
 
 
ANI
 
EBT
 
All Other
 
Total
 
2005
 
 
 
 
 
 
     
Revenue
 
$
565,660
 
$
-
 
$
-
 
$
565,660
 
Interest Expense
   
2,193
   
-
   
397
   
2,590
 
Depreciation and Amortization
   
52,242
   
-
   
4,018
   
56,260
 
Research and Development
   
2,525,292
   
-
   
-
   
2,525,292
 
Income (Loss) from Continuing Operations
   
(3,730,450
)
 
(3,734
)
 
(927,350
)
 
(4,661,534
)
Assets
   
301,870
   
-
   
886,111
   
1,187,981
 
Capital Expenditures
   
13,017
   
-
   
3,655
   
16,672
 
                           
2004
   
   
   
   
 
Revenue
 
$
382,522
 
$
-
 
$
-
 
$
382,522
 
Interest Expense
   
3,949
   
-
   
635
   
4,584
 
Depreciation and Amortization
   
50,185
   
-
   
4,743
   
54,928
 
Research and Development
   
2,611,583
   
-
   
-
   
2,611,583
 
Income (Loss) from Continuing Operations
   
(4,030,353
)
 
106,251
   
(687,924
)
 
(4,612,026
)
Assets
   
310,005
   
-
   
834,363
   
1,144,368
 
Capital Expenditures
   
116,613
   
-
   
2,374
   
118,987
 
 
   
   
   
   
 
2003
   
   
   
   
 
Revenue
   
773,959
   
-
   
-
   
773,959
 
Interest Expense
   
5,999
   
20
   
50,046
   
56,065
 
Depreciation and Amortization
   
37,653
   
-
   
6,766
   
44,419
 
Research and Development
   
1,861,660
   
-
   
-
   
1,861,660
 
Loss from Continuing Operations
   
(2,890,175
)
 
(361,784
)
 
(962,243
)
 
(4,214,202
)
Assets
   
1,424,724
   
527
   
2,358,766
   
3,784,017
 
Capital Expenditures
   
6,494
   
-
   
-
   
6,494
 
 
Financial information is furnished to the chief operating officer for review regarding each subsidiary of the Company.
 
The ANI segment consists of the activities of ANI and includes license revenues and contract research revenues related to ANI’s technology. In  both years, virtually all ANI revenues were contract research revenues. The Company’s EBT subsidiary previously sold electronic display products, but is now limiting itself pursuing licenses for its technologies to others for use in display products. All other segments include the Company’s general overhead.
 
The accounting policies applied by each of the segments are the same as those used by the Company.
 


NANO-PROPRIETARY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
 

 
 
17.    Subsequent Events :
 
During the period from January 1, 2006 through February 24, 2006, the Company received $1,500,000 in proceeds and issued 750,000 shares of common stock in connection with a private placement of the Company’s common stock.

18.    Quarterly Financial Information (Unaudited) :

   
First
 
Second
 
Third
 
Fourth
 
Total
 
   
Quarter
 
Quarter
 
Quarter
 
Quarter
 
Year
 
2005
                     
Revenues
 
$
68,815
 
$
88,544
 
$
245,917
 
$
162,384
 
$
565,660
 
Operating income (loss)
   
(1,472,793
)
 
(984,223
)
 
(1,014,643
)
 
(1,220,631
)
 
(4,692,290
)
Net (loss)
   
(1,469,192
)
 
(974,181
)
 
(1,005,078
)
 
(1,213,083
)
 
(4,661,534
)
Earnings (loss) per share
                               
Basic and Diluted
   
(0.02
)
 
(0.01
)
 
(0.01
)
 
(0.01
)
 
(0.05
)
                                 
2004
                               
Revenues
 
$
77,658
 
$
100,718
 
$
100,473
 
$
103,673
 
$
382,522
 
Operating income (loss)
   
(1,117,862
)
 
(1,269,201
)
 
(1,108,338
)
 
(1,137,023
)
 
(4,632,424
)
Net (loss)
   
(1,111,641
)
 
(1,263,529
)
 
(1,100,534
)
 
(1,136,322
)
 
(4,612,026
)
Earnings (loss) per share
                               
Basic and Diluted
   
(0.01
)
 
(0.01
)
 
(0.01
)
 
(0.01
)
 
(0.05
)
                                 
2003
                               
Revenues
   
444,452
   
160,380
   
88,195
   
80,932
   
773,959
 
Operating income (loss)
   
(749,524
)
 
(681,333
)
 
(1,200,627
)
 
(1,540,329
)
 
(4,171,813
)
Net (loss)
   
(770,969
)
 
(696,056
)
 
(1,212,280
)
 
(1,534,897
)
 
(4,214,202
)
Earnings (loss) per share
                               
Basic and Diluted
   
(0.01
)
 
(0.01
)
 
(0.01
)
 
(0.02
)
 
(0.05
)

Annual Earnings (loss) per share may not equal the sum of the four quarterly amounts due to rounding.
 
 
 

 


 
 
None
 
Item 9A.  Controls and Procedures.
 
Management is responsible for establishing and maintaining effective disclosure controls and procedures, as defined under Rule 13a-15 of the Securities Exchange Act of 1934, that are designed to cause the material information required to be disclosed by Nano-Proprietary in the reports it files or submits under the Securities Exchange Act of 1934 to be recorded, processed, summarized, and reported to the extent applicable within the time periods required by the Securities and Exchange Commission’s rules and forms. In designing and evaluating the disclosure controls and procedures, management recognized that a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with a company have been detected.
 
As of the end of the period covered by this report, Nano-Proprietary performed an evaluation under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of its disclosure controls and procedures pursuant to Rule 13a-15 of the Securities Exchange Act of 1934. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective at the reasonable assurance level.
 
Report on Management’s Assessment of Internal Control over Financial Reporting
 
The management of Nano-Proprietary, Inc. is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined under applicable Securities and Exchange Commission rules as a process designed under the supervision of the Company’s Chief Executive Officer and Chief Financial Officer and effected by the Company’s Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with U.S. generally accepted accounting principles. The Company’s internal control over financial reporting includes those policies and procedures that:
 
 
•  
Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
 
•  
Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and the directors of the Company; and
 
•  
Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.
 
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
 
As of December 31, 2005, management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of the Company’s internal control over financial reporting based on the criteria for effective internal control over financial reporting established in “Internal Control — Integrated Framework,” issued by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission. Based on the assessment, management determined that the Company’s internal control over financial reporting was effective as of December 31, 2005.
 
Sprouse & Anderson, L.L.P., the independent registered public accounting firm that audited the consolidated financial statements of the Company included in this Annual Report on Form 10-K, has issued an attestation report on management’s assessment of the Company’s internal control over financial reporting as of December 31, 2005. The report, which expresses -unqualified opinions on management’s assessment and on the effectiveness of the Company’s internal control over financial reporting as of December 31, 2005, is included in this Item under the heading “Attestation Report of Independent Registered Public Accounting Firm.”
 


 
Changes in Internal Control over Financial Reporting
 
No changes were made to the Company’s internal control over financial reporting (as defined in Rule 13a-15 under the Securities Exchange Act of 1934) during the last fiscal quarter that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
 
Attestation Report of Independent Registered Public Accounting Firm
 
To the Board of Directors and Stockholders of Nano-Proprietary, Inc.
 
We have audited management’s assessment, included in the accompanying Report on Management’s Assessment of Internal Control over Financial Reporting, that Nano-Proprietary, Inc. maintained effective internal control over financial reporting as of December 31, 2005, based on criteria established in Internal Control — Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Nano-Proprietary, Inc.’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting. Our responsibility is to express an opinion on management’s assessment and an opinion on the effectiveness of the company’s internal control over financial reporting based on our audit.
 
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, evaluating management’s assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
 
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
 
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
 
In our opinion, management’s assessment that Nano-Proprietary, Inc. maintained effective internal control over financial reporting as of December 31, 2005, is fairly stated, in all material respects, based on criteria established in Internal Control — Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Also in our opinion, Nano-Proprietary, Inc. maintained in all material respects, effective internal control over financial reporting as of December 31, 2005, based on criteria established in Internal Control — Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
 
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the balance sheets and the related statements of income, stockholders equity, and cash flows of Nano-Proprietary, Inc., and our report dated January 27, 2006 expresses an unqualified opinion. 
 
 
Sprouse & Anderson, L.L.P.
Austin, Texas
January 27, 2006
 


 

 
 
Item 9B.Other Information.
 
Nano-Proprietary completed a private placement of $1,500,000 whereby it issued 750,000 shares of common stock to accredited investors at a price of $2.00 per share. The proceeds will be used for working capital. A total of 375,000 shares were acquired by Pinnacle Fund LP and 375,000 shares were acquired by Karrison Nichols, both participants in previous private placements of the Company’s stock.
 

 
 

 
 

 
 
 
 
 
 
 
 
 
 
 
 
 



 
 
Directors and Executive Officers of the Registrant
 
The following sets forth the names, ages and certain information concerning the Directors and Executive Officers of Nano-Proprietary. 
 
Name 
Age
Class
Position
Director/Officer Since
Term Expires
                                             
         
                  
                                                
                           
                    
Marc W.  Eller
50
III
Director, Chairman, Chief Executive Officer
November 1995
2006
Dr. Zvi Yaniv
59
II
Director, President,  Chief Operating Officer
July 1996
2006
Douglas P. Baker
49
N/A
Chief Financial Officer
June 1996
N/A
John Ruberto
60
N/A
Senior Vice President
May 2005
N/A
Charles C.  Bailey
57
I  
Director
November 1999
2006
Ronald J.  Berman
49
III
Director
May 1996
2006
Eddie Lee
43
II 
Director
October 2001
2006
Dr. Robert Ronstadt
64
II
Director
January 2003
2006
David R.  Sincox
67
I  
Director
October 1994
2006
 
______________________
 
Marc W. Eller has served as the Company’s Chief Executive Officer since July 29, 1996. Mr. Eller is Chairman of the Board of Directors and has been a Director since November 1995. Prior to becoming CEO, Mr. Eller was involved in commercial real estate investment and in investment banking activities for publicly traded companies. Mr. Eller has a B.A. degree in Economics.
 
Dr. Zvi Yaniv has served as the Company’s President and Chief Operating Officer and a Director since July 29, 1996. Dr. Yaniv has degrees in physics, mathematics, and electro-optics as well as a Ph.D. in Physics. Prior to joining the Company, in May 1996, Dr. Yaniv operated a consulting practice and previously was President and CEO of Optical Imaging Systems Inc., a supplier of flat panel color liquid crystal displays to the avionics and defense industries.
 
Douglas P. Baker has been with the Company since June 17, 1996. Mr. Baker is a C.P.A. and has both a B.B.A. and a M.B.A. Immediately prior to joining Nano-Proprietary, Inc., Mr. Baker was a divisional controller for MascoTech, Inc. from 1991 to 1996. Mr. Baker also had prior experience in public accounting and as CFO of a privately held company.
 
John Ruberto has been with the Company since May 1, 2005. From 2002 to 2005, Mr. Ruberto was an independent management consultant. During 2001 and 2002, Mr. Ruberto was Executive Vice President of Strategy and Development at Eagle Picher Technologies and President of Eagle Picher Power. Prior to 2001 Mr. Ruberto had extensive corporate development, program management and business development experience at United Technologies Corporation and Gen Corp. Mr. Ruberto also served as a Principal Deputy Assistant to the U.S. Secretary of Defense where he managed system acquisition responsibilities for many defense programs.
 
Charles C. Bailey has been an attorney in private practice since 1995. Prior to that Mr. Bailey had a 20-year career in government. Positions held include Assistant Criminal District Attorney and Chief Prosecutor in Lubbock County,  Texas; General Counsel for the Texas Department of Public Safety; Assistant General Counsel for Governor Bill Clements; and Director of Legal Services and Franchise Taxes for the Texas State Comptroller’s Office. His last position with the state of Texas, from 1993 to 1995, was Executive Assistant and General Counsel to Lt. Governor Bob Bullock.
 
 
 
 


 
 
Ronald J. Berman has been a Director since May 1996. Mr. Berman co-founded BEG Enterprises, Inc. with Marc W. Eller and was its President from 1989 until 1998.  Mr. Berman currently is President of R.J. Berman Enterprises, Ltd., a real estate development company, Inergi Fitness, and Walkers Warehouse. Mr. Berman earned a Juris Doctor degree in 1980 from the University of Detroit. Prior to 1989, Mr. Berman was an attorney in private practice.
 
Eddie Lee is Chairman and CEO of Pacific Northern, Inc., a Company that he founded in 1987.  Pacific Northern, Inc. is the largest visual display company serving the retail jewelry industry.
 
Dr. Robert Ronstadt has been a Director since January 2003. Dr. Ronstadt became Vice President of Technology Commercialization for Boston University in June 2003.  At the same time, he became the Director of Boston University's Technology Commercialization Institute.  He was special advisor to the Chancellor of Boston University from January to May 2003. Prior to that, from 1998 to 2002, he was Director of the IC2 Institute at the University of Texas in Austin and the J. Marion West Chair of Constructive Capitalism. Dr. Ronstadt was a professor of entrepreneurship at the Pepperdine University School of Business Management from 1992 to 1998 and Babson College in Wellesley Massachusetts from 1975 to 1985.  From 1986 to 1992, he was the CEO of a software enterprise.
 
David R. Sincox has been a Director of the Company since October 1994. From 1987 through 2000, Mr. Sincox  served as the Vice President of Administration of Ref-Chem Construction Corporation, an engineering and construction firm. Since January 2001, Mr. Sincox has been President of Clear Lake Business Services, Inc. a consulting firm.
 
Shareholder Director Nominating Procedures

The Company does have a procedure in place for holders of the Company‘s common stock to recommend nominees to the Company’s Board of Directors. These procedures are set forth in Article 9(b) of the Company’s Restated Articles of Incorporation (the “Restated Articles”). A copy of the Company’s Restated Articles is filed as Exhibit 3(I) to this Annual Report on Form 10-K. As set forth in Article 9(b) of the Restated Articles, only persons who are nominated in accordance with the procedures set forth in that Article are eligible for election as Directors of the Company. Nominations of persons for election to the Board of Directors of the Company may be made at a meeting of shareholders by or at the direction of the Board of Directors or by any shareholder of the Company entitled to vote for the election of Directors at the meeting who complies with the notice procedures set forth in Article 9(b). Such nominations, other than those made by or at the direction of the Board of Directors, shall be made pursuant to timely notice in writing to the Secretary of the Corporation. To be timely, a shareholder's notice shall be delivered to or mailed and received at the principal executive offices of the Company not less than 60 days nor more than 90 days prior to the meeting; provided, however, that in the event that less than 70 days' notice or prior public disclosure of the date of the meeting is given or made to shareholders, notice by the shareholder to be timely must be so received not later than the close of business on the 10th day following the date on which such notice of the date of the meeting was mailed or such public disclosure was made. Such shareholder's notice shall set forth (i) as to each person whom the shareholder proposes to nominate for election or re-election as a Director, (A) the name, age, business address and residence address of such person, (B) the principal occupation or employment of such person, (C) the class and number of shares of the Company which are beneficially owned by such person, and (D) any other information relating to such person that is required to be disclosed in solicitations of proxies for election of Directors, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (including without limitation such person's written consent to being named in the proxy statement as a nominee and to serve as a Director if elected); and (ii) as to the shareholder giving the notice, (1) the name and address, as they appear on the Company’s books, of such shareholder and (2) the class and number of shares of the Company which are beneficially owned by such shareholder. No person shall be eligible for election as a Director of the Company unless nominated in accordance with the procedures set forth in Article 9(b) of the Restated Articles. The Chairman of the meeting shall, if the facts warrant, determine and declare to the meeting that a nomination was not made in accordance with the procedures prescribed herein, and if he should so determine, he shall so declare to the meeting and the defective nomination shall be disregarded.
 
Committees
 
The Board of Directors has four committees. The audit committee consists of Mr. Sincox and Mr. Bailey. The compensation committee consists of Mr. Lee and Mr. Berman. The nominating committee consists of Dr. Ronstadt and Mr. Bailey. The executive committee consists of Mr. Eller and Dr. Yaniv. 
 


 
Audit Committee Financial Expert 
 
The Board of Directors has determined that David R. Sincox, a member of the audit committee, is an “audit committee financial expert” and “independent” as defined under applicable SEC rules. The board’s affirmative determination was based upon, among other things, his experience as Vice President of Administration of Ref-Chem Construction Company and his consulting practice.
 
Code of Ethics
 
We have adopted a Code of Ethics within the meaning of Item 406(b) of Regulation S-B of the Securities Exchange Act of 1934. This Code of Ethics applies to all directors, officers, and employees of the Company. A copy of this Code of Ethics is publicly available on our website at www.nano-proprietary.com.
 
 
 
Section 16(a) Beneficial Ownership Reporting Compliance
 
Section 16(a) of the Securities of Exchange Act of 1934 requires Nano-Proprietary’s officers, and Directors, and persons who beneficially own more than 10 % of a registered class of Nano-Proprietary’s common stock, to file reports of ownership and changes in ownership with the Securities and Exchange Commission and NASDAQ. Officers, Directors, and beneficial owners of more than 10% of Nano-Proprietary’s common stock are required by the Securities and Exchange Commission regulations to furnish Nano-Proprietary with copies of all Section 16(a) forms that they file.
 
Based solely on review of the copies of such reports furnished to us, or written representations that no reports were required, we believe that for the period from January 1, 2005 through December 31, 2005, all Officers, Directors, and greater than 10% beneficial owners complied with all Section 16(a) filing requirements applicable to them, with the exception of Director Bailey as described below.
 
On October 11, 2005 Director Bailey exercised 25,000 options and sold the shares received from the exercise on the same day. The Form 4 for these transactions was due on October 13, 2005, but was not filed until October 14, 2005.
 
 
 
 
 
 
 
 
 
 


 
The following table sets forth the total cash compensation paid or to be paid, as well as certain other compensation paid or accrued, for services rendered during the fiscal years ended December 31, 2005, 2004 and 2003 by the Chief Executive Officer and all executive officers whose total annual salary and bonus exceeded $100,000 for the fiscal year ended December 31, 2005 (the "Named Executive Officers"):
 
 
SUMMARY COMPENSATION TABLE
 
 
       
Annual Compensation (1)
 
Long-Term
Compensation
 
 
Name and Principal Position
 
 
Year
 
 
Salary($)
 
 
Bonus($)
 
 
Securities
Underlying
Options(#)
 
                   
Marc W.  Eller,
   
2005
 
 
$250,000
 
 
-0-
 
 
700,000
 
Chief Executive Officer
 
 
2004
 
 
$200,000
 
 
-0-
 
 
750,000
 
 
 
 
2003
 
 
$145,000
 
 
-0-
 
 
280,000
 
 
 
 
 
 
 
 
 
 
 
 
 
Zvi Yaniv, President and
 
 
2005
 
 
$250,000
 
 
-0-
 
 
700,000
 
Chief Operating Officer
 
 
2004
 
 
$200,000
 
 
-0-
 
 
750,000
 
 
 
 
2003
 
 
$145,000
 
 
$147,917
 
 
280,000
 
 
 
 
 
 
 
 
 
 
 
 
 
Douglas P. Baker,
 
 
2005
 
 
$180,000
 
 
-0-
 
 
350,000
 
Chief Financial Officer
 
 
2004
 
 
$150,000
 
 
-0-
 
 
400,000
 
 
 
 
2003
 
 
$127,083
 
 
-0-
 
 
213,000
 
John Ruberto
 
 
 
 
 
 
 
 
 
 
 
 
 
Vice President
 
 
2005
 
 
$120,000
 
 
-0-
 
 
535,000
 
 
______________________
 
(1)
No Named Executive Officers received perquisites that exceeded in value the lesser of $50,000 or 10% of such officers' salary and bonus.
   
(2)
Mr. Ruberto started employment on May 1, 2005.
 
 

 


 
EMPLOYMENT AGREEMENTS
 
The Company currently has no employment agreements with any of its executive officers.
 
OPTION GRANTS IN LAST FISCAL YEAR
 
In 2002, Nano-Proprietary established its 2002 Equity Compensation Plan, which may be used to grant employees, including officers of Nano-Proprietary, incentive stock options designed to qualify under Section 422 of the Internal Code of 1986, or non-qualified stock options. The following table sets forth information concerning stock-option grants to the Named Executive Officers in 2005.
 
 
Name
Number of
Securities Underlying
Options
Granted(#)(1)
Percent of Total
Options Granted to
Employees in
Fiscal Year 2005
Exercise
or Base Price ($/Sh)
Expiration Date
Grant Date
Present Value (5)
           
Marc W. Eller
400,000 (2) 
13.93%
$2.17
1/1/15
$583,960 
 
300,000 (3) 
10.45%
$2.30
11/17/15
$421,470 
           
Dr. Zvi Yaniv
400,000 (2) 
13.93%
$2.17
1/1/15
$583,960 
 
300,000 (3) 
10.45%
$2.30
11/17/15
$421,470 
           
Douglas P. Baker
200,000 (2) 
6.96%
$2.17
1/1/15
$291,980 
 
150,000 (3) 
5.22%
$2.30
11/17/15
$210,735 
           
John Ruberto
535,000 (4) 
18.63%
$2.30
4/25/15
$827,806 
           
           
 
_____________
(1)
The options were granted for a term of ten (10) years, subject to earlier termination in certain events related to termination of employment.
(2)
For Mr. Eller and Dr. Yaniv, these options vest as follows: 200,000 if royalty or other agreements that will result in revenues totaling $3 million are executed in 2005 or 2006 and 200,000 options if the Company achieves profitability in 2005. The options for Mr. Baker vest according to the same milestones, but the amounts are 100,000 for each milestone. Since the Company did not achieve profitability in 2005, all options related to that milestone did not vest and expired December 31, 2005. The present value includes all options granted, including those which expired at the end of 2005.
(3)
These options will vest if the Company achieves profitability in 2006.
(4)
 
A total of 35,000 of these options vested on the grant date. The remaining 500,000 options are performance based options that vest when the Company receives commitments for future revenues related to specific sources. A total of 150,000 of these options vested by December 31, 2005. The remaining 350,000 may still vest in the future.
 (5)
 
The fair value of these options at the date of grant was estimated using a Black-Scholes option pricing model. The following weighted average assumptions were used to estimate the value of the options: a 3.5 year expected life of the options, a dividend yield of 0%, expected volatility for the shares of 100%, a turnover/forfeiture percentage of 0%, and a risk free rate of return of 3.5%.



AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR
AND FISCAL YEAR-END OPTION VALUES
 
The following table sets forth certain information concerning (i) the exercise of stock options by each of the Named Executive Officers during the last fiscal year ended December 31, 2005 and (ii) the number and intrinsic value of the options held by the Named Executive Officers at December 31, 2005. Year-end values are based on the closing price of $2.15 per share of the common stock on December 31, 2005, on the OTC Bulletin Board System. They do not reflect the actual amounts, if any, which may be realized upon the future exercise of remaining stock options and should not be considered indicative of future stock performance.
 
Name
 
Shares
Acquired
on Exercise (#)
 
Value
Realized ($)
 
Number of
Unexercised
Securities
Underlying
Options at
December 31, 2005 (#)
Exercisable/
Unexercisable
 
Value of
Unexercised
In-the-Money
Options at
December 31, 2005 ($)
Exercisable/
Unexercisable
 
 
 
 
 
 
 
 
 
 
 
Marc W.  Eller
 
 
0
 
 
0
 
 
230,000 / 700,000
 
 
$0 / $0
 
Dr. Zvi Yaniv
 
 
0
 
 
0
 
 
560,000 / 700,000
 
 
$185,200 / $0
 
Douglas P. Baker
 
 
0
 
 
0
 
 
725,000 / 350,000
 
 
$605,210 / $0
 
John Ruberto
 
 
0
 
 
0
 
 
185,000 / 350,000
 
 
$0 / $0
 
 
DIRECTOR COMPENSATION FOR 2005
 
 
All Directors who are not employees of the Company receive $150 per board meeting or committee meeting attended in person, and $50 per telephonic meeting. Reasonable expenses incurred by each Director in connection with his duties as a Director are also reimbursed by Nano-Proprietary.
 
All of Nano-Proprietary’s outside Directors participate in the 2002 Equity Compensation Plan, under which Nano-Proprietary may grant stock options to any Director. On July 25, 2005, each of the five outside Directors was granted an automatic grant of 50,000 options under the 2002 Equity Compensation Plan at a price of $2.12. These grants became exercisable in full on the date of the grant.
 
All of the Directors have retained the right to pursue additional business activities that are not competitive with the business of Nano-Proprietary, and do not adversely affect their performance as Directors. If, as, and when conflicts of interest arise, the nature of the conflict must be fully disclosed to the Board of Directors, and the person who is subject to the conflict must abstain from participating in any decision that may impact on his conflict of interest. Except for this disclosure and abstention policy, the Directors will not be in breach of any fiduciary duties owed to Nano-Proprietary or the shareholders by virtue of their participation in such additional business activities.
 
Compensation Committee Interlocks and Insider Participation

The Compensation Committee currently consists of Mr. Lee and Mr. Berman, neither of which is or has been an officer or employee of Nano-Proprietary. No interlocking relationship existed during the fiscal year ended December 31, 2005, between Nano-Proprietary’s Board of Directors or Compensation Committee and the board of directors or compensation committee of any other company.
 
 
 


 
 
 
CERTAIN BENEFICIAL OWNERS
 
 
The only persons or entities known to be the beneficial owner of 5% or more of the outstanding voting stock of the common stock of Nano-Proprietary, Inc. stock as of February 24, 2006, are listed below. For the purposes of this Annual Report on Form 10-K, beneficial ownership of securities is defined in accordance with the rules of the SEC to mean generally the power to vote or dispose of securities, regardless of any economic interest therein.
 
   
Beneficial Ownership
 
Percent of Outstanding Common Stock
         
Pinnacle Fund, L.P.
 
6,821,461
 
6.84%
Barry Kitt, General Partner
4965 Preston Park Blvd.,Suite 240
Plano, TX 75093
       
         
Jeffrey L. Feinberg
 
5,955,350
 
5.97%
JLF Asset Management LLC
2775 Via de la Valle, Suite 204
Del Mar, CA 92014
       
 
SECURITY OWNERSHIP OF MANAGEMENT
 
Set forth below is certain information with respect to beneficial ownership of Nano-Proprietary’s common stock as of February 24, 2006, by each Director, each Named Executive Officer and by the directors and executive officers as a group. Unless otherwise indicated, each person or member of the group listed has sole voting and investment power with respect to the shares of common stock listed.
 
 
Name
 
Options Included
in Beneficial
Ownership (1)
 
Common Stock
Beneficial
Ownership
 
Percentage
of Class
 
Dr. Robert Ronstadt
   
125,000
   
125,000
   
*
 
David R. Sincox
   
445,000
   
570,000
   
*
 
Charles C. Bailey
   
218,333
   
218,333
   
*
 
Marc W. Eller
   
230,000
   
247,500
   
*
 
Eddie Lee
   
216,667
   
216,667
   
*
 
Ronald J. Berman
   
689,383
   
1,104,925
   
1.10%
 
Dr. Zvi Yaniv
   
560,000
   
596,000
   
*
 
Douglas P. Baker
   
725,000
   
734,500
   
*
 
John Ruberto
   
185,000
   
185,000
   
*
 
All Executive Officers and 
Directors as a group (9 persons)
   
3,394,383
   
3,997,925
   
3.88%
 
 
_________________________
 
*
 Less than 1%
 
 
 (1)
 This column lists shares that are subject to options exercisable within sixty (60) days of February 24, 2006, and are included in common stock beneficial ownership pursuant to Rule 13d-3(d)(1) of the Exchange Act.
  
 
 
 
SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

 
Equity Compensation
Plans Not Approved by
the Shareholders of
the Nano-Proprietary
 
Number of Securities to
be issued upon exercise
of outstanding options
 
Weighted-average
exercise price of
outstanding options
 
Number of Securities remaining available for future issuance under
equity compensation
plans (3)
 
(a)
(b)
(c)
1992 Employee Plan (1)
977,000
$1.01
-
1992 Outside Directors
    Plan (2) 
327,716
$1.09
-
1998 Directors and 
    Officers Plan
550,000
$0.47
-
2002 Equity  
    Compensation Plan
4,848,435
$2.21
2,010,109
Total
6,703,151
$1.57
2,010,109
 

 
(1)
The 1992 Employee Plan was originally approved by shareholders and authorized 3.0 million shares. The plan was subsequently amended twice by the Board to increase the authorized number of shares and is therefore classified as a plan not approved by our shareholders.
   
(2)
The 1992 Outside Directors Plan was originally approved by shareholders and authorized 500,000 shares. The plan was subsequently amended by the Board to increase the authorized number of shares and is therefore classified as a plan not approved by our shareholders
   
(3)
This column excludes securities reflected in column (a)
 
There are no equity compensation plans approved by shareholders at the present time.
 
The 1992 Employee Plan was created in 1992 for the purpose of granting incentive or non-qualified stock options to employees of, or contractors for, the Company. A total of 6.5 million shares were authorized under the plan. All options granted under this plan were priced at the fair market value of our common stock on the date of grant, or greater, and have a life of ten (10) years from their date of grant, subject to earlier termination as set forth in such plan. The plan expired in 2002; however, options granted prior to such plan’s expiration remain exercisable, subject to the terms of the respective option grants.
 
The 1992 Outside Directors’ Plan was established in 1992 for the purpose of granting non-qualified options to non-employee Directors of the Company. A total of 1.0 million options were authorized under the plan. All options granted under this plan were priced at the fair market value of our common stock or greater on the date of grant and have a life of ten (10) years from their date of grant, subject to earlier termination as set forth in such plan.  The plan expired in 2002; however, options granted prior to such plan’s expiration remain exercisable, subject to the terms of the respective option grants.
 
In 1998, the Company’s Board of Directors established the 1998 Directors’ and Officers Plan to award non-qualified options to Officers and Directors. All options granted under this plan were priced at the fair market value of our common stock, or greater, on the date of grant and have a life of ten (10) years from their date of grant, subject to earlier termination as set forth in such plan.  A total of 2.5 million options were granted under this plan; however no options remain available for granting under this plan.
 


In 2002, the Company’s Board of Directors established the 2002 Equity Compensation Plan for the purpose of granting incentive or non-qualified stock options to employees or directors of the Company. All options granted under this plan were priced at the fair market value of our common stock, or greater, on the date of grant and have a life of up to ten (10) years from their date of grant, subject to earlier termination as set forth in such plan.  A total of 5,000,000 options were initially authorized under this plan. This plan was amended December 31, 2004 to increased the authorized shares by 3,000,000 to a total of 8,000,000 shares.
 
For a further description of each of the stock option plans described above, please see Note 8 to the Consolidated Financial Statements herein.
 
 
In October 1998, EBT entered into a Patent Assignment and Royalty Agreement with Advanced Technology Incubator, Inc., (“ATI”) a corporation based in Austin, Texas and owned by Dr. Zvi Yaniv, the Company’s President and Chief Operating Officer. Under the terms of the agreement, ATI agreed to assign U.S. Patent No. 5,469,187 related to certain LCD technology to EBT in exchange for an initial payment of $200,000. In addition, ATI is entitled to receive a royalty of 5% of gross revenue related to products using this patent. EBT may terminate this assignment at any time upon 30 days written notice to ATI. The assignment may be terminated by ATI if, within two years of the first sale or lease of a display unit using this technology, cumulative royalty payments under the agreement have not totaled $500,000, or if payments do not equal $500,000 in any one-year period following this initial two-year period. If the assignment is terminated by ATI, EBT will be granted a non-exclusive worldwide license to use the technology under terms similar to those contained in this agreement. There have been no sales or leases of display units using this technology, therefore the two year period that could result in minimum payments being due has not yet started.

 
Audit Fees
 
The aggregate fees billed to the Company by Sprouse & Anderson, L.L.P. for the audit of Nano-Proprietary’s annual financial statements and for the review of the financial statements included in its quarterly reports on Form 10-Q for the Fiscal Years ended December 31, 2005 and 2004 totaled $42,700 and $24,650, respectively.
 
Audit-Related Fees
 
Nano-Proprietary did not incur or pay any fees to Sprouse & Anderson, L.L.P., and Sprouse & Anderson, L.L.P. did not provide any services related to audit-related fees in the last two fiscal years.
 
Tax Fees
 
There were no fees billed to Nano-Proprietary by Sprouse & Anderson, L.L.P. for services rendered to Nano-Proprietary during the last two fiscal years for tax compliance, tax advice, or tax planning.
 
 All Other Fees
 
There were no fees billed to Nano-Proprietary by Sprouse & Anderson, L.L.P. for services rendered to Nano-Proprietary during the last two fiscal years, other than the services described above under “Audit Fees.”
 
It is the audit committee’s policy to pre-approve all services provided by Sprouse & Anderson, L.L.P. All services provided by Sprouse & Anderson, L.L.P. during the years ended December 31, 2005 and 2004 were pre-approved by the audit committee.
 
As of the date of this filing, Nano-Proprietary current policy is to not engage Sprouse & Anderson, L.L.P. to provide, among other things, bookkeeping services, appraisal or valuation services, or internal audit services. The policy provides that Nano-Proprietary engage Sprouse & Anderson, L.L.P. to provide audit, tax, and other assurance services, such as review of SEC reports or filings.
 
 
 
 
 The Audit Committee considered and determined that the provision of the services other than the services described under “Audit Fees” is compatible with maintaining the independence of the independent auditors.
 
 
 
 
(a)  
Exhibits: See Index to Exhibits on page 60 for a descriptive response to this item.
 
(b)  
None
 
 
SIGNATURES
 
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
 
 
NANO-PROPRIETARY, INC.
 
By:    /s/ Marc W. Eller                                       
                Marc W.  Eller,
                Chief Executive Officer
                March 2, 2006
 
In accordance with the Exchange Act, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
Signature
 Title
 Date
     
 
/s/  Marc W. Eller
Marc W.  Eller 
Chairman, Chief Executive 
Officer (Principal Executive Officer and
Director)
March 2, 2006
     
/s/ Douglas P.  Baker
Douglas P.  Baker 
Vice President and
Chief Financial Officer 
(Principal Financial Officer and Principal Accounting Officer)
March 2, 2006
     
Dr. Robert Ronstadt*
David R.  Sincox*
Eddie Lee*
Ronald J.  Berman* 
Charles G.  Bailey*
Dr. Zvi Yaniv*          
Directors
 
March 2, 2006
 
*By:         //s// Douglas P. Baker   
          (Douglas P. Baker,
          Attorney-in-Fact)
 
 

 

INDEX TO EXHIBITS
 
The exhibits indicated by an asterisk (*) have been previously filed with the Securities
and Exchange Commission and are incorporated herein by reference.
 
EXHIBIT
NUMBER
DESCRIPTION OF EXHIBIT
3(i).1
Restated Articles of Incorporation of Company, as filed March 1, 2006 with the Secretary of State for the State of Texas.
3(ii).1
Amended and Restated Bylaws of the Company.
4.1 *
Form of Certificate for shares of the Company’s common stock (Exhibit 4.1 to the Company’s Registration Statement on Form SB-2[No.33-51446-FW] dated January 7, 1993).
4.2*
Amended and Restated Rights Agreement dated as of November 16, 2000, between the Company and American Securities Transfer, Incorporated, as Rights Agent, which includes as Exhibit A the form of Statement of Resolution establishing and designating series of preferred stock as “Series  H Junior Participating Preferred Stock” and fixing and determining the relative rights and preferences thereof, as Exhibit B the form of Rights Certificate, and as Exhibit C the Summary of Rights to Purchase Preferred Shares. (Exhibit 4.1 to the Company’s Current Report on Form 8-K dated as of November 16, 2000).
4.3*
Form of Regulation D Subscription agreement by and between the Company and the participants of private placements. (Exhibit 4.3 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2004)
4.4*
Form of Registration Rights Agreement by and between the Company and the participants of private placements. (Exhibit 4.4 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2004)
10.1*
Amended and Restated 1992 Outside Directors’ Stock Option Plan (Exhibit 4.2 to the Company’s Registration Statement on Form S-8 [No. 333-56547] dated June 9, 1998).
10.2*
1998 Directors and Officers Stock Option Plan (Exhibit 4.3 to the Company’s Registration Statement on Form S-8 [No. 333-56547] dated June 9, 1998).
10.3*
Amended and Restated 1992 Stock Option Plan (Exhibit 4.1 to the Company’s Registration Statement on Form S-8 [No. 333-56457] dated June 9, 1998)
10.4*
Amended and Restated 2002 Equity Compensation Plan. (Exhibit 10.4.to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2004)
10.5*
Patent Assignment and Royalty Agreement between Electronic Billboard Technology, Inc. and Advanced Technology, Incubator, Inc. dated as of October 6, 1998. (Exhibit 10.18 to the Company’s Current Report on Form 10-KSB dated as of March 31, 1999).
10.6*
Lease agreement between the Company and Industrial Properties Corporation dated as of February 15, 2004. (Exhibit 10.11 to the Company’s Annual Report on Form 10-KSB for the fiscal year ended December 31, 2004).
10.7*
Patent License Agreement, dated as of March 26, 1999, by and between the Company and Canon, Inc. (Exhibit 10.1 to the Company’s amended Current Report on Form 8-K/A dated as of April 16, 1999).
10.8*
Agreement of Research and Development by and between the Applied Nanotech, Inc. and Futaba Corporation (Exhibit 10.1 to the Company’s Current Report on Form 8-K dated as of January  1, 2001)
10.9*
 
Agreement of Research and Development by and between the Applied Nanotech, Inc. and Futaba Corporation for Phase II development (Exhibit 10.14 to the Company’s Annual Report on From 10-KSB for the fiscal year ended December 31, 2001).
10.10*
 
Agreement for HyFED™ Development Team Phase II by and between Field Emission Picture Element Technology, Inc. and Electrovac Ges.m.b.H. (Exhibit 10.2 to the Company’s Current Report on Form S-2 date August 24, 2001)



EXHIBIT
NUMBER
DESCRIPTION OF EXHIBIT
10.11*
Agreement for HyFED™ Development Team Phase II by and between Field Emission Picture Element Technology, Inc. and Imaging System Technology, Inc. (Exhibit 10.3 to the Company’s Current Report on Form S-2 date August 24, 2001)
10.12*
Agreement for HyFED™ Development Team Phase II by and between Field Emission Picture Element Technology, Inc. and Supertex, Inc. (Exhibit 10.4 to the Company’s Current Report on Form S-2 date August 24, 2001)
10.13*
Agreement for HyFED™ Development Team Phase II by and between Field Emission Picture Element Technology, Inc. and Schott Fiber Optics. (Exhibit 10.5 to the Company’s Current Report on Form S-2 date August 24, 2001)
10.14*
Agreement for HyFED™ Development Team Phase II by and between Field Emission Picture Element Technology, Inc. and Lead Sangyo Co., Ltd. (Exhibit 10.6 to the Company’s Current Report on Form S-2 date August 24, 2001)
10.15*
Agreement for HyFED™ Development Team Phase II by and between Field Emission Picture Element Technology, Inc. and Shanghai Novel Color Picture Tube Co., Ltd. (Exhibit 10.7 to the Company’s Current Report on Form S-2 date August 24, 2001)
10.16*
Agreement for HyFED™ Development Team Phase II by and between Field Emission Picture Element Technology, Inc. and Shanghai Vacuum Electron Devices Co., Ltd. (Exhibit 10.8 to the Company’s Current Report on Form S-2 date August 24, 2001)
10.17*
Nano-Proprietary, Inc. Audit Committee Charter (Exhibit 10.23 to the Company’s Annual Report on Form 10-KSB for the fiscal year ended December 31, 2002)
10.18
Nano-Proprietary, Inc. Compensation Committee Charter
10.19
Nano-Proprietary, Inc. Nominating Committee Charter
10.21*
Research/Development and License Agreement entered into by Applied Nanotech, Inc. dated as of September 11, 2002 (Exhibit 10.1 to the Company’s Current Report on Form 8-K dated as of September 27, 2002).
10.22*
Patent License Agreement between SI Diamond Technology, Inc. and Till Keesman (Exhibit 10 to the Company’s Quarterly Report on Form 10-QSB for the quarter ended June 30, 2000)
10.23*
Second Addendum to Patent License Agreement by and among Nano-Proprietary, Inc. and Till Keesman (Exhibit 10.1 to the Company’s Current Report on Form 8-K dated as of November 18, 2002).
10.24*
Development, Purchase, and License Agreement for Hydrogen Sensor Products and related Services between, Nano-Proprietary, Inc. Applied Nanotech, Inc. and Kelman Ltd. (Exhibit 10.1 to the Company’s Current Report on Form 8-K dated as of July 13, 2005).
11
Computation of (Loss) per Common Share
14*
Nano-Proprietary, Inc. Code of Ethics (Exhibit 14 to the Company’s Annual Report on Form 10-KSB for the fiscal year ended December 31, 2004)
21
Subsidiaries of the Company
24
Powers of Attorney.
31.1
Rule 13a-14(a)/15d-14(a) Certificate of Marc W. Eller, Chief Executive Officer
31.2
Rule 13a-14(a)/15d-14(a) Certificate of Douglas P. Baker, Chief Financial Officer
32.1
Section 1350 Certificate of Marc W. Eller, Chief Executive Officer
32.2
Section 1350 Certificate of Douglas P. Baker, Chief Financial Officer

 
 
Page 61
 
EX-3.I.1 2 ex3i-1.htm EXHIBIT 3 (I).1 Exhibit 3 (i).1

 

EXHIBIT 3(i).1



OF

NANO-PROPRIETARY, INC.

Pursuant to the provisions of Article 4.07 (B) of the Texas Business Corporation Act (the "TBCA"), Nano-Proprietary, Inc. (the "Corporation") adopts the following Restated Articles of Incorporation (the "Restated Articles"). The Restated Articles accurately copy the Amended and Restated Articles of Incorporation of the Corporation currently in effect, and all amendments thereto that are in effect to date, and contain no change in any provision thereof.

ARTICLE ONE

The name of the corporation is Nano-Proprietary, Inc.

ARTICLE TWO

The period of its duration is perpetual.

ARTICLE THREE

The objects and purposes for which the Corporation is organized, the nature of the business to be conducted by the Corporation, and the powers which may be exercised by the Corporation are stated and declared to be as follows:

(a) To enter into and engage in any business activities that lawfully may be conducted by a Corporation organized and existing under the Texas Business Corporation Act (the "TBCA") either directly, or through affiliated or subsidiary companies which may be formed under the laws of any State or foreign nation where the conduct of such activities is lawful;

(b) To enter into and engage in business activities either for its own account, or for the account of others, as agent, and either as agent or principal, to enter upon or engage in any kind of business of any nature whatsoever, in which corporations organized under the TBCA may engage; and to the extent not prohibited thereby to enter upon and engage in any kind of business of any nature whatsoever in any other state of the United States of America, any foreign nation, and any territory of any country to the extent permitted by the laws of such other state, nation or territory;

(c) To acquire, organize and create subsidiary and affiliated companies under the laws of any state or foreign nation;

(d) To engage in any other lawful act or activity for which a Corporation may be organized under the TBCA; and

(e) Nothing in this Article shall be construed as authorizing the Corporation to transact any business in the State of Texas prohibited by any law of the State of Texas, or to engage in any activity in the State of Texas which lawfully cannot be engaged in without first obtaining a license under the laws of the State of Texas and such license cannot be granted to a corporation, or to transact any of the business referred to in Section (B)(3)(a) or Section (B)(4) of Article 2.01 of the TBCA.

ARTICLE FOUR

The Corporation is hereby authorized to issue a total of 122,000,000 shares of capital stock which shall be subdivided into classes as follows:

DIVISION A - COMMON STOCK

One Hundred Twenty Million (120,000,000) shares of the Corporation's capital stock shall be denominated as Common Stock, have a par value of $0.001 per share, and have the rights, powers and preferences set forth in this paragraph.

(i) The holders of Common Stock shall share ratably, with all other classes of common equity, in any dividends that may, from time to time, be declared by the Board of Directors;

(ii) No dividends may be paid with respect to the Corporation's Common Stock, however, until dividend distributions to the holders of Preferred Stock, if any, have been paid in accordance with the certificate or certificates of designation relating to such Preferred Stock;


1





(iii) The holders of Common Stock shall share ratably, with all other classes of common equity, in any assets of the Corporation that are available for distribution to the holders of common equity securities of the Corporation upon the dissolution or liquidation of the Corporation;

(iv) The holders of Common Stock shall be entitled to cast one vote per share on all matters that are submitted for a vote of the shareholders;

(v) There are no redemption or sinking fund provisions that are applicable to the Common Stock of the Corporation; and

(vi) Subject only to the requirements of the TBCA and the foregoing limitations, the Board of Directors is expressly authorized to issue shares of Common Stock without stockholder approval, at any time and from time to time, to such persons and for such consideration as the Board of Directors shall deem appropriate under the circumstances.

DIVISION B - PREFERRED STOCK

Two Million (2,000,000) shares of the Corporation's authorized capital stock shall be denominated as Preferred Stock, par value of $1.00 per share. Shares of Preferred Stock may be issued from time to time in one or more series as the Board of Directors, by resolution or resolutions, may from time to time determine, each of said series to be distinctively designated. The voting powers, preferences and relative, participating, optional and other special rights, and the qualifications, limitations or restrictions thereof, if any, of each such series of Preferred Stock may differ from those of any and all other series of Preferred Stock at any time outstanding, and the Board of Directors is hereby expressly granted authority to fix or alter, by resolution or resolutions, the designation, number, voting powers, preferences and relative, participating, optional and other special rights, and the qualifications, limitations and restrictions thereof, of each such series of Preferred Stock, including, but without limiting the generality of the foregoing, the following:

(i) The distinctive designation of, and the number of shares of Preferred Stock that shall constitute, each series of Preferred Stock, which number (except as otherwise provided by the Board of Directors in the resolution establishing such series) may be increased or decreased (but not below the number of shares of such series then outstanding) from time to time by the Board of Directors without prior approval of the holders of such series;

(ii) The rights in respect of dividends, if any, of such series of Preferred Stock, the extent of the preference or relation, if any, of such dividends to the dividends payable on any other class or classes or any other series of the same or other class or classes of capital stock of the Corporation, and whether such dividends shall be cumulative or noncumulative;

(iii) The right, if any, of the holders of such series of Preferred Stock to convert the same into, or exchange the same for, shares of any other class or classes or of any other series of the same or any other class or classes of capital stock of the Corporation and the terms and conditions of such conversion or exchange, including, without limitation, whether or not the number of shares of such other class or series into which shares of such series may be converted or exchanged shall be adjusted in the event of any stock split, stock dividend, subdivision, combination, reclassification or other transaction or series of transactions affecting the class or series into which such series of Preferred Stock may be converted or exchanged;

(iv) Whether or not shares of such series of Preferred Stock shall be subject to redemption, and the redemption price or prices and the time or times at which, and the terms and conditions on which, shares of such series of Preferred Stock may be redeemed;

(v) The rights, if any, of the holder of such series of Preferred Stock upon the voluntary or involuntary liquidation, dissolution or winding up of the Corporation or in the event of any merger or consolidation of or sale of assets by the Corporation;
 
(vi) The terms of any sinking fund or redemption or repurchase amount, if any, to be provided for shares of such series of Preferred Stock;

(vii) The voting owners, if any, of the holders of any series of Preferred Stock generally or with respect to any particular matter, which may be less than, equal to or greater than one vote per share, and which may, without limiting the generality of the foregoing, include the right, voting as a series by itself or together with the holders of any other series of Preferred Stock or all series of Preferred Stock as a class, to elect one or more Directors of the Corporation (which, without limiting the generality of the foregoing, may include a specified number or portion of the then-existing number of authorized Directorships of the Corporation, or a specified number or portion of Directorships in addition to the then existing number of authorized Directorships of the Corporation), generally or under such specific circumstances and on such conditions, as shall be provided in the resolution or resolutions of the Board of Directors adopted pursuant hereto; and


2




(viii) Such other powers, preferences and relative, participating, optional and other special rights, and the qualifications, limitations and restrictions thereof, as the Board of Directors shall determine.

Notwithstanding the foregoing, and with the sole exception of shares issued pursuant to the duly adopted stock option plans of the Corporation, no shares of Preferred Stock shall be issued or sold to any officer or director of the Corporation, or any shareholder who directly or indirectly owns more than 5 % of the issued and outstanding voting stock of the Corporation, or any affiliate of such person, without the affirmative vote of a majority in interest of the disinterested shareholders of the Corporation. Upon the creation of any new class or series of Preferred Stock of the Corporation, the Board of Directors shall prepare and file with the records of the Corporation a certificate setting forth the rights and preferences of such class or series of Preferred Stock, which certificate shall be deemed an amendment to these Restated Articles and shall not require the consent of any shareholder.



DIVISION C - SERIES OF PREFERRED STOCK

SERIES H JUNIOR PARTICIPATING PREFERRED STOCK

The designations, preferences, limitations and relative rights of the Series H Junior Participating Preferred Stock of the Corporation are as follows:

1. Designation and Amount. There shall be a series of shares of preferred stock that shall be designated as "Series H Junior Participating Preferred Stock," and the number of shares constituting such series shall be Six Hundred Thousand (600,000).

2. Dividends and Distributions.

(A) Subject to the prior and superior rights of the holders of any shares of any series of shares of preferred stock ranking prior and superior to the Series H Junior Participating Preferred Stock with respect to dividends, the holders of shares of Series H Junior Participating Preferred Stock, in preference to the holders of shares of any class or series of shares of the Corporation ranking prior to the Series H Junior Participating Preferred Stock, shall be entitled to receive, when, as and if declared by the Board of Directors out of funds legally available for the purpose, quarterly dividends payable in cash on the 15th day of January, April, July and October in each year (each such date being referred to herein as a "Quarterly Dividend Payment Date"), commencing on the first Quarterly Dividend Payment Date after the first issuance of a share or fraction of a share of Series H Junior Participating Preferred Stock, in an amount per share (rounded to the nearest cent) equal to the greater of (a) $1.00 or (b) subject to the provision for adjustment hereinafter set forth, the Adjustment Number (as defined below) times the aggregate per share amount of all cash dividends, and the Adjustment Number times the aggregate per share amount (payable in kind) of all non-cash dividends or other distributions other than a dividend payable in shares of common stock or a subdivision of the outstanding shares of common stock (by reclassification or otherwise), declared on the shares of common stock of the Corporation (the "Common Stock") since the immediately preceding Quarterly Dividend Payment Date, or, with respect to the first Quarterly Dividend Payment Date, since the first issuance of any share or fraction of a share of Series H Junior Participating Preferred Stock. The "Adjustment Number" shall initially be 100. In the event the Corporation shall at any time after June 18, 1998 (the "Rights Declaration Date") (i) declare any dividend on Common Stock payable in Common Stock, (ii) subdivide the outstanding Common Stock or (iii) combine the outstanding Common Stock into a smaller number of shares, then in each such case the Adjustment Number in effect immediately prior to such event shall be adjusted by multiplying such Adjustment Number by a fraction the numerator of which is the number of shares of Common Stock outstanding immediately after such event and the denominator of which is the number of shares of Common Stock that were outstanding immediately prior to such event.

(B) The Corporation shall declare a dividend or distribution on the Series H Junior Participating Preferred Stock as provided in paragraph (A) above immediately after it declares a dividend or distribution on the Common Stock (other than a dividend payable in Common Stock); provided that, in the event no dividend or distribution shall have been declared on the Common Stock during the period between any Quarterly Dividend Payment Date and the next subsequent Quarterly Dividend Payment Date, a dividend of $1.00 per share on the Series H Junior Participating Preferred Stock shall nevertheless be payable on such subsequent Quarterly Dividend Payment Date.

(C) Dividends shall begin to accrue and be cumulative on outstanding Series H Junior Participating Preferred Stock from the Quarterly Dividend Payment Date next preceding the date of issue of such Series H Junior Participating Preferred Stock, unless the date of issue of such shares is prior to the record date for the first Quarterly Dividend Payment Date, in which case dividends on such shares shall begin to accrue from the date of issue of such shares, or unless the date of issue is a Quarterly Dividend Payment Date or is a date after the record date for the determination of holders of Series H Junior Participating Preferred Stock entitled to receive a quarterly dividend and before such Quarterly Dividend Payment Date, in either of which events such dividends shall begin to accrue and be cumulative from such Quarterly Dividend Payment Date. Accrued but unpaid dividends shall not bear interest. Dividends paid on the Series H Junior Participating Preferred Stock in an

3


amount less than the total amount of such dividends at the time accrued and payable on such shares shall be allocated pro rata on a share by share basis among all such shares at the time outstanding. The Board of Directors may fix a record date for the determination of holders of Series H Junior Participating Preferred Stock entitled to receive payment of a dividend or distribution declared thereon, which record date shall be no more than 30 days prior to the date fixed for the payment thereof.

3. Voting Rights. The holders of Series H Junior Participating Preferred Stock shall have the following voting rights:

(A) Each share of Series H Junior Participating Preferred Stock shall entitle the holder thereof to a number of votes equal to the Adjustment Number on all matters submitted to a vote of the shareholders of the Corporation.

(B) Except as otherwise provided herein or by law, the holders of Series H Junior Participating Preferred Stock and the holders of the Common Stock shall vote together as one class on all matters submitted to a vote of shareholders of the Corporation.

 
(C)
(i) If at any time dividends on any Series H Junior Participating Preferred Stock shall be in arrears in an amount equal to six (6) quarterly dividends thereon, the occurrence of such contingency shall mark the beginning of a period (herein called a "default period") which shall extend until such time when all accrued and unpaid dividends for all previous quarterly dividend periods and for the current quarterly dividend period on all shares of Series H Junior Participating Preferred Stock then outstanding shall have been declared and paid or set apart for payment. During each default period, all holders of Preferred Stock (including holders of the Series H Junior Participating Preferred Stock) with dividends in arrears in an amount equal to six (6) quarterly dividends thereon, voting as a class, irrespective of series, shall have the right to elect two (2) Directors.

(ii) During any default period, such voting right of the holders of Series H Junior Participating Preferred Stock may be exercised initially at a special meeting called pursuant to subparagraph (iii) of this Section 3(C) or at any annual meeting of stockholders, and thereafter at annual meetings of stockholders, provided that such voting right shall not be exercised unless the holders of ten percent (10%) in number of shares of Preferred Stock outstanding shall be present in person or by proxy. The absence of a quorum of the holders of Common Stock shall not affect the exercise by the holders of Preferred Stock of such voting right. At any meeting at which the holders of Preferred Stock shall exercise such voting right initially during an existing default period, they shall have the right, voting as a class, to elect Directors to fill such vacancies, if any, in the Board of Directors as may then exist up to two (2) Directors or, if such right is exercised at an annual meeting, to elect two (2) Directors. If the number which may be so elected at any special meeting does not amount to the required number, the holders of Preferred Stock shall have the right to make such increase in the number of Directors as shall be necessary to permit the election by them of the required number. After the holders of the Preferred Stock shall have exercised their right to elect Directors in any default period and during the continuance of such period, the number of Directors in any default period and during the continuance of such period, the number of Directors shall not be increased or decreased except by vote of the holders of the Preferred Stock as herein provided or pursuant to the rights of any equity securities ranking senior to or pari passu with the Preferred Stock.

(iii) Unless the holders of Preferred Stock shall, during an existing default period, have previously exercised their right to elect Directors, the Board of Directors may order, or any stockholder or stockholders owning in the aggregate not less than ten percent (10%) of the total number of shares of Preferred Stock outstanding, irrespective of series, may request, the calling of special meeting of the holders of Preferred Stock, which meeting shall thereupon be called by the President, a Vice President or the Secretary of the Corporation. Notice of such meeting and of any annual meeting at which holders of Preferred Stock are entitled to vote pursuant to this Paragraph (C)(iii) shall be given to each holder of record of Preferred Stock by mailing a copy of such notice to him or her at his or her last address as the same appears on the books of the Corporation. Such meeting shall be called for a time not earlier than 10 days and not later than 50 days after such order or request or in default of the calling of such meeting within 50 days after such order or request, such meeting may be called on similar notice by any stockholder or stockholders owning in the aggregate not less than ten percent (10%) of the total number of shares of Preferred Stock outstanding. Notwithstanding the provisions of this Paragraph (C)(iii), no such special meeting shall be called during the period within 50 days immediately preceding the date fixed for the next annual meeting of the stockholders.

(iv) In any default period, the holders of Common Stock, and other classes of stock of the Corporation if applicable, shall continue to be entitled to elect the whole number of Directors until the holders of Preferred Stock shall have exercised their right to elect two (2) Directors voting as a class, after the exercise of which right (x) the Directors so elected by the holders of Preferred Stock shall continue in office until their successors shall have been elected by such holders or until the expiration of the default period, and (y) any vacancy in the Board of Directors may (except as provided in Paragraph (C)(ii) of this Section 3) be filled by vote of a majority of the remaining Directors theretofore elected by the holders of the class of stock which elected the Director whose office shall have become vacant. References in this Paragraph (C) to Directors elected by the holders of a particular class of stock shall include Directors elected by such Directors to fill vacancies as provided in clause (y) of the foregoing sentence.


4


(v) Immediately upon the expiration of a default period, (x) the right of the holders of Preferred Stock as a class to elect Directors shall cease, (y) the term of any Directors elected by the holders of Preferred Stock as a class shall terminate, and (z) the number of Directors shall be such number as may be provided for in the certificate of incorporation or bylaws irrespective of any increase made pursuant to the provisions of Paragraph (C)(ii) of this Section 3 (such number being subject, however, to change thereafter in any manner provided by law or in the certificate of incorporation or bylaws). Any vacancies in the Board of Directors effected by the provisions of clauses (y) and (z) in the preceding sentence may be filled by a majority of the remaining Directors.


(D) Except as set forth herein or as provided by law, holders of Series H Junior Participating Preferred Stock shall have no special voting rights and their consent shall not be required (except to the extent they are entitled to vote with holders of the Common Shares as set forth herein) for taking any corporate action.

4. Certain Restrictions.

(A) Whenever quarterly dividends or other dividends or distributions payable on the Series H Junior Participating Preferred Stock as provided in Section 2 are in arrears, thereafter and until all accrued and unpaid dividends and distributions, whether or not declared, on Series H Junior Participating Preferred Stock outstanding shall have been paid in full, the Corporation shall not:

(i) declare or pay dividends on, make any other distributions on, or redeem or purchase or otherwise acquire for consideration any shares ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series H Junior Participating Preferred Stock;

(ii) declare or pay dividends on or make any other distributions on any shares ranking on a parity (either as to dividends or upon liquidation, dissolution or winding up) with the Series H Junior Participating Preferred Stock, except dividends paid ratably on the Series H Junior Participating Preferred Stockand all such parity shares on which dividends are payable or in arrears in proportion to the total amounts to which the holders of all such shares are then entitled;

(iii) redeem or purchase or otherwise acquire for consideration any shares ranking on a parity (either as to dividends or upon liquidation, dissolution or winding up) with the Series H Junior Participating Preferred Stock, provided that the Corporation may at any time redeem, purchase or otherwise acquire any such parity shares in exchange for any shares of the Corporation ranking junior (both as to dividends and upon dissolution, liquidation or winding up) to the Series H Junior Participating Preferred Stock; or

(iv) purchase or otherwise acquire for consideration any shares of Series H Junior Participating Preferred Stock, or any shares ranking on a parity with the Series H Junior Participating Preferred Stock, except in accordance with a purchase offer made in writing or by publication (as determined by the Board of Directors) to all holders of such shares upon such terms as the Board of Directors, after consideration of the respective annual dividend rates and other relative rights and preferences of the respective series and classes, shall determine in good faith will result in fair and equitable treatment among the respective series or classes.

(B) The Corporation shall not permit any subsidiary of the Corporation to purchase or otherwise acquire for consideration any shares of the Corporation unless the Corporation could, under paragraph (A) of this Section 4, purchase or otherwise acquire such shares at such time and in such manner.

5. Reacquired Shares. Any Series H Junior Participating Preferred Stock purchased or otherwise acquired by the Corporation in any manner whatsoever shall be retired and canceled promptly after the acquisition thereof. All such shares shall upon their cancellation become authorized but unissued shares of preferred stock and may be reissued as part of a new series of shares of Preferred Stock.

6. Liquidation, Dissolution or Winding Up.

(A) Upon any liquidation (voluntary or otherwise), dissolution or winding up of the Corporation, no distribution shall be made to the holders of shares ranking junior (either as to dividends or upon liquidation or winding up) to the Series H Junior Participating Preferred Stock, unless, prior thereto, the holders of Series H Junior Participating Preferred Stock shall have received $1.00 per share, plus an amount equal to accrued and unpaid dividends and distributions thereon, whether or not declared, to the date of such payment (the "Series H Liquidation Preference"). Following the payment of the full amount of the Series H Liquidation Preference, no additional distributions shall be made to the holders of Series H Junior Participating Shares unless, prior thereto, the holders of Common Stock shall have received an amount per share (the "Common Adjustment") equal to the quotient obtained by dividing (i) the Series H Liquidation Preference by (ii) the Adjustment Number. Following the payment of the full amount of the Series H Liquidation Preference and the Common Adjustment in respect of all outstanding shares of Series H Junior Participating Preferred Stock and the Common Stock, respectively, holders of Series H Junior Participating Preferred Stock and holders of the Common Stock shall receive their ratable and proportionate share of the remaining assets to be distributed in the ratio of the Adjustment Number to 1 with respect to such Preferred Stock and the Common Stock, on a per share basis, respectively.


5




(B) In the event, however, that there are not sufficient assets to permit payment in full of the Series H Liquidation Preference and the liquidation preferences of all other series of shares of preferred stock, if any, that rank on a parity with the Series H Junior Participating Preferred Stock, then such remaining assets shall be distributed ratably to the holders of such parity shares in proportion to their respective liquidation preferences. In the event, however, that there are not sufficient assets available to permit payment in full of the Common Adjustment, then such remaining assets shall be distributed ratably to the holders of the Common Stock.

7. Consolidation, Merger, etc. In case the Corporation shall enter into any consolidation, merger, or other transaction in which the Common Stock are exchanged for or changed into other shares or securities, cash and/or other property, then in any such case, the Series H Junior Participating Preferred Stock shall at the same time be similarly exchanged or changed in an amount per share equal to the Adjustment Number times the aggregate amount of shares, securities, cash and/or any other property (payable in kind), as the case may be, into which or for which each Common Share is changed or exchanged.

8. No Redemption. The Series H Junior Participating Stocks shall not be redeemable. Notwithstanding the foregoing sentence of this Section, the Corporation may acquire Series H Junior Participating Preferred Stock in any other manner permitted by law.

9. Ranking. The Series H Junior Participating Preferred Stock shall rank junior to all other series of the Corporation's preferred stock as to the payment of dividends and the distribution of assets, unless the terms of any such series shall provide otherwise.

10. Amendment. At any time that any Series H Junior Participating Preferred Stock are outstanding, these Restated Articles shall not be amended in any manner which would materially alter or change the powers, preferences or special rights of the Series H Junior Participating Preferred Stock so as to affect them adversely without the affirmative vote of the holders of a majority or more of the outstanding Series H Junior Participating Preferred Stock, voting separately as a class.

11. Fractional Shares. Series H Junior Participating Preferred Stock may be issued in fractions of a share that shall entitle the holder, in proportion to such holder's fractional shares, to exercise voting rights, receive dividends, participate in distributions and to have the benefit of all other rights of holders of Series H Junior Participating Preferred Stock.


DIVISION D - PROVISIONS APPLICABLE TO ALL CLASSES OF STOCK

No holder of any stock of the Corporation shall be entitled as of right to purchase or subscribe for any part of any unissued or treasury stock of the Corporation, or of any additional stock of any class, to be issued by reason of any increase of the authorized capital stock of the Corporation, or to be issued from any unissued or additionally authorized stock, or of bonds, certificates of indebtedness, debentures or other securities convertible into stock of the Corporation, but any such unissued or treasury stock, or any such additional authorized issue of new stock or securities convertible into stock, may be issued and disposed of by the Board of Directors to such persons, firms, corporations or associations, and upon such terms as the Board of Directors may, in its discretion, determine, without offering to the shareholders then of record, or any class of shareholders, any thereof, on the same terms or any terms.

ARTICLE FIVE

The Corporation will not commence business until it has received for the issuance of its shares consideration of the value of not less than $1000.00 consisting of money paid, labor done, or property actually received.

ARTICLE SIX

The address of the registered office and the name of its registered agent is as follows:

C T Corporation
811 Dallas Avenue
Houston, Texas 77002

ARTICLE SEVEN

(a) The business and affairs of the Corporation shall be conducted and managed by, or under the direction of, the Board of Directors. Except as otherwise provided for or fixed pursuant to the provisions of Article 4 of these Restated Articles relating to the rights of the holders of any series of Preferred Stock to elect additional directors, the total number of directors constituting the entire Board of Directors shall be not less than three (3) nor more than nine (9), with the then-authorized number of directors being fixed from time to time solely by or pursuant to a resolution passed by the Board of Directors.


6




(b) The Board of Directors shall have the power to make, adopt, alter, amend and repeal from time to time the By-Laws of this Corporation, subject to the right of the shareholders entitled to vote with respect thereto to adopt, alter, amend and repeal the By-Laws; provided, however, that By-Laws shall not be adopted, altered, amended or repealed by the stockholders of the Corporation except by the vote of the holders of not less than sixty percent (60%) of the outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, considered for this purpose as one class.

(c) No director of the Corporation shall be liable to the Corporation or its shareholders for monetary damages for an act or omission (or an alleged act or omission) in a director's capacity as director, except that this Article Seven (c) does not eliminate or limit the liability of a director to the extent the director is found liable for:

(1) a breach of a director's duty of loyalty to the Corporation or its shareholders;

(2) an act or omission not in good faith which constitutes a breach of duty of the director to the Corporation, or an act or omission which involves intentional misconduct or a knowing violation of-the law;

(3) a transaction from which a director received an improper benefit, whether or not the benefit resulted from an action taken within the scope of the director's office;

(4) an act or omission for which the liability of a director is expressly provided for by an applicable statute; or

(5) an act related to an unlawful stock repurchase or payment of a dividend.

If the Texas Miscellaneous Corporation Laws Act or the TBCA or any other applicable law is amended or adopted to authorize action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by such law(s), as so amended or adopted. Any repeal or modification of the foregoing paragraph shall not adversely affect any right of protection of a director of the Corporation existing at the time of such repeal or modification.

(d) The Board of Directors shall be divided into three classes, designated as Class I, Class II, and Class III. Each class shall consist, as nearly as may be possible, of one-third of the total number of directors constituting the entire Board of Directors. Initially, Class I directors shall be elected for a one-year term, Class II directors for a two year term and Class III directors for a three-year term. At the annual meeting of shareholders beginning in 1993, successors to the class of directors whose term expires at that annual meeting shall be elected for a three-year term. If the number of directors is changed, any increase or decrease shall be apportioned among the classes so as to maintain the number of directors in each class as nearly as possible, and any additional director of that class elected to fill a vacancy resulting from an increase in such class shall hold office for a term that shall coincide with the remaining term of that class, but in no case shall a decrease in the number of directors shorten the term of any incumbent director. A director shall hold office until the annual meeting for the year in which his term expires and until his successor shall be elected and shall qualify, subject, however, to prior death, resignation, retirement, disqualification or removal from office. Any vacancy on the Board of Directors that results from an increase in the number of directors may be filled only by action of majority of the Board of Directors then in office, provided that a quorum is present; any other vacancy occurring in the Board of Directors may be filled only by action of a majority of the directors then in office, even if less than a quorum, or by a sole remaining director. Any director elected to fill a vacancy not resulting from an increase in the number of directors shall have the same remaining term as that of his predecessor.

(e) Notwithstanding the foregoing, whenever, pursuant to the provisions of Article 4 of these Restated Articles, the holders of any one or more series of Preferred Stock shall have the right, voting separately as a series or together with holders of other such series, to elect directors at an annual or special meeting of shareholders, the election, term of office, filling of vacancies and other features of such directorships shall be governed by the terms of these Restated Articles and such directors so elected shall not be divided into classes pursuant to this Article 7 (e) unless expressly provided by such terms.

(f) Directors must be at least 21 years of age and need not be shareholders. There shall be no qualifications for directors of the Corporation other than as set forth in these Amended and Restated Articles.


7




(g) The number of directors presently constituting the Board of Directors of the Corporation is seven (7), and the names, addresses and class of the persons now serving as directors are as follows:

Address
Class
     
Ronald J. Berman
Jupiter, Florida
III
Marc W. Eller
Dallas, Texas
III
Eddie Lee
Dallas, Texas
II
Dr. Robert Ronstadt
Boston, Massachusetts
II
David R. Sincox
Houston, Texas
I
Dr. Zvi Yaniv
Austin, Texas
II
Charles C. Bailey
Austin, Texas
I
     



ARTICLE EIGHT

[Deleted pursuant to Article 4.07 (B) of the TBCA, as amended.]

ARTICLE NINE

(a) At an annual meeting of the shareholders, only such business shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual meeting, business must be otherwise properly brought before the meeting by a shareholder (i) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors, (ii) otherwise properly brought before the meeting by or at the direction of the Board of Directors, or (iii) otherwise properly brought before the meeting by a shareholder. For business to be properly brought before an annual meeting by a shareholder, the shareholder must have given timely notice thereof in writing to the Secretary of the Corporation. To be timely, a shareholder's notice must be delivered to or mailed and received at the principal executive offices of the Corporation not less than 60 days nor more than 90 days prior to the meeting; provided, however, that in the event that less than 70 days' notice or prior to public disclosure of the date of the meeting is given or made to shareholders, notice by the shareholder to be timely must be so received not later than the close of business on the 10th day following the day on which such notice of the date of the annual meeting was mailed or such public disclosure was made. A shareholder's notice to the Secretary shall set forth as to each matter the shareholder proposes to bring before the annual meeting (i) a brief description of the business desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting, (ii) the name and address, as they appear on the Corporation's books, of the shareholder proposing such business, (iii) the class and number of shares of the Corporation which are beneficially owned by the shareholder, and (iv) any material interest of the shareholder in such business. The Chairman of the annual meeting shall, if the facts warrant, determine and declare to the meeting that business was not properly brought before the meeting in accordance with the provisions of this Article 9(a), and if he should so determine, he shall so declare to the meeting and any such business not properly brought before the meeting shall not be transacted.

(b) Only persons who are nominated in accordance with the procedures set forth in this Article 9(b) shall be eligible for elections as Directors. Nominations of persons for election to the Board of Directors of the Corporation may be made at a meeting of shareholders by or at the direction of the Board of Directors or by any shareholder of the Corporation entitled to vote for the election of Directors at the meeting who complies with the notice procedures set forth in this Article 9(b). Such nominations, other than those made by or at the direction of the Board of Directors, shall be made pursuant to timely notice in writing to the Secretary of the Corporation. To be timely, a shareholder's notice shall be delivered to or mailed and received at the principal executive offices of the Corporation not less than 60 days nor more than 90 days prior to the meeting; provided, however, that in the event that less than 70 days' notice or prior public disclosure of the date of the meeting is given or made to shareholders, notice by the shareholder to be timely must be so received not later than the close of business on the 10th day following the date on which such notice of the date of the meeting was mailed or such public disclosure was made. Such shareholder's notice shall set forth (i) as to each person whom the shareholder proposes to nominate for election or re-election as a Director, (A) the name, age, business address and residence address of such person, (B) the principal occupation or employment of such person, (C) the class and number of shares of the Corporation which are beneficially owned by such person, and (D) any other information relating to such person that is required to be disclosed in solicitations of proxies for election of Directors, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (including without limitation such person's written consent to being named in the proxy statement as a nominee and to serving as a Director if elected); and (ii) as to the shareholder giving the notice, (1) the name and address, as they appear on the

8




Corporation's books, of such shareholder and (2) the class and number of shares of the Corporation which are beneficially owned by such shareholder. No person shall be eligible for election as a Director of the Corporation unless nominated in accordance with the procedures set forth in this Article 9(b). The Chairman of the meeting shall, if the facts warrant, determine and declare to the meeting that a nomination was not made in accordance with the procedures prescribed herein, and if he should so determine, he shall so declare to the meeting and the defective nomination shall be disregarded.

ARTICLE TEN

No shareholder of the corporation shall have the right of cumulative voting at any election of directors or upon any other matter.

ARTICLE ELEVEN

(a) With respect to any matter for which the affirmative vote of the holders of a specified portion of the shares entitled to vote is required by the TBCA, including, but not limited to, the amendment of these Restated Articles pursuant to Article 4.02 of the TBCA, the approval of any action or plan of merger or exchange pursuant to Article 5.03 of the TBCA or the disposition of assets requiring special authorization of shareholders pursuant to Article 5.10 of the TBCA, the approval of those matters shall be the affirmative vote of the majority of the shares entitled to vote on those matters, rather than the affirmative vote otherwise required by the TBCA.

  (b) With respect to any matter for which the affirmative vote of the holders of a specified portion of the shares of any class or series is required by the TBCA, including, but not limited to, those matters identified in paragraph (a) of this Article Eleven, the approval of those matters shall be the affirmative vote of the holders of a majority of the shares of that class or series, rather than the affirmative vote of that class or series otherwise required by the TBCA.

(c) If the TBCA or any other applicable law is amended or adopted with respect to a matter requiring the affirmative vote of the holders of a specified portion of the shares entitled to vote on that matter, then this Article Eleven shall also require a vote of a majority of the holders of the shares entitled to vote on that matter, rather than the affirmative vote otherwise required.


IN WITNESS WHEREOF, the undersigned has executed these Restated Articles as of February 16, 2006.


 
NANO-PROPRIETARY, INC.
   
   
   
   
 
/s/ Douglas P. Baker
 
Douglas P. Baker
 
Vice President and Chief
 
Financial Officer

 
 
 
 
 
9
EX-3.II.1 3 ex3ii-1.htm EXHIBIT 3 (II).1 Exhibit 3 (ii).1

 

 
Exhibit 3(ii).1
 
AMENDED AND RESTATED BYLAWS
 
OF
 
NANO-PROPRIETARY, INC.
 
(Adopted by Resolution of the Board of Directors on February 16, 2006)
 
ARTICLE I.
 
CAPITAL STOCK
 
 
Section 1. Form of Certificates. The Company shall deliver certificates representing shares to which shareholders are entitled. Such certificates shall be signed by (i) the Chairman of the Board, the President or a Vice President and (ii) either the Secretary or an Assistant Secretary and (iii) shall be sealed with the seal of the Company or a facsimile thereof. The signatures of such officers upon a certificate may be facsimiles. In case any officer who has signed or whose facsimile signature has been placed upon such certificate shall have ceased to be such officer before such certificate is issued, it may be issued by the Company with the same effect as if he were such officer at the date of its issuance.
 
Section 2. Shareholders of Record. The Board of Directors of the Company may appoint one or more transfer agents or registrars of any class of stock of the Company. The Company shall be entitled to treat the holder of record of any shares of the Company as the owner thereof for all purposes, and shall not be bound to recognize any equitable or other claim to, or interest in, such shares or any rights deriving from such shares, on the part of any other person, including (but without limitation) a purchaser, assignee or transferee, unless and until such other person becomes the holder of record of such shares, whether or not the Company shall have either actual or constructive notice of the interest of such other person.
 
Section 3. Transfer of Shares. The shares of the Company shall be transferable on the stock certificate books of the Company by the holder of record thereof, or his duly authorized attorney or legal representative, upon surrender for cancellation of the certificate for such shares. All certificates surrendered for transfer shall be canceled and no new certificate shall be issued until a former certificate or certificates for a like number of shares shall have been surrendered and canceled except that in the case of a lost, destroyed or mutilated certificate, a new certificate may be issued therefor upon such conditions for the protection of the Company and any transfer agent or registrar as the Board of Directors or the Secretary may prescribe.
 
Section 4. Lost Certificates. The Board of Directors may direct a new certificate to be issued in place of any certificate theretofore issued by the Company alleged to have been
 



 
lost, stolen or destroyed, upon the making of an affidavit of the fact by the person claiming the certificate of stock to be lost, stolen or destroyed. When authorizing such issue of a new certificate, the Board of Directors may, in its discretion and as a condition precedent to the issuance thereof, require the owner of such lost, stolen or destroyed certificate, or such owner's legal representative, to advertise the same in such manner as the Board of Directors shall require and/or to give the Company a bond in such sum as it may direct as indemnity against any claim that may be made against the Company with respect to the certificate alleged to have been lost, stolen or destroyed.
 
Section 5. Voting Securities Owned by the Company. Powers of attorney, proxies, waivers of notice of meeting, consents and other instruments relating to securities owned by the Company may be executed in the name of and on behalf of the Company by the Chairman of the Board, the President, any Vice President or the Secretary, and any such officer may, in the name of and on behalf of the Company, take all such action as any such officer may deem advisable to vote in person or by proxy at any meeting of security holders of any corporation in which the Company may own securities, and at any such meeting shall possess and may exercise any and all rights and powers incident to the ownership of such securities and which, as the owner thereof, the Company might have exercised and possessed if present. The Board of Directors may, by resolution, from time to time confer like powers upon any other person or persons.
 
ARTICLE II.
 
MEETINGS OF SHAREHOLDERS
 
Section 1. Place of Meetings. All meetings of shareholders shall be held at the registered office of the Company, in the City of Austin, Texas, or at such other place within or without the State of Texas as may be designated by the Board of Directors or officer calling the meeting.
 
Section 2. Annual Meetings. The Annual Meetings of shareholders shall be held on such date and at such time as shall be designated from time to time by the Board of Directors and stated in the notice of the meeting, at which meetings the shareholders shall elect by a plurality vote a Board of Directors, and transact such other business as may properly be brought before the meeting.
 
Section 3. Special Meetings. Special Meetings of the shareholders may only be called by the Board of Directors, the Chairman of the Board, the President or the holders of not less than ten percent (10%) of all shares outstanding and entitled to vote at such meeting. Only business related to the purposes set forth in the notice of the meeting may be transacted at a special meeting.
 
Section 4. Notice of Meeting. Written or printed notice of all meetings stating the place, day and hour of the meeting and, in case of a special meeting, the purpose or purposes for which the meeting is called, shall be delivered to each shareholder of record entitled to vote at such meetings not less than ten (10) nor more than sixty (60) days before the date
 



 
of the meeting, either personally or by mail, by or at the direction of the Chairman of the Board, the President, the Secretary or the officer or person calling the meeting. If mailed, such notice shall be deemed to be delivered when deposited in the United States mail addressed to the shareholder at his address as it appears on the stock transfer books of the Company, with postage thereon prepaid.
 
Section 5. Closing of Transfer Books and Fixing Record Date. For the purpose of determining shareholders entitled to notice of or to vote at any meeting of shareholders or any adjournment thereof, the Board of Directors may either provide that the stock transfer books shall be closed for a stated period of not less than ten (10) nor more than sixty (60) days before the meeting, or it may fix in advance a record date for any such determination of shareholders, such date to be not less than ten (10) days nor more than sixty (60) days prior to the meeting. If the stock transfer books are not closed and no record date is fixed for the determination of shareholders entitled to notice of or to vote at a meeting of shareholders, then the date on which the notice of the meeting is mailed shall be the record date for such determination of shareholders. When a determination of shareholders entitled to vote at any meeting of shareholders has been made as herein provided, such determination shall apply to any adjournment thereof except where the determination has been made through the closing of the stock transfer books and the stated period of closing has expired.
 
Section 6. Voting List. The officer or agent having charge of the stock transfer books for shares of the Company shall make, at least ten days before each meeting of shareholders, a complete list of the shareholders entitled to vote at such meeting or any adjournment thereof, arranged in alphabetical order, with the address of and the number of shares held by each, which list, for a period of ten days prior to such meeting, shall be kept on file at the registered office of the Company and shall be subject to inspection by any shareholder at any time during usual business hours. Such list shall also be produced and kept open at the time and place of the meeting and shall be subject to the inspection of any shareholder during the whole time of the meeting. The original stock transfer books shall be prima facie evidence as to who are the shareholders entitled to examine such list or to vote at any meeting of shareholders. Failure to comply with any requirements of this Section 6 shall not affect the validity of any action taken at such meeting.
 
Section 7. Voting at Meetings. Except as otherwise provided in the Restated Articles of Incorporation of the Company, as amended to date (the "Articles of Incorporation"), each holder of shares of capital stock of the Company entitled to vote shall be entitled to one vote for each share of such stock, either in person or by proxy executed in writing by him or by his duly authorized attorney-in-fact. No proxy shall be valid after eleven months from the date of its execution unless otherwise provided in the proxy. A proxy shall be revocable unless expressly provided therein to be irrevocable and unless otherwise made irrevocable by law. At each election for Directors, every holder of shares of the Company entitled to vote shall have the right to vote, in person or by proxy, the number of shares owned by him for as many persons as there are Directors to be elected, and for whose election he has a right to vote, but in no event shall he be permitted to cumulate his votes for one or more Directors.
 



 
All voting, including on the election of Directors but except where otherwise provided herein or required by law or the Articles of Incorporation, may be by a voice vote, provided, however, that upon demand therefor by a shareholder entitled to vote or such shareholder's proxy, a stock vote shall be taken. Every stock vote shall be taken by ballots, each of which shall state the name of the shareholder or proxy voting and such other information as may be required under the procedure established for the meeting.
 
All elections of Directors shall be determined by a plurality of the votes cast, and except as otherwise required by applicable law or the Articles of Incorporation, all other matters shall be determined by a majority of the votes cast.
 
Section 8. Quorum; Adjournment. Except as otherwise provided in the Articles of Incorporation of the Company, the holders of a majority of shares entitled to vote, represented in person or by proxy, shall constitute a quorum at a meeting of shareholders. Except as otherwise provided by law, the Articles of Incorporation or these Bylaws, the affirmative vote of the holders of a majority of the shares entitled to vote and thus represented at a meeting at which a quorum is present shall be the act of the shareholders' meeting. If a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of the majority of the shares of stock entitled to vote who are present, in person or by proxy, may adjourn the meeting to another place, date or time without notice other than announcement at the meeting, until a quorum shall be present or represented.
 
When a meeting is adjourned to another place, date or time, written notice need not be given of the adjourned meeting if the place, date and time thereof are announced at the meeting at which the adjournment is taken; provided, however, that if the date of any adjourned meeting is more than thirty (30) days after the date for which the meeting was originally noticed, or if a new record date is fixed for the adjourned meeting, written notice of the place, date and time of the adjourned meeting shall be given in conformity herewith. At any adjourned meeting, any business may be transacted which might have been transacted at the original meeting.
 
Section 9. Officers. The Chairman of the Board shall preside at, and the Secretary shall keep the records of, each meeting of shareholders. In the absence of either such officer, his duties shall be performed by another officer of the Company appointed at the meeting.
 
Section 10. Inspectors of Election. In advance of any meeting of shareholders, the Board of Directors may appoint inspectors of election, who need not be shareholders, to act at such meeting or any adjournment thereof. If inspectors of election are not so appointed, the person presiding at any such meeting may, and on the request of any shareholder entitled to vote at the meeting and before voting begins shall, appoint inspectors of election. If any person who is appointed fails to appear or act, the vacancy may be filled by appointment made by the Board of Directors in advance of the meeting, or at the meeting by the person presiding at the meeting. Each inspector, before entering upon the discharge of his duties, shall take an oath faithfully to execute the duties of inspector at such meeting.
 



 
If inspectors of election are appointed as aforesaid, they shall determine from the lists referred to in Section 6 of this Article II the number of shares outstanding, the shares represented at the meeting, the existence of a quorum and the voting power of shares represented at the meeting, determine the authenticity, validity and effect of proxies, receive votes or ballots, hear and determine all challenges and questions in any way arising in connection with the right to vote or the number of votes which may be cast, count and tabulate all votes or ballots, determine the results, and do such acts as are proper to conduct the election or vote with fairness to all shareholders entitled to vote thereat.
 
The inspectors shall make a report in writing of any challenge or question matter which is determined by them, and execute a sworn certificate of any facts found by them.
 
ARTICLE III.
 
DIRECTORS
 
Section 1. Number and Classification of Board of Directors. The business and affairs of the Company shall be managed by or under the direction of the Board of Directors which may exercise all such powers of the Company and do all such lawful acts and things as are not by law or by the Articles of Incorporation or by these Bylaws directed or required to be exercised or done by the shareholders of the Company. Pursuant to Article Seven of the Company's Articles of Incorporation, the total number of Directors constituting the entire Board of Directors shall not be less than three (3) nor more than nine (9), with the then-authorized number of Directors being fixed from time to time solely by or pursuant to a resolution passed by the Board of Directors. The Directors shall be divided into three classes, Class I, Class II and Class III. Such classes shall be as nearly equal in number of Directors as possible.
 
Directors need not be shareholders of the Company. All Directors shall be elected in accordance with the procedures specified in the Company's Articles of Incorporation, and each Director so elected shall hold office for a term of three years and until his or her successor is duly elected and qualified, or until his or her earlier resignation or removal.
 
At each annual election, the Directors chosen to succeed those whose terms then expire shall be of the same class as the Directors they succeed, unless, by reason of any intervening changes in the authorized number of Directors, the Board of Directors shall designate one or more Directorships whose term then expires as Directorships of another class in order more nearly to achieve equality of number of Directors among the classes.
 



 
Notwithstanding the rule that the three classes shall be as nearly equal in number of Directors as possible, in the event of any change in the authorized number of Directors, each Director then continuing to serve as such shall nevertheless continue as a Director of the class of which he is a member until the expiration of his current term, or his prior death, resignation, disqualification or removal. No decrease in the number of Directors constituting the Board of Directors shall shorten the term of any incumbent Director.
 
Section 2. Newly Created Directorships and Vacancies. Newly created Directorships resulting from any increase in the number of Directors may be filled by the affirmative vote of a majority of the Directors then in office for a term of office continuing only until the next election of one or more Directors by the shareholders entitled to vote thereon; provided, however, that the Board of Directors shall not fill more than two such Directorships during the period between two successive annual meetings of shareholders. Except as provided in Section 1 of this Article III, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other cause shall be filled by the affirmative vote of a majority of the remaining Directors then in office, even though less than a quorum of the Board of Directors. Any Director elected to fill any such vacancy shall hold office for the remainder of the full term of the Director whose departure from the Board of Directors created the vacancy and until such newly elected Director's successor shall have been duly elected and qualified.
 
Section 3. Nomination of Directors. Nominations for the election of Directors may be made by the Board of Directors or a committee appointed by the Board of Directors or by any shareholder (a "Nominator") entitled to vote in the election of Directors. Such nominations, other than those made by the Board of Directors or a committee appointed by the Board of Directors, shall be made in writing pursuant to timely notice delivered to or mailed and received by the Secretary of the Company as set forth in Article Nine (b) of the Company's Articles of Incorporation.
 
Section 4. Place of Meetings and Meetings by Telephone. Meetings of the Board of Directors may be held either within or without the State of Texas, at whatever place is specified by the officer calling the meeting. Meetings of the Board of Directors may also be held by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other. Participation in such a meeting by means of conference telephone or similar communications equipment shall constitute a presence in person at such meeting, except where a Director participates in a meeting for the express purpose of objecting to the transaction of any business on the ground that the meeting is not lawfully called or convened. In the absence of specific designation by the officer calling the meeting, the meetings shall be held at the registered office of the Company in the City of Austin, Texas.
 
Section 5. Regular Meetings. The Board of Directors shall meet each year immediately following the annual meeting of the shareholders at the place of such meeting, for the transaction of such business as may properly be brought before the meeting. Regular meetings of the Board of Directors may be held without notice at such time and at such place as may from time to time be determined by the Board of Directors. No notice of any kind to either old or new members of the Board of Directors for such annual or regular meetings shall be necessary.
 



 
Section 6. Special Meetings. Special meetings of the Board of Directors may be held at any time upon the call of the Chairman of the Board, the Chief Executive Officer, the Secretary of the Company, or a majority of the Directors then in office. Notice shall be sent by mail or telegram to the last known address of the Director at least three days before the meeting. Notice of the time, place and purpose of such meeting may be waived in writing before or after such meeting, and shall be equivalent to the giving of notice. Attendance of a Director at such meeting shall also constitute a waiver of notice thereof, except where he attends for the announced purpose of objecting to the transaction of any business on the ground that the meeting is not lawfully called or convened. Except as otherwise provided by these Bylaws, neither the business to be transacted at, nor the purpose of, any regular or special meeting of the Board of Directors need be specified in the notice or waiver of notice of such meeting.
 
Section 7. Quorum and Voting. Except as otherwise provided by law, the Articles of Incorporation of the Company or these Bylaws, a majority of the number of Directors fixed in the manner provided in these Bylaws as from time to time amended shall constitute a quorum for the transaction of business. Except as otherwise provided by law, the Articles of Incorporation of the Company or these Bylaws, the affirmative vote of a majority of the Directors present at any meeting at which there is a quorum shall be the act of the Board of Directors. Any regular or special Directors' meeting may be adjourned from time to time by those present, whether or not a quorum is present.
 
Section 8. Compensation. Unless otherwise restricted by the Articles of Incorporation or these Bylaws, the Board of Directors shall have the authority to fix the compensation of Directors. The Directors may be paid their expenses, if any, of attendance at each meeting of the Board of Directors and may be paid a fixed sum for attendance at each meeting of the Board of Directors or a stated salary as Director. No such payment shall preclude any Director from serving the Company in any other capacity and receiving compensation therefore. Members of special or standing committees may be allowed like compensation for attending committee meetings.
 
Section 9. Removal; Resignation. No Director of the Company shall be removed from his office as a Director by vote or other action of the shareholders or otherwise except (a) with cause, as defined below, by the affirmative vote of the holders of at least a majority of the voting power of all outstanding shares of capital stock of the Company entitled to vote in the election of Directors, voting together as a single class, or (b) without cause by (i) the affirmative vote of at least 60% of all Directors then in office at any regular or special meeting of the Board of Directors called for that purpose or (ii) the affirmative vote of the holders of at least 60% of the voting power of all outstanding shares of capital stock of the Company entitled to vote in the election of Directors, voting together as a single class.
 



 
Except as may otherwise be provided by law, cause for removal of a Director shall be construed to exist only if: (a) the Director whose removal is proposed has been convicted, or where a Director is granted immunity to testify where another has been convicted, of a felony by a court of competent jurisdiction and such conviction is no longer subject to direct appeal; (b) such Director has been found by the affirmative vote of at least 60% of all Directors then in office at any regular or special meeting of the Board of Directors called for that purpose or by a court of competent jurisdiction to have been negligent or guilty of misconduct in the performance of his duties to the Company in a matter of substantial importance to the Company; or (c) such Director has been adjudicated by a court of competent jurisdiction to be mentally incompetent, which mental incompetency directly affects his ability as a Director of the Company.
 
No proposal by a shareholder to remove a Director of the Company shall be voted upon at a meeting of the shareholders unless such shareholder shall have delivered or mailed in a timely manner (as set forth in this Section 9) and in writing to the Secretary of the Company (a) notice of such proposal, (b) a statement of the grounds, if any, on which such Director is proposed to be removed, (c) evidence, reasonably satisfactory to the Secretary of the Company, of such shareholder's status as such and of the number of shares of each class of the capital stock of the Company beneficially owned by such shareholder, (d) a list of the names and addresses of other beneficial owners of shares of the capital stock of the Company, if any, with whom such shareholder is acting in concert, and of the number of shares of each class of the capital stock of the Company beneficially owned by each such beneficial owner, and (e) an opinion of counsel, which counsel and the form and substance of which opinion shall be reasonably satisfactory to the Board of Directors of the Company (excluding the Director proposed to be removed), to the effect that, if adopted at a duly called special or annual meeting of the shareholders of the Company by the required vote as set forth in the first paragraph of this Section 9, such removal would not be in conflict with the laws of the State of Texas, the Articles of Incorporation of the Company or these Bylaws. To be timely in connection with an annual meeting of shareholders, a shareholder's notice and other aforesaid items shall be delivered to or mailed and received at the principal executive offices of the Company not less than ninety nor more than 180 days prior to the date on which the immediately preceding year's annual meeting of shareholders was held. To be timely in connection with the removal of any Director at a special meeting of the shareholders, a shareholder's notice and other aforesaid items shall be delivered to or mailed and received at the principal executive offices of the Company not less than forty days nor more than sixty days prior to the date of such meeting; provided, however, that in the event that less than fifty days' notice or prior public disclosure of the date of the special meeting of shareholders is given or made to the shareholders, the shareholder's notice and other aforesaid items to be timely must be so received not later than the close of business on the seventh day following the day on which such notice of date of the meeting was mailed or such public disclosure was made. Within thirty days (or such shorter period that may exist prior to the date of the meeting) after such shareholder shall have delivered the aforesaid items to the Secretary of the Company, the Secretary and the Board of Directors of the Company shall respectively determine whether the items to be ruled upon by them are reasonably satisfactory and shall notify such shareholder in writing of
 



 
their respective determinations. If such shareholder fails to submit a required item in the form or within the time indicated, or if the Secretary or the Board of Directors of the Company determines that the items to be ruled upon by them are not reasonably satisfactory, then such proposal by such shareholder may not be voted upon by the shareholders of the Company at such meeting of shareholders. The presiding person at each meeting of shareholders shall, if the facts warrant, determine and declare to the meeting that a proposal to remove a Director of the Company was not made in accordance with the procedures prescribed by these Bylaws, and if he should so determine, he shall so declare to the meeting and the defective proposal shall be disregarded. Beneficial ownership shall be determined as specified in Section 6 of Article VIII of these Bylaws.
 
Any Director of the Company may resign at any time by giving written notice to the Chairman of the Board or the Secretary. Such resignation shall take effect at the date of the receipt of such notice or at any later time specified therein and, unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.
 
Section 10. Executive and Other Committees. The Board of Directors, by resolution adopted by a majority of the full Board of Directors, may designate from among its members an executive committee and other committees, each of which shall be comprised of two or more members and, to the extent provided in such resolution, shall have and may exercise all of the authority of the Board of Directors.
 
Notwithstanding the foregoing paragraph of this Section 10, no such committee shall have the authority of the Board of Directors to:
 
a.
amend the Articles of Incorporation of the Company;
 
b.
amend, alter or repeal the Bylaws of the Company or adopt new Bylaws for the Company;
 
c.
alter or repeal any resolution of the Board of Directors;
 
d.
approve a plan of merger or consolidation;
 
e.
take definitive action on any reclassification or exchange of securities, or repurchase by the Company of any of its equity securities;
 
f.
declare a dividend on the capital stock of the Company;
 
g.
call a special meeting of the shareholders;
 
h.
recommend any proposal to the shareholders for action by the shareholders;
 
i.
fill vacancies in the Board of Directors or any such committee;
 



j.
fill any Directorship to be filled by reason of an increase in the number of Directors;
     
k.
elect or remove officers or members of any such committee; or
     
l.
fix the compensation of any member of such committee.
 
The designation of any such committee and the delegation thereto of authority shall not operate to relieve the Board of Directors, or any member thereof, of any responsibility imposed upon it or him by law, nor shall such committee function where action of the Board of Directors is required under applicable law. The Board of Directors shall have the power at any time to change the membership of any such committee and to fill vacancies in it. A majority of the members of any such committee shall constitute a quorum. Each such committee may elect a chairman and appoint such subcommittees and assistants as it may deem necessary. Except as otherwise provided by the Board of Directors, meetings of any committee shall be conducted in accordance with the provisions of Sections 4 and 6 of this Article III as the same shall from time to time be amended. Any member of any such committee elected or appointed by the Board of Directors may be removed by the Board of Directors whenever in its judgment the best interests of the Company will be served thereby, but such removal shall be without prejudice to the contract rights, if any, of the person so removed. Election or appointment of a member of a committee shall not of itself create contract rights.
 
ARTICLE IV.
 
OFFICERS
 
Section 1. General. The officers of the Company shall be appointed by the Board of Directors and shall consist of a Chairman of the Board, a Chief Executive Officer or President, or both, one or more Vice Presidents, a Chief Financial Officer and a Secretary. The Board of Directors may also choose such other officers and agents as the Board of Directors, in its sole and absolute discretion, shall deem necessary or appropriate. Any number of offices may be held by the same person, unless the Articles of Incorporation or these By-laws provide otherwise.
 
Section 2. Election; Term of Office. The Board of Directors, at its first meeting held after each Annual Meeting of Shareholders, shall elect a Chairman of the Board, a Chief Executive Officer or a President, or both, one or more Vice Presidents, a Secretary and a Chief Financial Officer, and may also elect at that meeting or any other meeting, such other officers and agents as it shall deem necessary or appropriate. Each officer of the Company shall exercise such powers and perform such duties as shall be determined from time to time by the Board of Directors together with the powers and duties which are customarily exercised by such officer; and each officer of the Company shall hold office until such officer's successor is elected and qualified or until such officer's earlier resignation or removal. Any officer may resign at any time upon written notice to the
 



 
Company. The Board of Directors may at any time, with or without cause, by the affirmative vote of a majority of Directors then in office, remove an officer.
 
Section 3. Chairman of the Board. The Chairman of the Board shall preside at all meetings of the shareholders and the Board of Directors, and shall have such other duties and powers as may be prescribed by the Board of Directors from time to time.
 
Section 4. Chief Executive Officer. The Chief Executive Officer shall be the chief executive officer of the Company, shall have general and active management of the business of the Company, and shall see that all orders and resolutions of the Board of Directors are carried into effect. The Chief Executive Officer shall have and exercise such further powers and duties as may be specifically delegated to or vested in the Chief Executive Officer from time to time by these By-laws or the Board of Directors. In the absence of the Chairman of the Board or in the event of his inability or refusal to act, or if the Board has not designated a Chairman, the Chief Executive Officer shall perform the duties of the Chairman of the Board, and when so acting, shall have all the powers and be subject to all of the restrictions upon the Chairman of the Board.
 
Section 5. Vice President. In the absence of the Chief Executive Officer or in the event of his inability or refusal to act, the Vice President (or in the event that there be more than one vice president, the vice presidents in the order designated by the Board of Directors, or in the absence of any designation, then in the order of their election) shall perform the duties of the President, and when so acting, shall have all the powers of and be subject to all the restrictions upon the President. The vice presidents shall perform such other duties and have such other powers as the Board of Directors or the President may from time to time prescribe.
 
Section 6. Secretary. The Secretary shall attend all meetings of the Board of Directors and all meetings of the shareholders, and record all the proceedings thereat in a book or books to be kept for that purpose; the Secretary shall also perform like duties for the standing committees when required. The Secretary shall give, or cause to be given notice of meetings of shareholders and special meetings of the Board of Directors, and shall perform such other duties as may be prescribed by the Board of Directors or the President. If the Secretary shall be unable or shall refuse to cause to be given notice of all meetings of the shareholders and special meetings of the board of Directors, and if there be no assistant secretary, then either the Board of Directors or the President may choose another officer to cause such notice to be given. The Secretary shall have custody of the seal of the Company and the Secretary or any assistant secretary, if there be one, shall have authority to affix same to any instrument requiring it and when so affixed, it may be attested to by the signature of the Secretary or by the signature of any such assistant secretary. The Board of Directors may give general authority to any other officer to affix the seal of the Company and to attest to the affixing by his or her signature. The Secretary shall see that all books, reports, statements, certificates and other documents and records required by law to be kept or filed are properly kept or filed, as the case may be.
 



 
Section 7. Chief Financial Officer. The Chief Financial Officer shall have the custody of the corporate funds and securities and shall keep complete and accurate accounts of all receipts and disbursements of the Company, and shall deposit all moneys and other valuable effects of the Company in its name and to its credit in such banks and other depositories as may be designated from time to time by the Board of Directors. The Chief Financial Officer shall disburse the funds of the Company, taking proper vouchers and receipts for such disbursements, and shall render to the Board of Directors, at its regular meetings, or when the Board of Directors so requires, an account of all his or her transactions as Chief Financial Officer and of the financial condition of the Company. The Chief Financial Officer shall, when and if required by the Board of Directors, give and file with the Company a bond, in such form and amount and with such surety or sureties as shall be satisfactory to the Board of Directors, for the faithful performance of his or her duties as Chief Financial Officer. The Chief Financial Officer shall have such other powers and perform such other duties as the Board of Directors or the Chief Executive Officer shall from time to time prescribe.
 
Section 8. Other Officers. Such other officers as the Board of Directors may choose shall perform such duties and have such powers as from time to time may be assigned to them by the Board of Directors. The Board of Directors may delegate to any other officer of the Company the power to choose such other officers and to prescribe their respective duties and powers.
 
Section 9. Resignations. Any officer may resign at any time by giving written notice to the Board of Directors, the Chairman of the Board, the President or the Secretary which shall be deemed to constitute notice to the Company. Such resignation shall take effect upon receipt of such notice or at any later time specified therein; and, unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.
 
Section 10. Removal. Any officer or agent may be removed, either with or without cause, at any time, by the Board of Directors at any meeting called for that purpose; provided, however, that the President may remove any agent appointed by him.
 
Section 11. Vacancies. Whenever any vacancies shall occur in any office by death, resignation, increase in the number of offices of the Company, or otherwise, the officer so elected shall hold office until his successor is chosen and qualified. The Board of Directors may at any time remove any officer of the company, whenever in its judgment the best interests of the Company will be served thereby, but such removal shall be without prejudice to the contract rights, if any, of the person so removed. Election or appointment of an officer or agent shall not of itself create contract rights.
 



 
ARTICLE V
 
INDEMNIFICATION
 
Section 1. Indemnification of Directors and Officers in Third Party Proceedings. The Company may indemnify any Director or officer of the Company who was or is an "authorized representative" of the Company (which shall mean for the purposes of this Article V a Director or officer of the Company, or a person serving at the request of the Company as a Director, officer, partner or trustee of another corporation, partnership, joint venture, trust or other enterprise) and who was or is a "party" (which shall include for purposes of this Article V the giving of testimony or similar involvement) or is threatened to be made a party to any "third party proceeding" (which shall mean for purposes of this Article V any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of the Company) by reason of the fact that such person was or is an authorized representative of the Company, against expenses (which shall include for purposes of this Article V attorney's fees and disbursements), judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such third party proceeding if such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the best interests of the Company, or with respect to a criminal third party proceeding (which shall include for purposes of this Article any investigation which could or does lead to a criminal third party proceeding) if such person had not reasonable cause to believe such conduct was unlawful. The termination of any third party proceeding by judgment, order, settlement, indictment, conviction or upon a plea of no contest or its equivalent, shall not, of itself, create a presumption that the authorized representative did not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal third party proceeding, had reasonable cause to believe that such conduct was unlawful.
 
Section 2. Indemnification of Directors and Officers in Corporate Proceedings. The Company may indemnify any Director or officer of the Company who was or is an authorized representative of the Company and who was or is a party or is threatened to be made a party to any "corporate proceeding" (which shall mean for purposes of this Article V any threatened, pending or completed action or suit by or in the right of the Company to procure a judgment in its favor or any investigative proceeding by or on behalf of the Company) by reason of the fact that such person was or is an authorized representative of the Company, against expenses (including attorneys' fees and disbursements) actually and reasonably incurred by such person in connection with the defense or settlement of such corporate proceeding if such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the best interests of the Company, except that no indemnification shall be made in the performance of such person's duty to the Company unless and only to the extent that the court in which such corporate proceeding was pending shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such authorized representative is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper.
 



 

 
 
Section 3. Indemnification of Authorized Representatives. To the extent that an authorized representative of the Company who neither was nor is a Director or officer of the Company has been successful on the merits or otherwise in defense of any third party or corporate proceeding or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses actually and reasonably incurred by such person in connection therewith. Such an authorized representative may, at the discretion of the Company, be indemnified by the Company in any other circumstance to any extent if the Company would be required by Section 1 or 2 of this Article V to indemnify such person in such circumstances to such extent as if such person were or had been a Director or officer of the Company.
 
Section 4. General Terms. Any indemnification under Section 1 and Section 2 of this Article V (unless ordered by a court) shall be made by the Company only as authorized in the specific case upon a determination that indemnification of the Director, officer, employee or agent is proper under the circumstances because he had met the applicable standard of conduct set forth in Section 1 and Section 2 of this Article V. Such determination shall be made (i) by the Board of Directors by a majority vote of a quorum consisting of Directors who were not parties to such action, suit or proceeding, or (ii) if such a quorum of disinterested Directors so directs, by independent legal counsel in written opinion, or (iii) by the shareholders.
 
Section 5. Amendment. Any amendment to Article V shall not apply to any liability of a Director, officer, employee or agent arising out of a transaction or omission occurring prior to the adoption of such amendment, but any such liability based on a transaction or omission occurring prior to the adoption of such amendment shall be governed by Article V of these By-laws, as in effect at the time of such transaction or omission.
 
Section 6. Insurance and Trust Fund. In furtherance and not in limitation of the powers conferred by statute:
 
 
a. the Company may purchase and maintain insurance on behalf of any person who is or was a Director, officer, employee or agent of the Company, or is serving at the request of another corporation as a Director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his power to indemnify him against such liability under the provisions of law; and
 
b. the Company may create a trust fund, grant a security interest and/or use other means (including without limitation, letters of credit, surety bonds, and/or other similar arrangements), as well as enter into contracts providing indemnification to the fullest extent permitted by law and including as part thereof provisions with respect to any or all of the foregoing, to ensure the payment of such amount as may become necessary to effect indemnification as provided therein, or elsewhere.
 



 

 
 
Section 7. Indemnification of Employees and Agents of the Company. The Company may, to the extent authorized from time to time by the Board of Directors, grant rights to indemnification, including the right to be paid by the Company the expenses incurred in defending any proceeding in advance of its final disposition, to any employee or agent of the Company to the fullest extent of the provisions of the Section or otherwise with respect to the indemnification and advancement of expenses of Directors and officers of the Company. Notwithstanding any other provision of these by-laws, no officer, Director, agent or employee of the Company shall receive indemnification payments under this section in advance of the final disposition of any action or proceeding against such officer, Director, agent or employee unless the Company shall have received, prior to the date of such payment, a written undertaking to repay the amounts advanced by the Company if it shall subsequently be determined that the officer, Director, agent or employee was not entitled to indemnification for such costs under the terms of these By-Laws.
 
ARTICLE VI.
 
CONTRACTS AND TRANSACTIONS WITH DIRECTORS AND OFFICERS
 
Section 1. General Procedure. No contract or transaction between the Company and one or more of its Directors or officers, or between the Company and any other corporation, partnership, association or other organization in which one or more of the Company's Directors or officers are Directors or officers or have a financial interest, shall be void or voidable solely for this reason, solely because the Director or officer is present at or participates in the meeting of the Company's Board of Directors or committee which authorizes the contract or transaction, or solely because his or their votes are counted for such purpose, if:
 
a. The material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the Board of Directors or committee in good faith authorizes the contract or transaction by the affirmative vote of a majority of the disinterested Directors, even though the disinterested Directors constitute less than a quorum; or
 
b. The material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known to the shareholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the shareholders; or
 
c. The contract or transaction is fair to the Company as of the time it is authorized, approved or ratified by the Board of Directors, the committee thereof, or the shareholders.
 



 

 
 
Section 2. Determination of Quorum. Common or interested Directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee which authorizes the contract or transaction as provided in Section 1 of this Article VI.
 
ARTICLE VII.
 
NOTICES
 
 
Section 1. Notice. Whenever, under the provisions of the laws of Texas or the Articles of Incorporation or these By-laws, any notice, request, demand or other communication is required to be or may be given or made to any officer, Director, or registered shareholder, it shall be construed to mean that such notice, request, demand or other communication must be given or made in person, but the same may be given or made by mail, telegraph, cablegram, telex, or telecopier to such officer, Director or registered shareholder. Any such notice, request, demand or other communication shall be considered to have been properly given or made, in the case of mail, when deposited in the mail or delivered to the appropriate office for telegraph or cable transmission, and in other cases when transmitted by the party giving or making the same, directed to the officer or Director at his address as it appears on the record of shareholders, or, if the shareholder shall have filed with the Secretary of the Company a written request that notices to him be mailed to some other address, then directed to the shareholder at such other address. Notice to Directors may also be given in accordance with Section 6 of Article III hereof.
 
Whenever, under the provisions of the laws of this state or the Articles of Incorporation or these By-laws, any notice, request, demand or other communication is required to be or may be given or made to the Company, it shall also not be construed to mean that such notice, request, demand or other communication must be given or made in person, but that the same may be given or made to the Company by mail, telegraph, cablegram, telex or telecopier. Any such notice, request, demand or other communication shall be considered to have been properly given or made, in the case of mail, telegram or cable, when deposited in the mail or delivered to the appropriate office for telegraph or cable transmission.
 
Section 2. Waivers of Notice. Whenever any written notice is required to be given under the provisions of the Articles of Incorporation, these By-laws or a statute, a waiver thereof in writing, signed by the person or persons entitled to such notice, whether before or after the time stated therein, shall be deemed equivalent to the giving of such notice. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the shareholders, Directors, or members of a committee of Directors need be specified in any written waiver of notice of such meeting.
 
Attendance of a person, either in person or by proxy at any meeting, without protesting prior to the conclusion of the meeting the lack of notice of such meeting, shall constitute a waiver of notice of such meeting.
 



 
 
 
ARTICLE VIII.
 
MISCELLANEOUS PROVISIONS
 
 
Section 1. Offices. The principal office of the Company shall be located in Austin, Texas, unless and until changed by resolution of the Board of Directors. The Company may also have offices at such other places as the Board of Directors may designate from time to time, or as the business of the Company may require. The principal office and registered office may be, but need not be, the same.
 
Section 2. Resignations. Any Director or officer may resign at any time. Such resignations shall be made in writing and shall take effect at the time specified therein, or, if no time be specified, at the time of its receipt by the President or Secretary. The acceptance of a resignation shall not be necessary to make it effective, unless expressly so provided in the resignation.
 
Section 3. Fixing Record Dates for Payment of Dividends and Other Purposes. For the purpose of determining shareholders entitled to receive payment of any dividend or in order to make a determination of shareholders for any other proper purpose, the Board of Directors of the Company may provide that the stock transfer books shall be closed for a stated period but not to exceed, in any case, sixty days. In lieu of closing the stock transfer books, the Board of Directors may fix in advance a date as the record date for any such determination of shareholders, such date to be not more than sixty days prior to the date on which the particular action requiring such determination of shareholders is to be taken. If the stock transfer books are not closed and no record date is fixed for the determination of shareholders entitled to receive payment of a dividend, then the date on which the resolution of the Board of Directors declaring such dividend is adopted shall be the record date for such determination of shareholders.
 
Section 4. Corporate Seal. The corporate seal, if the Company shall have a corporate seal, shall have inscribed thereon the name of the Company. The seal may be used by causing it or a facsimile thereof to be impressed or affixed or otherwise reproduced.
 
Section 5. Separability. If one or more of the provisions of these Bylaws shall be held to be invalid, illegal or unenforceable, such invalidity, illegality or unenforceability shall not affect any other provision hereof and these Bylaws shall be construed as if such invalid, illegal or unenforceable provision or provisions had never been contained herein.
 
Section 6. Beneficial Owners. The Company shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and to hold liable for calls and assessments a person registered on its books as the owner of shares, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise provided by law. "Beneficial Owner" as used in these Bylaws means any of the following:
 



 

 
 
a. a person who individually or with any of his affiliates or associates beneficially owns (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended) any capital stock of the Company, directly or indirectly;
 
b. a person who individually or with any of his affiliates or associates has either of the following rights:
 
(i) to acquire capital stock of the Company, whether such right is exercisable immediately or only after the passage of time, pursuant to any agreement, arrangement or understanding, or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise;
 
(ii) to vote capital stock of the Company pursuant to any agreement, arrangement or understanding; or
 
c. a person who has any agreement, arrangement or understanding for the purpose of acquiring, holding, voting or disposing of capital stock of the Company with any other person who beneficially owns or whose affiliates beneficially own (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended), directly or indirectly, such shares of capital stock.
 
Section 7. Dividends. Dividends upon the capital stock of the Company, subject to the provisions of the Articles of Incorporation, if any, may be declared by the Board of Directors at any regular or special meeting or by any Committee of the Board of Directors having such authority at any meeting thereof, and may be paid in cash, in property, in shares of capital stock, or in any combination thereof. Before payment of any dividend, there may be set aside out of any funds of the Company available for dividends such sum or sums as the Board of Directors from time to time, in its absolute discretion, deems proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for any proper purpose, and the Board of Directors may modify or abolish any such reserve.
 
Section 8. Disbursements. All notes, checks, drafts, and orders for the payment of money issued by the Company shall be signed in the name of the Company by such officers or such other persons as the Board of Directors may from time to time designate.
 
ARTICLE IX.
 
AMENDMENT OF BYLAWS
 
Section 1. Vote Requirements. The Board of Directors shall have the power to make, adopt, alter, amend and repeal from time to time the Bylaws of this Company, subject to the right of the shareholders entitled to vote with respect thereto to adopt, alter, amend and repeal the Bylaws; provided, however, that Bylaws shall not be adopted, altered, amended or repealed by the shareholders of the Company, except by the vote of the holders of not less than sixty percent (60%) of the outstanding shares of the capital stock of the Company entitled to vote generally in the election of Directors, considered for this purpose as one class.
 
 
[Remainder of This Page is Blank]
 



 
CERTIFICATE OF CORPORATE SECRETARY
 
 
The undersigned, acting in his capacity as Corporate Secretary of Nano-Proprietary, Inc. (the "Company") attests that the foregoing Amended and Restated Bylaws were duly adopted and approved by the Board of Directors of the Company at a meeting which was duly called and held on February 16, 2006.
 
 
 
NANO-PROPRIETARY, INC.


By: /s/ Douglas P. Baker                       
 
Douglas P. Baker,
Corporate Secretary

EX-10.18 4 ex1018.htm EXHIBIT 10.18 Exhibit 10.18

 
Exhibit 10.18
 
 

CHARTER OF THE COMPENSATION COMMITTEE
 
NANO-PROPRIETARY, INC.
 
1.
PURPOSE
 
The purpose of the Compensation Committee (the "Committee") of NANO-PROPRIETARY, INC. (the "Company") is to help to ensure that the executive officers of the Company and its subsidiaries are compensated in a manner consistent with the compensation strategy of the Company as determined by the Board of Directors (the "Board"), the treatment of all executive officers in an equitable and consistent manner, the Company's need to compete in recruiting and retaining qualified executive officers and the requirements of all appropriate regulatory bodies. The Committee shall also communicate to the stockholders the compensation policies of the Company and the method for establishing compensation for the Chief Executive Officer ("CEO") and the other executive officers of the Company.
 
To carry out this purpose, the Committee shall:

(1)
 Review and approve corporate goals and objectives relevant to compensation of the executive officers.
(2)
 Evaluate the performance of the executive officers in light of those goals and objectives.
(3)
 Determine and approve the compensation level of the executive officers based on this evaluation.
(4)
 Determine and approve awards under the Company’s incentive compensation plans.
(5)
 Make recommendations to the Board with respect to new or amended incentive compensation plans and equity based plans.
 
2.
COMMITTEE MEMBERSHIP AND ORGANIZATION
 
The Committee shall be comprised of no fewer than two members. Each member of the Committee shall be "independent" as defined by the rules of the National Association of Securities Dealers ("NASD") and the Securities and Exchange Commission ("SEC"). In addition, each member shall be a "Non-employee Director" for purposes of Rule 16b-3 under the Securities Exchange Act of 1934 and shall satisfy the requirements of an "outside director" for purposes of Section 162(m) of the Internal Revenue Code. Each member shall be free of any relationship that, in the opinion of the Board, would interfere with his or her individual exercise of independent judgment. The members of the Committee shall be appointed and replaced by the Board. The Board shall appoint one of the members as Chair.
 
This Committee shall communicate with and work closely with the Board. To foster such communication, the Chairman of the Board, the CEO and CFO of the Company may be invited to attend meetings on a non-voting basis, provided the CEO and CFO each may not be present during voting on or discussion of his or her compensation, unless the committee requests the CEO or CFO to be present for a portion of the discussion so that the committee can clarify any questions that it has or obtain any information that it may need.
 
 
 
 

 
 
3.    COMMITTEE RESPONSIBILITIES AND AUTHORITY
 
To carry out the purpose expressed in Paragraph 1 above, the Committee shall have the responsibilities and authority set forth below:
 
(1)
Review from time to time and approve the Company's compensation strategy to ensure that management is rewarded appropriately for its contributions to Company growth and profitability and that the executive compensation strategy supports Company objectives and stockholder interests.
(2)
Determination of all elements of compensation for the Company’s executive officers. The CEO and the CFO each may not be present during voting on or discussion of his or her compensation unless the committee requests the CEO or CFO to be present for a portion of the discussion so that the committee can clarify any questions that it has or obtain any information that it may need.  
(3)
Determine the long-term incentive component of compensation for the executive officers based on the considerations adopted by the Board.
(4)
Annually review the performance of the CEO and, with the assistance of the CEO, the executive officers of the Company, and report on the Committee's review to the Board, if requested.
(5)
Produce the annual Board Compensation Committee Report to Stockholders, if required, on the factors and criteria on which the compensation for the CEO and other executive officers in the last year was based, to be included in the Company's proxy statement for its annual meeting or Annual Report on Form 10-K filed with the SEC.
(6)
Develop the Company's incentive compensation strategy with respect to the total number of incentive awards to be granted, the relative participation of senior management and other employees, and the types of awards to be granted.
(7)
Recommend and approve, subject to submission to stockholders when appropriate, all new equity-related incentive plans.
(8)
Determine eligibility for awards under the Company's incentive compensation plans and the terms under which awards are granted.
(9)
Allocate awards under the Company's incentive compensation plans, provided that the Committee may delegate to the CEO or another executive officer the authority to allocate Stock options or other equity instruments allowed by the Company’s plans among employees who are not executive officers, subject to applicable law and the limits and guidelines established by the Committee.
(10)
Assure that the Company's executive incentive compensation program, including the annual and long-term incentive plans, is administered in a manner consistent with the Company's incentive compensation strategy.
(11)
Approve annual retainer and meeting fees for directors and members of Board committees, including expense reimbursement limits and per diem allowances, and fix the terms and awards of stock compensation for members of the Board.
(12)
Review with the CEO matters relating to management succession, including identifying and hiring potential candidates for executive office, consulting on hiring any executive officers as well as overseeing any termination of any executive officers.
(13)
Obtain advice, assistance, reports or opinions from internal or external legal, accounting or other advisors, including consulting firms, to assist in the evaluation of director, CEO or senior executive compensation, as necessary.
(14)
Form and delegate authority to subcommittees, or delegate authority to members, when appropriate, provided that such subcommittees will be composed exclusively of members of this Committee and will operate pursuant to a written charter.
 
 
 
 
 

 
 

(15)
Review and re-examine this Charter at least annually and make recommendations to the Board with respect to any proposed changes.
(16)
Annually report to the full Board regarding its own performance against the responsibilities outlined in this Charter and as otherwise established by the Board.
(17)
Such other duties and responsibilities as may be assigned to the Committee, from time to time, by the Board or the Chairman, or as designated in compensation plan documents.
 
Delegation by the Board of responsibilities to the Committee shall not preclude the Board from taking any action permitted to be taken under governing law, rules or regulations applicable to the Company, provided that the Committee shall have sole authority to retain and terminate any consulting firm used to assist in the evaluation of director, CEO or senior executive compensation, including sole authority to approve the consulting firm's fees and other retention terms.
 
4.
MEETING AND MINUTES
 
 
(1)
The Committee will meet at least twice annually and will also meet, as required, in response to the needs of the Board and as necessary to fulfill their responsibilities. 
(2)
The Committee will maintain written minutes of its meetings, which minutes will be filed with the minutes of the meetings of the Board.

* * * *
 
This Charter was duly adopted and approved by the Board on February 16, 2006.
 
EX-10.19 5 ex1019.htm EXHIBIT 10.19 Exhibit 10.19

 
Exhibit 10.19
 

CHARTER OF THE NOMINATING COMMITTEE
 
NANO-PROPRIETARY, INC.
 
1.
PURPOSE:
 
The purpose of the Nominating Committee (the "Committee") of NANO-PROPRIETARY, INC. (the "Company") is to assist the Company's Board of Directors (the "Board") in identifying individuals qualified to become directors of the Company under criteria approved by the Board.

2.
COMMITTEE MEMBERSHIP AND ORGANIZATION:
 
The Committee shall be comprised of at least two members. Each member of the Committee shall be "independent" as defined by the rules of the National Association of Securities Dealers ("NASD") and the Securities and Exchange Commission ("SEC"). Each member shall be free of any relationship that, in the opinion of the Board, would interfere with his or her individual exercise of independent judgment. The members of the Committee shall be appointed and replaced by the Board. The Board shall appoint one of the members as Chair. The Chairman of the Board may be invited to attend meetings on a non-voting basis.
 
This Committee shall communicate with and work closely with the Board.
 
3.
AUTHORITY:
 
The Committee shall have the necessary resources and authority, without further action by the Board, to discharge its duties and responsibilities, including the authority to retain outside counsel, search firms and other experts and consultants, as the Committee deems appropriate, and to cause the Company to pay the fees and other compensation of such advisors.
 
4.
COMMITTEE RESPONSIBILITIES:
 
To carry out the purposes expressed in Paragraph 1 above, the Committee shall have the following responsibilities:
 

(1)
Evaluate the suitability of potential nominees for membership on the Board, taking into consideration the Board's current composition, including expertise, and balance of inside, outside and independent directors, and considering the general qualifications of the potential nominees.
(2)
Determine the desired qualifications, expertise and characteristics for potential directors and conduct searches for director candidates that have corresponding attributes. Evaluate and recommend nominees for election to the Board, including candidates suggested or nominated by a director or executive officer of the Company or by a stockholder of the Company (if the nomination is made in accordance with the Company's charter documents and applicable law).
 

 




(3)
Review the qualifications of incumbent directors to determine whether to recommend them as nominees for re-election to the Board.
(4)
Evaluate the current composition, organization, size and governance of the Board and its committees; determine future requirements; and make recommendations to the Board concerning the appointment of directors to committees of the Board and chairs of committees of the Board.
(5)
Oversee the Board's performance evaluation process, including conducting surveys of director observations, suggestions and preferences. The Committee shall also evaluate the performance of individual directors.
(6)
Evaluate and recommend termination of service of individual members of the Board as appropriate, for cause or for other proper reasons.
(7)
Make regular written reports to the Board.
(8)
Review and re-examine this Charter at least annually and make recommendations to the Board with respect to any proposed changes.
(9)
Annually report to the full Board regarding its own performance against the responsibilities outlined in this Charter and as otherwise established by the Board.
(10)
Obtain advice, assistance, reports or opinions from internal or external legal, accounting or other advisors, including director search firms.
(11)
Make such recommendations to the Board as the Committee may consider appropriate and consistent with its purpose, and take such other actions and perform such other services as may be referred to it from time to time by the Board.

 

5.
MEETING AND MINUTES:
 
(1)
The Committee will meet at least twice annually and will also meet, as required, in response to the needs of the Board and as necessary to fulfill their responsibilities.
(2)
The Committee will maintain written minutes of its meetings, which minutes will be filed with the minutes of the meetings of the Board.

* * * *
 
This Charter was duly adopted and approved by the Board on February 16, 2006.
 
EX-11 6 ex-11.htm EXHIBIT 11 Exhibit 11


EXHIBIT 11

NANO-PROPRIETARY, INC.

COMPUTATION OF (LOSS) PER COMMON SHARE


   
Three months ended December 31,
 
Year ended December 31,
 
   
2005
 
2004
 
2003
 
2005
 
2004
 
2003
 
                           
Net income (loss) applicable
                                     
to common shareholders
 
$
(1,213,083
)
$
(1,136,322
)
$
(1,534,897
)
$
(4,661,534
)
$
(4,612,026
)
$
(4,214,202
)
                                       
Weighted average number
                                     
of common shares
   
99,634,507
   
96,018,127
   
95,424,044
   
98,957,812
   
96,609,237
   
87,366,507
 
                                       
Net income (loss) per
                                     
per share
 
$
(0.01
)
$
(0.01
)
$
(0.02
)
$
(0.05
)
$
(0.05
)
$
(0.05
)


No computation of diluted loss per common share is included for the any periods because such computation results in an antidilutive loss per common share.


 
EX-21 7 ex21.htm EXHIBIT 21 Exhibit 21

 

EXHIBIT 21
Subsidiaries of the Company



       
Doing Business
Subsidiary
 
State of Incorporation
 
under the Following Names
         
Sign Builders of
 
Delaware
 
Sign Builders of America, Inc.
America, Inc.
 
 
 
         
Applied Nanotech, Inc.
 
Delaware
 
Applied Nanotech, Inc.
         
Electronic Billboard
 
Delaware
 
Electronic Billboard
Technology, Inc.
     
Technology, Inc.
         


EX-24 8 ex24.htm EXHIBIT 24 Exhibit 24
 
Exhibit 24
 
 
NANO-PROPRIETARY, INC.
POWER OF ATTORNEY
 
 
NANO-PROPRIETARY, INC. ANNUAL REPORT ON FORM 10-K
 
 
The undersigned, in his capacity as a director of Nano-Proprietary, Inc. (the "Company"), after reviewing the Company's Form 10-K, does hereby appoint Douglas P. Baker, his true and lawful attorney to execute in his name, place and stead, in his capacity as a Director of said Company, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and all instruments necessary or incidental in connection therewith, including all amendments, and to file the same with the Securities and Exchange Commission. Said attorney shall have the full power and authority to do and perform, in the name and on behalf of the undersigned, in any and all capacities, every act whatsoever requisite or necessary to be done in the premises, as fully and to all intents and purposes as the undersigned might or could do in person, the undersigned hereby ratifying and approving the acts of said attorney.
 
IN TESTIMONY WHEREOF, the undersigned has executed this instrument this 1st day of March, 2006.
 
/s/ Robert Ronstadt

Dr. Robert Ronstadt

 

 
NANO-PROPRIETARY, INC.
POWER OF ATTORNEY
 
 
NANO-PROPRIETARY, INC. ANNUAL REPORT ON FORM 10-K
 
 
The undersigned, in his capacity as a director of Nano-Proprietary, Inc. (the "Company"), after reviewing the Company's Form 10-K, does hereby appoint Douglas P. Baker, his true and lawful attorney to execute in his name, place and stead, in his capacity as a Director of said Company, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and all instruments necessary or incidental in connection therewith, including all amendments, and to file the same with the Securities and Exchange Commission. Said attorney shall have the full power and authority to do and perform, in the name and on behalf of the undersigned, in any and all capacities, every act whatsoever requisite or necessary to be done in the premises, as fully and to all intents and purposes as the undersigned might or could do in person, the undersigned hereby ratifying and approving the acts of said attorney.
 
IN TESTIMONY WHEREOF, the undersigned has executed this instrument this 1st day of March, 2006.
 
/s/ David R. Sincox

David R. Sincox
 


 
NANO-PROPRIETARY, INC.
POWER OF ATTORNEY
 
 
NANO-PROPRIETARY, INC. ANNUAL REPORT ON FORM 10-K
 
 
The undersigned, in his capacity as a director of Nano-Proprietary, Inc. (the "Company"), after reviewing the Company's Form 10-K, does hereby appoint Douglas P. Baker, his true and lawful attorney to execute in his name, place and stead, in his capacity as a Director of said Company, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and all instruments necessary or incidental in connection therewith, including all amendments, and to file the same with the Securities and Exchange Commission. Said attorney shall have the full power and authority to do and perform, in the name and on behalf of the undersigned, in any and all capacities, every act whatsoever requisite or necessary to be done in the premises, as fully and to all intents and purposes as the undersigned might or could do in person, the undersigned hereby ratifying and approving the acts of said attorney.
 
IN TESTIMONY WHEREOF, the undersigned has executed this instrument this 1st day of March, 2006.
 
/s/ Eddie Lee

Eddie Lee
 
 

 
 
 
NANO-PROPRIETARY, INC.
POWER OF ATTORNEY
 
 
NANO-PROPRIETARY, INC. ANNUAL REPORT ON FORM 10-K
 
 
The undersigned, in his capacity as a director of Nano-Proprietary, Inc. (the "Company"), after reviewing the Company's Form 10-K, does hereby appoint Douglas P. Baker, his true and lawful attorney to execute in his name, place and stead, in his capacity as a Director of said Company, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and all instruments necessary or incidental in connection therewith, including all amendments, and to file the same with the Securities and Exchange Commission. Said attorney shall have the full power and authority to do and perform, in the name and on behalf of the undersigned, in any and all capacities, every act whatsoever requisite or necessary to be done in the premises, as fully and to all intents and purposes as the undersigned might or could do in person, the undersigned hereby ratifying and approving the acts of said attorney.
 
IN TESTIMONY WHEREOF, the undersigned has executed this instrument this 1st day of March, 2006.
 
/s/ Ronald J. Berman

Ronald J. Berman
 

 
NANO-PROPRIETARY, INC.
POWER OF ATTORNEY
 
 
NANO-PROPRIETARY, INC. ANNUAL REPORT ON FORM 10-K
 
 
The undersigned, in his capacity as a director of Nano-Proprietary, Inc. (the "Company"), after reviewing the Company's Form 10-K, does hereby appoint Douglas P. Baker, his true and lawful attorney to execute in his name, place and stead, in his capacity as a Director of said Company, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and all instruments necessary or incidental in connection therewith, including all amendments, and to file the same with the Securities and Exchange Commission. Said attorney shall have the full power and authority to do and perform, in the name and on behalf of the undersigned, in any and all capacities, every act whatsoever requisite or necessary to be done in the premises, as fully and to all intents and purposes as the undersigned might or could do in person, the undersigned hereby ratifying and approving the acts of said attorney.
 
IN TESTIMONY WHEREOF, the undersigned has executed this instrument this 1st day of March, 2006.
 
/s/ Charles G. Bailey

Charles G. Bailey
 

 
NANO-PROPRIETARY, INC.
POWER OF ATTORNEY
 
 
NANO-PROPRIETARY, INC. ANNUAL REPORT ON FORM 10-K
 
 
The undersigned, in his capacity as a director of Nano-Proprietary, Inc. (the "Company"), after reviewing the Company's Form 10-K, does hereby appoint Douglas P. Baker, his true and lawful attorney to execute in his name, place and stead, in his capacity as a Director of said Company, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and all instruments necessary or incidental in connection therewith, including all amendments, and to file the same with the Securities and Exchange Commission. Said attorney shall have the full power and authority to do and perform, in the name and on behalf of the undersigned, in any and all capacities, every act whatsoever requisite or necessary to be done in the premises, as fully and to all intents and purposes as the undersigned might or could do in person, the undersigned hereby ratifying and approving the acts of said attorney.
 
IN TESTIMONY WHEREOF, the undersigned has executed this instrument this 1st day of March, 2006.
 
/s/ Zvi Yaniv

Dr. Zvi Yaniv
EX-31 9 ex31-1.htm EXHIBIT 31.1 Exhibitg 31.1

 

EXHIBIT 31.1
Certificate of Chief Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002


I, Marc W. Eller, certify that:

1.    I have reviewed this annual report on Form 10-K for the year ended December 31, 2005 of Nano-Proprietary, Inc. (“NNPP”);

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations and cash flows of NNPP as of, and for, the periods presented in this report.

4.    NNPP’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for NNPP and have:

(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to NNPP, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals.

(c)    Evaluated the effectiveness of NNPP’s disclosure control’s and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)    Disclosed in this report any change in NNPP’s internal control over financial reporting that occurred during NNPP’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, NNPP’s internal control over financial reporting; and

5.    NNPP’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to NNPP’s auditors and the audit committee of NNPP’s board of directors:

(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect NNPP’s ability to record, process, summarize and report financial information; and

(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in NNPP’s internal control over financial reporting. 


Date: March 1, 2006  

 
/s/ Marc W. Eller                     
Marc W. Eller, Chairman of the Board
and Chief Executive Officer

EX-31.2 10 ex31-2.htm EXHIBIT 31.2 Exhibit 31.2


EXHIBIT 31.2
Certificate of Chief Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 


I, Douglas P. Baker, certify that:

1.    I have reviewed this annual report on Form 10-K for the year ended December 31, 2005 of Nano-Proprietary, Inc. (“NNPP”);

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations and cash flows of NNPP as of, and for, the periods presented in this report.

4.    NNPP’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for NNPP and have:

(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to NNPP, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals.

(c)    Evaluated the effectiveness of NNPP’s disclosure control’s and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)    Disclosed in this report any change in NNPP’s internal control over financial reporting that occurred during NNPP’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, NNPP’s internal control over financial reporting; and

5.    NNPP’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to NNPP’s auditors and the audit committee of NNPP’s board of directors:

(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect NNPP’s ability to record, process, summarize and report financial information; and

(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in NNPP’s internal control over financial reporting. 


Date: March 1, 2006 

 
/s/Douglas P. Baker
Douglas P. Baker
Chief Financial Officer
EX-32.1 11 ex32-1.htm EXHIBIT 32.1 Exhibit 32.1

 

 
EXHIBIT 32.1
 

Certificate of Chief Executive Officer
Section 1350 Certification
 

In connection with the annual report of Nano-Proprietary, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2005, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Marc W. Eller, the Chief Executive Officer of the Company,certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

2. The information contained in this Report fairly presents, in all material respects, the financial conditions and results of operations of the Company.



Date:    March 1, 2006
/s/ Marc W. Eller
 
Marc W. Eller
 
Chairman and Chief Executive Officer
EX-32.2 12 ex32-2.htm EXHIBIT 32.2 Exhibit 32.2

 

 
EXHIBIT 32.2
 

Certificate of Chief Financial Officer
Section 1350 Certification
 

In connection with the annual report of Nano-Proprietary, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2005, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Douglas P, Baker, the Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

2. The information contained in this Report fairly presents, in all material respects, the financial conditions and results of operations of the Company.



Date:     March 1, 2006
/s/ Douglas P. Baker
 
Douglas P. Baker
 
Chief Financial Officer

-----END PRIVACY-ENHANCED MESSAGE-----